Clinical trial NCT01446159
Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Keywords: MEDI-573, breast cancer, metastatic, aromatase inhibitor, anti-IGF
Sponsor: MedImmune LLC
Start date: 2011-06-13; Completion date: 2019-06-28
Enrollment: 188 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.

Detailed description:
This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-evaluation phase (Phase 1b) and a randomization phase (Phase 2).

Arms: arm 1: Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons. arm 2: Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons. arm 3: Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons. arm 4: Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Interventions: intervention 1: MEDI-573 intervention 2: Aromatase Inhibitor
Intervention descriptions: intervention 1: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons. intervention 2: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Protocol documents:
Prot_000.pdf: 
MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
1 of 113
A Phase 1b/2 Randomized Study of MEDI-573 in 
Combination with an Aromatase Inhibitor (AI) Versus AI 
Alone in Women with Metastatic Breast Cancer (MBC)
Sponsor Protocol Number:
CD-ON-MEDI-573-1030
Application Number:
IND 103091
EudraCT number 2011-000198-29
Investigational Product:
MEDI-573
Sponsor:
MedImmune, LLC, a wholly-owned subsidiary of 
AstraZeneca PLC, One MedImmune Way, 
Gaithersburg, Maryland, 20878, USA
Medical Monitor:
CRO:
Quintiles Inc.
Protocol History, Date
Original Protocol, 30Mar2011
Amendment 1, 09Feb2012
Amendment 2, 05Dec2012
Amendment 3, 25Jul2016


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
2 of 113
TABLE OF CONTENTS
1
INTRODUCTION.........................................................................................................13
1.1
Disease Background ...........................................................................................13
1.1.1Insulin-like Growth Factor Signaling / Insulin Receptor Isoform A..........14
1.2
Description of MEDI-573...................................................................................14
1.2.1Product Derivation......................................................................................14
1.2.2Summary of Nonclinical Experience with MEDI-573 ...............................14
1.2.3Clinical Experience with MEDI-573..........................................................16
1.3
Research Hypothesis...........................................................................................18
1.4
Rationale for Study Conduct...............................................................................18
1.5
Benefit-risk and Ethical Assessment ..................................................................19
2
STUDY OBJECTIVES.................................................................................................21
2.1
Primary Objective...............................................................................................21
2.2
Secondary Objectives .........................................................................................21
2.3
Exploratory Objectives .......................................................................................21
3
STUDY DESIGN..........................................................................................................22
3.1
Overview of Study Design..................................................................................22
3.1.1Phase 1b (Dose-evaluation Phase)..............................................................22
3.1.2Phase 2 (Randomization Phase)..................................................................22
3.2
Estimated Duration of Subject Participation ......................................................23
3.3
Study-stopping Criteria.......................................................................................24
3.4
Rationale for Study Design, Doses, and Control Groups ...................................24
4
STUDY PROCEDURES...............................................................................................26
4.1
Subject Participation and Identification..............................................................26
4.2
Subject Selection and Withdrawal......................................................................26
4.2.1Inclusion Criteria ........................................................................................27
4.2.2Exclusion Criteria .......................................................................................28
4.2.3Withdrawal Criteria ....................................................................................30
4.2.4Replacement of Subjects.............................................................................31
4.3
Treatment Assignment........................................................................................31
4.4
Blinding ..............................................................................................................32
4.5
Study Treatment..................................................................................................32
4.5.1Investigational Products..............................................................................32
4.5.2Other Study Medications ............................................................................33
4.5.3Treatment Regimens...................................................................................33
4.5.3.1
Phase 1b……… ........................................................................33
4.5.3.2
Phase 2…….. ............................................................................33
4.5.3.3
Investigational Product Preparation..........................................34


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
3 of 113
4.5.4Treatment Administration...........................................................................35
4.5.5Monitoring of Dose Administration ...........................................................36
4.5.6Phase 1b (Dose-evaluation Phase)..............................................................37
4.5.7Phase 2 (Randomization Phase)..................................................................37
4.5.8Management of Toxicities, Dose Reductions and Dose Delays.................38
4.5.8.1
Dose-limiting Toxicity..............................................................39
4.5.9Treatment Compliance................................................................................39
4.6
Concomitant Medications...................................................................................39
4.6.1Permitted Concomitant Medications ..........................................................39
4.6.2Excluded Concomitant Medications...........................................................40
4.7
Subject Completion.............................................................................................40
4.8
End of the Study .................................................................................................40
5
STUDY PROCEDURES...............................................................................................41
5.1
Schedule of Study Procedures ............................................................................41
5.1.1Screening (All Subjects Unless Otherwise Specified)................................50
5.1.2Treatment Period.........................................................................................51
5.1.2.1
Cycle 1, Day 1 (All Subjects Unless Otherwise Specified)......51
5.1.2.2
Cycle 1, Day 2 (For Phase 1b only)..........................................52
5.1.2.3
Cycle 1, Day 8 (All Subjects Unless Otherwise Specified)......53
5.1.2.4
Cycle 1, Day 15 (Plus/Minus 2 Days, All Subjects Unless 
Otherwise Specified)..................................................53
5.1.2.5
Cycle 2 and Every Cycle Thereafter, Day 1 (Plus/Minus 2 
Days, All Subjects Unless Otherwise Specified) .......53
5.1.2.6
Every 9 Weeks Minus 7 Days (All Subjects) Through 24 
Months Post Study Entry ...........................................55
5.1.2.7
Every 6 Months Plus/Minus 7 Days, Beginning > 24 
Months Post Study Entry (All Subjects) ....................55
5.1.3End-of-Treatment Visit (All Subjects Unless Otherwise Specified)..........56
5.1.3.1
End-of-Treatment Visit (For subjects continuing on 
treatment under Amendment 3 only) .........................57
5.1.4Posttreatment Follow-up Period .................................................................57
5.1.4.1
30 Days (Plus/Minus 3 Days) and 60 Days (Plus/Minus 5 
Days) Posttreatment (All Subjects Unless 
Otherwise Specified)..................................................57
5.1.4.2
Every 9 Weeks (Plus/Minus 7 Days) Posttreatment for 
Subjects Without Progressive Disease Through 24 
Months Posttreatment.................................................58
5.1.4.3
Every 3 Months (Plus/Minus 7 Days) Posttreatment................59


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
4 of 113
5.1.4.4
Every 6 Months (Plus/Minus 7 Days) Posttreatment 
Beginning > 24 Months Post Study Entry For 
Subjects Without PD..................................................59
5.2
Description of Study Procedures ........................................................................59
5.2.1Medical History, Physical Examination, Electrocardiogram, Weight 
and Vital Signs..........................................................................59
5.2.2Clinical Laboratory Tests............................................................................60
5.2.3Pharmacokinetic Evaluation and Methods .................................................61
5.2.4Immunogenicity Evaluation and Methods..................................................62
5.2.5Biomarker Evaluation and Methods ...........................................................62
5.2.6Disease Evaluation and Methods................................................................63
5.2.6.1
Tumor Assessments and Response Criteria..............................63
5.2.6.2
Patient-reported Outcomes........................................................66
5.2.7Estimate of Volume of Blood to Be Collected ...........................................67
6
ASSESSMENT OF SAFETY .......................................................................................68
6.1
Safety Parameters ...............................................................................................68
6.1.1Adverse Events ...........................................................................................68
6.1.2Serious Adverse Events ..............................................................................68
6.2
Assessment of Safety Parameters .......................................................................69
6.2.1Assessment of Severity...............................................................................69
6.2.2Assessment of Relationship........................................................................70
6.2.2.1
Relationship to Investigational Product....................................70
6.2.2.2
Relationship to Protocol Procedures.........................................70
6.3
Recording of Safety Parameters .........................................................................71
6.3.1Recording of Adverse Events and Serious Adverse Events .......................71
6.4
Reporting Requirements for Safety Parameters..................................................71
6.4.1Study Reporting Period and Follow-up for Adverse Events ......................71
6.4.2Reporting of Serious Adverse Events.........................................................71
6.4.2.1
Study Reporting Period and Follow-up for Serious Adverse 
Events.........................................................................71
6.4.2.2
Notifying the Sponsor of Serious Adverse Events ...................72
6.4.2.3
Safety Reporting to Investigators, Institutional Review 
Boards or Independent Ethics Committees, and 
Regulatory Authorities...............................................73
6.4.3Other Events Requiring Immediate Reporting ...........................................73
6.4.3.1
Overdose ...................................................................................73
6.4.3.2
Pregnancy..................................................................................74
6.4.3.3
Events Meeting Study Stopping Criteria ..................................74
6.5
Safety Management During the Study................................................................74


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
5 of 113
7
STATISTICAL CONSIDERATIONS..........................................................................75
7.1
General Considerations.......................................................................................75
7.2
Analysis Populations...........................................................................................75
7.3
Endpoints ............................................................................................................76
7.3.1Primary Endpoints ......................................................................................76
7.3.1.1
Primary Safety Endpoint...........................................................76
7.3.1.2
Primary Efficacy Endpoint .......................................................76
7.3.2Secondary Endpoints ..................................................................................77
7.3.2.1
Safety and Tolerability of MEDI-573 in Phase 2 .....................77
7.3.2.2
Pharmacokinetic Endpoint........................................................77
7.3.2.3
Pharmacodynamic Endpoints....................................................77
7.3.2.4
Immunogenicity of MEDI-573 .................................................77
7.3.2.5
Secondary Efficacy Endpoints..................................................78
7.3.3Exploratory Endpoints................................................................................79
7.4
Planned Analysis.................................................................................................79
7.5
Sample Size and Power Calculations..................................................................79
8
DIRECT ACCESS TO SOURCE DOCUMENTS .......................................................80
9
QUALITY CONTROL AND QUALITY ASSURANCE............................................80
9.1
Data Collection ...................................................................................................80
9.2
Study Monitoring................................................................................................81
9.3
Audit and Inspection of the Study ......................................................................81
10
ETHICS.........................................................................................................................82
10.1
Regulatory Considerations..................................................................................82
10.2
Institutional Review Board or Independent Ethics Committee ..........................83
10.3
Informed Consent ...............................................................................................83
10.4
Withdrawal of Consent for Continued Study Participation................................84
11
DATA HANDLING AND RECORD KEEPING.........................................................85
12
FINANCING AND INSURANCE ...............................................................................85
13
PUBLICATION POLICY.............................................................................................86
14
REFERENCES..............................................................................................................86
15
SUMMARY OF PROTOCOL AMENDMENTS AND ADMINISTRATIVE 
CHANGES TO THE PROTOCOL .......................................................................92
LIST OF IN-TEXT TABLES
Table 4.5.3.1-1
Summary of Dose Cohorts...................................................................33
Table 4.5.8-1
MEDI-573 Dose Delays or Discontinuation for Toxicity....................38


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
6 of 113
Table 5.1-1
Schedule of Subject Evaluations: Screening and Treatment Periods -
All Subjects Unless Otherwise Specified (not applicable for subjects 
continuing on treatment under Amendment 3) ....................................42
Table 5.1-2
Schedule of Subject Evaluations: Screening and Treatment (Subjects 
continuing treatment under Amendment 3 only).................................45
Table 5.1-3
Schedule of Study Procedures: Follow-up Period- All Subjects Unless 
Otherwise Specified (not applicable for subjects continuing on 
treatment under Amendment 3) ...........................................................48
Table 5.1-4
Schedule of Study Procedures: Follow-up Period (Subjects continuing 
treatment under Amendment 3 only)...................................................50
Table 5.2.6.1-1
Evaluation of Overall Response...........................................................66
LIST OF IN-TEXT FIGURES
Figure 3.1.2-1
Study Flow Diagram............................................................................23
LIST OF APPENDICES
Appendix 1
Signatures...........................................................................................100
Appendix 2
Karnofsky Performance Status Scale.................................................103
Appendix 3
Aromatase Inhibitor Subject Diary....................................................104
Appendix 4
New York Heart Association Cardiac Performance Status Assessment 
Function Scale....................................................................................106
Appendix 5
National Cancer Institute Common Terminology Criteria for Adverse 
Events Version 4.0 (NCI CTCAE V4.0) ...........................................107
Appendix 6
Brief Pain Inventory - Short Form.....................................................108
Appendix 7
.............................................................................110
Appendix 8
.........................................................................112


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
7 of 113
List of Abbreviations
Abbreviation or 
Specialized Term
Definition
ADA
antidrug antibody
AE
adverse event
AI
aromatase inhibitor
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC
area under the concentration-time curve
KhCG
beta human chorionic gonadotropin
Cmax
maximum observed concentration
CNS
central nervous system
CR
complete response
CRF
case report form
CT
computed tomography
CTC
circulating tumor cell
CXR
chest x-ray
DLT
dose-limiting toxicity
DMC
data monitoring committee
DR
duration of response
ECG
electrocardiogram
ECOG
Eastern Cooperative Oncology Group
 
ER
estrogen receptor
EU
European Union
FDA
Food and Drug Administration
FISH
fluorescence in situ hybridization
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
GLP
Good Laboratory Practice
Hb
hemoglobin
HbA1c
hemoglobin A1c
HEENT
head, eyes, ears, nose, and throat
HIPAA
Health Insurance Portability and Accountability Act
HER-2
human epidermal growth factor receptor 2
HR
hormone receptor
HR+
hormone receptor positive
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IGF
insulin-like growth factor
IGF-I
insulin-like growth factor I
IGF-II
insulin-like growth factor II


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
8 of 113
Abbreviation or 
Specialized Term
Definition
IGF-1R
insulin-like growth factor 1 receptor
IGF-2R
insulin-like growth factor 2 receptor
IM
immunogenicity
IR
insulin receptor
IR-A
insulin receptor isoform A
IR-B
insulin receptor isoform B
IRB
Institutional Review Board
IRS
insulin receptor substrate
IV
intravenous
IXRS
interactive web or voice response system
KLH
Keyhole Limpet Hemocyanin
KPS
Karnofsky Performance Status
MAb
monoclonal antibody
MBC
metastatic breast cancer
MedDRA
Medical Dictionary for Regulatory Activities
MEDI
MedImmune
MEDI-573
human immunoglobulin G2 lambda MAb directed against human IGF-I and 
IGF-II
MRI
magnetic resonance imaging
MTD
maximum tolerated dose
NCI CTCAE
National Cancer Institute Common Terminology Criteria for Adverse Events
OR
objective response
ORR
objective response rate
OS
overall survival
PD
progressive disease
PFS
progression-free survival
PgR
progesterone receptor
PgR+
progesterone receptor positive
PK
pharmacokinetics
PR
partial response
PRO
patient-reported outcome
Q3W
once every 3 weeks
RECIST
Response Evaluation Criteria In Solid Tumors
RT-PCR
reverse transcriptase polymerase chain reaction
SAE
serious adverse event
SD
stable disease
SID
subject identification
SMC
Safety Monitoring Committee
TTP
time to progression
ULN
upper limit of normal
VEGF
vascular endothelial growth factor


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
9 of 113
Study Abstract
TITLE
A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI 
Alone in Women with Metastatic Breast Cancer (MBC)
OBJECTIVES
Primary Objective
Phase 1b (Dose-evaluation Phase)
The primary objective of the dose-evaluation phase is to evaluate the safety and tolerability of 3 dose levels of 
MEDI-573 in combination with an AI in subjects with hormone receptor positive (HR+), human epidermal 
growth factor receptor 2 (HER2)-negative MBC.
Phase 2 (Randomization Phase)
The primary objective of the randomization phase is to evaluate the progression-free survival (PFS) of 
subjects with HR+, HER2-negative MBC treated with MEDI-573 and an AI versus treatment with an AI 
alone. 
Secondary Objectives 
•
To describe the safety and tolerability of MEDI-573 when used in combination with an AI
•
To evaluate the anti-tumor activity of MEDI-573 when used in combination with an AI versus treatment 
with an AI alone
•
To evaluate overall survival (OS) in subjects treated with MEDI-573 when used in combination with an 
AI versus treatment with an AI alone
•
To describe the pharmacokinetics (PK) of MEDI-573 when used in combination with an AI
•
To evaluate the pharmacodynamics of MEDI-573 when used in combination with an AI on circulating 
levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II)
•
To evaluate the immunogenicity (IM) of MEDI-573 when used in combination with an AI
Exploratory Objectives
•
 
.
•
 
STUDY DESIGN  
This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and 
pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. 
This study has 2 phases: a dose-evaluation phase (Phase 1b) and a randomization phase (Phase 2).
Phase 1b (Dose-evaluation Phase)
In the Phase 1b portion of the study, 3 cohorts (Cohorts A, B, and C) will be examined. In Cohorts A, B, and 
C, 3 to 6 evaluable subjects will receive 
 or 
MEDI-573, respectively, by IV infusion on Day 1 
of each 21-day cycle. Subjects in each of the 3 cohorts will also be given an AI of the investigator’s choice 
(letrozole, anastrozole, or exemestane) orally once daily. Subjects will be treated until unacceptable toxicity, 
documentation of disease progression, or subject withdrawal for other reasons. Eligible subjects are 
considered evaluable if they receive 1 full cycle of MEDI-573 and are followed for safety through the dose-
limiting toxicity (DLT) evaluation period (defined as 21 days following the first dose of MEDI-573) or if the 
subject experiences a DLT. Enrollment into Cohorts A, B, and C will be initiated sequentially. Approximately 
9-18 evaluable subjects will be required for the Phase 1b portion of this study. Nonevaluable subjects will be 
replaced in the same dose cohort. Up to 20 investigational sites in North America may participate in the Phase 
1b portion of the study.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
CONFIDENTIAL AND PROPRIETARY
10 of 113
Phase 2 (Randomization Phase)
Following evaluation of the safety of MEDI-573 at the 45 mg/kg dose level in combination with an AI, 
approximately 178 subjects with HR+, HER2-negative MBC will be randomized into the Phase 2 portion of 
the study in a 1:1 ratio to receive MEDI-573 at 45 mg/kg and an AI (Arm 1) or an AI alone (Arm 2). A limit 
of approximately 30 subjects with metastases to bone-only will be randomized to reflect the proportion of 
subjects with bone-only metastases in the target population. MEDI-573 will be administered via IV infusion 
on Day 1 of each 21-day cycle. An AI of the investigator’s choice will be given orally once daily. Subjects 
will be treated until unacceptable toxicity, documentation of disease progression, or other reasons for subject 
withdrawal. Approximately 100 investigational sites worldwide will participate in the Phase 2 portion of the 
study. 
Randomization will be stratified by geographic region (North America vs rest of world) and AI type 
(letrozole, anastrozole, or exemestane). All subjects will be followed every 9 weeks (three 21-day cycles) until 
disease progression and then followed for survival every 3 months until the end of the study (up to 36 months 
from the date the last subject is entered into the trial or when the sponsor stops the study). As of 10Jul2016, 
this milestone will have been met. All follow-up for any subjects that have discontinued treatment by 
10Jul2016 (whether or not they have progressed), will end, as per the original protocol. However, as of 
Amendment 3, subjects still on treatment at that time will be allowed to continue treatment until they meet one 
of the criteria for treatment discontinuation. The end of the study will therefore be when the last subject still 
on treatment as of 10Jul2016 finishes the 60-day (+/- 3 days) safety follow-up following treatment 
discontinuation.
SUBJECT POPULATION
Adult (age P 18 years [P 20 years for subjects enrolled in Japan]) postmenopausal females with HR+, HER2-
negative MBC
TREATMENT
Phase 1b (Dose-evaluation Phase)
In Phase 1b, all subjects will be treated with MEDI-573 at doses of 10 mg/kg (as a 60-minute IV infusion
[+ 20 minutes for potential overfill]), 30 mg/kg, or 45 mg/kg (as a 90-minute IV infusion [+ 20 minutes for 
potential overfill]) on Day 1 of each 21-day cycle in combination with an AI of the investigator’s choice orally 
once daily. Subjects will be treated until unacceptable toxicity, documentation of disease progression, or other 
reasons for subject withdrawal. 
Phase 2 (Randomization Phase)
Following Phase 1b, approximately 178 subjects with MBC will be randomly assigned in a 1:1 ratio in Phase 
2 to receive 1 of the following regimens, depending on treatment assignment:
Arm 1: MEDI-573 45 mg/kg IV infusion on Day 1 of each 21-day cycle plus an AI (investigator’s choice) 
orally once daily
Arm 2: AI (investigator’s choice) orally once daily
Subjects will be treated with the assigned regimen until documentation of progressive disease, initiation of 
alternative anticancer therapy, unacceptable toxicity, or another reason for treatment discontinuation is 
observed.
ASSESSMENT OF ENDPOINTS
Primary Endpoints
Phase 1b (Dose-evaluation Phase)
The primary endpoints for safety are the number of subjects with a DLT as well as the adverse events (AEs)
and serious adverse events (SAEs) occurring during the protocol-specified period. The number and percentage 
of subjects with DLT in the Evaluable Population for Phase 1b will be summarized. Adverse events, 
treatment-related AEs and SAEs will be summarized by system organ class and Medical Dictionary for 
Regulatory Activities preferred term, severity, and relationship to investigational product. Safety analysis will 
be descriptive in nature and no formal statistical comparison will be made. 
Phase 2 (Randomization Phase)
The primary endpoint is PFS, measured from randomization until the documentation of disease progression 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
11 of 113
(according to Response Evaluation Criteria in Solid Tumors, Version 1.1) or death due to any cause, 
whichever occurs first.
Progression-free survival will be evaluated using the Kaplan-Meier method and comparisons among the 
treatment groups will be performed using a log-rank test. Progression-free survival will be summarized based 
on the Intent-to-Treat Population in the Randomization Phase of the study as the primary analysis. Several 
sensitivity analyses may be conducted based on different analysis populations, tumor response determined by 
different reviewers, different methods of handling missing data, or other statistical analysis methods. The 
details of the sensitivity analyses will be described in the statistical analysis plan. 
Secondary Endpoints
Efficacy 
Endpoints include objective response rate, time to response, duration of response, time to progression, OS, and 
change in tumor size. Response Evaluation Criteria in Solid Tumors (version 1.1) guidelines will be used to 
evaluate tumor response. The time to event data, including time to response, duration of response, time to 
progression, and OS, will be evaluated using Kaplan-Meier methods. The objective response rate and the 
change in tumor size will be analyzed using appropriate statistical methods.
Safety 
The safety endpoints include AEs, SAEs, and changes in clinical laboratory evaluations from baseline. Safety 
analysis will be descriptive in nature and no formal statistical comparison will be made.
Other 
MEDI-573 PK: Individual MEDI-573 concentrations will be tabulated by dose cohort along with descriptive 
statistics. Noncompartmental PK data analysis will be performed for data obtained from each dose cohort with 
scheduled PK sample collection. Descriptive statistics will be used to assess noncompartmental PK parameters 
(area under the concentration-time curve, maximum observed concentration, systemic clearance, and 
concentration half-life).
MEDI-573 pharmacodynamics: Circulating IGF-I and IGF-II levels will be summarized by dose cohort and 
summarized using descriptive statistics. The time-course of circulating IGF will be graphed based on dose 
group.
MEDI-573 IM: Analysis of IM results will be assessed by summarizing the number and percentage of subjects 
who develop detectable anti-MEDI-573 antibodies for all subjects entered in Phase 1b and Phase 2 (Arm 1). 
The impact of anti-MEDI-573 antibodies on PK will be assessed.
Exploratory Endpoints
The variables to be included in the exploratory analyses may include:
•
Evaluation of biomarkers related to MEDI-573 treatment
•
Evaluation of patient-reported outcomes 
Descriptive statistics will be used to describe the exploratory analyses. Depending on the nature of the data, 
geometric mean and other appropriate statistical summaries might be used as well.
PLANNED ANALYSIS
Two formal analyses are planned for the study. The primary analysis of PFS and safety will be performed 
after 122 PFS events have occurred. The final analysis of OS and safety will be performed at the end of study.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
12 of 113
SAMPLE SIZE AND POWER CALCULATIONS   
In the Phase 1b portion of the study, a minimum of 9 evaluable subjects (3 subjects each for the MEDI-573 
dose of 
 and 
mg/kg) will be required to determine the safety and tolerability of 3 dose levels of 
MEDI-573 in combination with an AI. Up to 18 evaluable subjects (6 subjects each at 
mg/kg and 
 
mg/kg doses) may be needed if a DLT occurs. A subject will be considered evaluable if the subject receives 1 
full cycle of MEDI-573 and is followed for safety through the DLT evaluation period (defined as 21 days 
following the first dose of MEDI-573) or if the subject experiences a DLT. Any nonevaluable subject will be 
replaced.
In the Phase 2 portion of the study, the primary objective is to compare PFS among subjects treated with 
mg/kg MEDI-573 when co-administered with an AI. The assumed median PFS for subjects with single-
agent AI alone is 9.4 months (Mouridsen et al, 2001), and the expected median PFS for subjects receiving the 
mg/kg dose of MEDI-573 plus an AI is 13.4 months, which represents an improvement in PFS of 42.6% 
and corresponds to a hazard ratio of 0.7. Based on these assumptions, a total of 122 events (ie, subjects with 
disease progression or death) are required to provide 75% power for the log-rank test at a 2-sided significance 
level of 0.2. With a planned accrual period of 12 months and a minimum follow-up period of 14 months, it is 
estimated that a total of approximately 178 subjects are needed to observe 122 PFS events by the end of the 
minimum follow-up period.  The primary analysis (log-rank test) will be performed after 122 PFS events have 
occurred.  If the expected median PFS in MEDI-573 arm is 13.8 or 14.4 months (corresponding to hazard ratio
of 0.68 or 0.653), the power will change to 80% or 85%, respectively, with 122 PFS events.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
13 of 113
1
INTRODUCTION
1.1
Disease Background
Breast cancer represents a heterogeneous group of diseases with distinct biological features 
and clinical course, and the optimal management requires an individual strategy on the basis 
of tumor biology. Metastatic breast cancer (MBC) provides one of the greatest treatment 
challenges as the optimal approach to treatment is evolving, and also because development of 
drug resistance can render available options ineffective. The incidence of MBC appears to be 
decreasing and patients with MBC are living longer (Martin et al, 2006; Chia et al, 2007; 
Jemal et al, 2010). These observations seem to be linked to the introduction of agents, such 
as the third-generation aromatase inhibitors (AI) and targeted therapies, and to a 
lesser extent, to improvements in palliative care, cancer prevention, and screening techniques 
(Chia et al, 2007). Despite these advances, most women with MBC have a limited survival 
time of 18-24 months, and only 20% of them will be alive 5 years after the initial diagnosis 
of distant metastasis has been made (Gligorov and Lotz, 2008; Gueth et al, 2009). Since 
treatment of metastatic disease is not likely to be curative, the main goals are to prolong 
progression-free survival (PFS) and overall survival (OS), reduce disease symptoms, and 
achieve the best possible quality of life for the patient (Smith, 2006).
Approximately two-thirds of breast cancer patients have hormone receptor-positive (HR+) 
tumors. Endocrine manipulation is the cornerstone of therapy in HR+ tumors. Tamoxifen was
for many years the most widely used first-line hormonal therapy for postmenopausal patients 
with hormone-sensitive advanced or MBC. Aromatase inhibitors, which have shown superior 
efficacy in advanced disease compared with tamoxifen, have now largely replaced tamoxifen 
as first-line therapy in postmenopausal women (Gibson et al, 2007). Their long-term 
efficacy, however, is limited by relapse of disease and development of resistance following 
adjuvant endocrine therapy. Despite documented levels of estrogen receptor (ER) at relapse 
in either locally recurrent or secondary metastatic tumors, up to 50% of patients with 
HR+/ER-positive (ER+) primary breast cancer who develop metastatic disease do not 
respond to first-line endocrine treatment (de novo resistance), and the remainder will 
eventually relapse despite an initial response (acquired resistance) (Ring and Dowsett, 2004). 
Several preclinical models have been proposed to explain the mechanisms of hormone 
resistance, including estrogen hypersensitivity and aberrant growth signaling pathways. A 
greater understanding of the biology of resistance may aid to define regimens combining AIs 
and novel targeted agents to enhance the efficacy of ER+ breast cancer treatment.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
14 of 113
1.1.1
Insulin-like Growth Factor Signaling / Insulin Receptor Isoform A
Insulin-like growth factors (IGFs), IGF-I and IGF-II, are small polypeptides involved in 
regulating cell proliferation, survival, differentiation and transformation. Both ligands 
are expressed ubiquitously and act as endocrine, paracrine, and autocrine growth factors 
(Pollak, 2008; De Meyts, 2004; Tao et al, 2007; Ryan and Goss, 2008). Insulin-like growth 
factor I and IGF-II exert their various actions through binding to the IGF-I receptor tyrosine 
kinase (IGF-1R) and insulin receptor isoform A (IR-A) activating multiple intracellular 
signaling cascades, including the insulin receptor substrate (IRS) proteins, Akt, 
and mitogen-activated protein kinase pathways (Sciacca et al, 1999; Chitnis et al, 2008; 
Belfiore et al, 2009; Baserga, 2009). Both IR-A and IGF-1R are involved in IGF signaling 
and play significant roles in cancer development and progression (Frasca et al, 2008).The 
overexpression of IR-A and IGF-II has also been proposed as a potential mechanism that 
may lead to the resistance to IGF-1R-directed therapies (Hendrickson and Haluska, 2009; 
Zhang et al, 2007).
Numerous preclinical studies have reported that down regulation of IGF-1R expression 
or inhibition of signaling leads to the inhibition of tumor growth, both in vitro and in vivo 
(Ryan and Goss, 2008; Sachdev and Yee, 2007; Baserga, 2005). Inhibition of IGF 
signaling has also been shown to increase the susceptibility of tumor cells to 
chemotherapeutic agents in vivo (Tao et al, 2007; Chitnis et al, 2008; Ryan and Goss, 2008; 
Yuen and Macaulay, 2008). Dual inhibition of both the IR-A and IGF-1R receptors may 
enhance therapeutic efficacy against IGF-driven cancers (Sachdev and Yee, 2007).
1.2
Description of MEDI-573
MEDI-573 is briefly described below. Refer to the current Investigator’s Brochure for 
details.
1.2.1
Product Derivation
MEDI-573 is a human immunoglobulin G2 lambda monoclonal antibody (MAb) generated 
with Xenomouse® technology that selectively binds to human IGF-I and IGF-II. The 
antibody was isolated from mice immunized alternately with soluble recombinant human 
IGF-II (hIGF-II) and hIGF-I coupled to keyhole limpet hemocyanin (KLH).
1.2.2
Summary of Nonclinical Experience with MEDI-573
MEDI-573 inhibited both IGF-I- and IGF-II-stimulated phosphorylation of IGF-1R and 
downstream signaling proteins including protein kinase B (Akt) and mitogen-activated 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
15 of 113
protein kinase in a number of engineered NIH3T3 and human tumor cell lines. Further, 
MEDI-573 inhibited autocrine phosphorylation of these signaling molecules. Functionally, 
MEDI-573 effectively inhibited the growth of a number of engineered NIH3T3 and human 
tumor cell lines. In vivo, MEDI-573 significantly inhibited the growth of implanted Clone 32 
and P12 tumors, which overexpress human IGF-1R and either human IGF-II or IGF-I, 
respectively.
Using mRNA expression profiles, ER+ breast cancers can be further classified by 
hierarchical cluster analysis into luminal-A and luminal-B subtypes. Luminal-A cancers are 
histologically low grade and sensitive to neoadjuvant endocrine therapy. In contrast, 
luminal-B cancers are often high grade, less sensitive to neoadjuvant endocrine therapy, and 
have more cancer proliferation markers and poorer prognosis. In the MedImmune mRNA 
expression studies in ER+, progesterone receptor-positive (PgR+) and human epidermal 
growth factor receptor 2 (HER2)-negative primary tumor tissues, a positive correlation was 
found between mRNA ratios of IR-A and IR-B (insulin receptor isoform B) and the 
expression of multiple proliferation genes, as well as a more prominent IR-A:IR-B 
expression differential (UCt) in luminal-B breast cancers classified according to 
conventional methods. Therefore, these findings support the assertion that the significant 
increase of IR-A: IR-B ratio in patients with luminal-B tumors may be related to the high rate 
of tumor cell proliferation and poor prognosis observed in patients with this tumor subtype. 
The association of increased IR-A:IR-B ratio with the luminal-B subtype suggests the 
luminal-B patients could benefit more by co-targeting IGF-1R and IR-A therapy and it 
emphasizes the potential importance of targeting IR-A in this subgroup.
Based on the results of a single dose, non-Good Laboratory Practice (GLP), intravenous (IV)
infusion, toxicity, pharmacokinetics (PK), and pharmacodynamics study in cynomolgus 
monkeys (the relevant toxicology species) with MEDI-573 at doses of 
g, 
MEDI-573 was well tolerated and there was no evidence of test article-related local or 
systemic toxicity. MEDI-573 at doses of 
, administered once weekly for a 
total of 13 doses showed no evidence of test article-related local or systemic toxicity in a 
GLP, 13-week, repeat dose, 30-minute continuous IV infusion, toxicity study in cynomolgus 
monkeys. There were no test article-related effects on behavior or on heart rate, respiration 
rate, body temperature, blood pressure, or electrocardiography measurements taken in 
anesthetized monkeys. In the GLP tissue cross-reactivity study, no tissue cross-reactivity was 
observed in the brain, heart, or lung of the human or cynomolgus monkey tissues examined. 
There were no clinical observations of adverse findings at the injection site. There were also 
no macroscopic or microscopic observations of adverse findings at the injection site 7 days 
after the final dose. In summary, MEDI-573 was well tolerated in cynomolgus monkeys 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
16 of 113
following administration of up to 13 once-weekly doses, by 30-minute continuous IV 
infusion; the no observed adverse effect level was 
, the highest dose tested, which 
resulted in a dose-normalized area under the concentration-time curve (AUC/dose) of 
 
 
 
 
.
1.2.3
Clinical Experience with MEDI-573
The first clinical study of MEDI-573 in humans (Study MI-CP184) was designed as a 
Phase 1, multicenter, open-label, single-arm, dose-escalation and dose-expansion study to 
evaluate the safety, tolerability, maximum tolerated dose (MTD), and optimal biologically 
effective dose of MEDI-573 in adult subjects with advanced solid tumors refractory to 
standard therapy or for which no standard therapy exists. Secondary objectives include PK, 
pharmacodynamics, immunogenicity (IM), and antitumor activity. MEDI-573 has been 
administered at doses of 0.5, 1.5, 5, 10 or 15 mg/kg given once every 7 days and at a dose of 
30 or 45 mg/kg once every 21 days.
A total of 43 patients, including 23 in the dose-escalation phase and 20 in the dose-expansion 
phase with urothelial (bladder) cancer, received MEDI-573. The MTD was not reached after 
enrolling patients through the highest dose level on the weekly (15 mg/kg) or every 3 week 
(45 mg/kg) schedules. No dose-limiting toxicities (DLTs) (P Grade 3 adverse event (AE)
during the first cycle) were observed at any dose level. Overall, the most common AEs were 
decreased appetite (46.5%), fatigue (41.9%), nausea (32.6%), diarrhea (25.6%), vomiting 
(23.3%), and abdominal pain (20.9%). The most common treatment-related AEs were fatigue 
(27.9%), decreased appetite (23.2%), nausea (18.6%), diarrhea (16.3%), and anemia (11.6%). 
Of all the treatment-related AEs, most were Y Grade 2, with 1 report each of Grade P 3 
fatigue and hypoglycemia. Overall, 34 serious adverse events (SAEs) occurred in 
17 subjects; 1 subject treated with 15.0 mg/kg experienced 2 treatment-related SAEs. Five of 
43 patients (11.6%) in the dose-escalation phase and 1 of 20 patients (5.0%) in the dose-
expansion phase discontinued treatment because of AEs. Three deaths occurred during the 
study, all because of progressive disease and none considered related to MEDI-573 
treatment. Clinically, significant changes in serum glucose related to study treatment were 
rare, observed in 1 of 43 patients. No clinically significant changes to insulin or somatotropin 
levels, to hematologic parameters, or in ECGs were observed.
Following the first dose in Study CP184, MEDI-573 exhibited nonlinear PK. Serum exposure 
of free MEDI-573 increased more than dose-proportionally from 0.5 m/kg to 1.5 mg/kg. 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
17 of 113
After weekly and once every 3 weeks (Q3W) repeated doses, serum trough concentration 
increased with each dose and reached steady state in approximately 3-4 weeks. Free IGF-I 
and free IGF-II concentrations in plasma were fully suppressed following administration of 
MEDI-573. At doses above 5 mg/kg weekly and 30 or 45 mg/kg Q3W, MEDI-573 produced 
sustained suppression of both IGF-I and IGF-II throughout the dosing interval. None of the 
subjects in Study CP184 tested positive for antidrug antibodies (ADA) against MEDI-573 
throughout the study.
 
 
 
 
-573 Q3W dose cohort tested borderline-positive for ADA with titer of Y 1:39 
on Study Day 273 and 294. Serum exposure of free MEDI-573 in this ADA positive subject 
was slightly lower compared to others in the same cohort, suggesting a possible impact of 
ADA on MEDI-573 PK. No suppression of free IGF-I and IGF-II in plasma was observed in 
AI alone cohort. Following IV administration of MEDI-573 at 
in 
combination of an AI, free IGF-II in plasma was fully suppressed through all dosing 
intervals, except 1 subject in 
 dose cohort with detectable free IGF-II from Day 273 
through Day 399 and other 3 subjects in the same cohort with a detectable free IGF-II at a 
single time-point. Free IGF-I was not fully suppressed at the 2 low dose levels of 
 
. At the high dose level of 
, free IGF-I in plasma was fully 
suppressed in 66 subjects (79%).
Between June 2011 and June 2013, a total of 185 patients (safety population) were enrolled 
into Study CD-ON-MEDI-573-1030. The Phase 1b portion of the study treated a total of 
9 subjects, 3 subjects each received MEDI-573 at 
 in combination with an
AI. In Phase 2, a total of 176 patients were enrolled in the intent-to-treat population, with 
90 subjects receiving MEDI-573 and AI and 86 subjects receiving AI-only.  
One hundred and four (104) total progression events (radiologic progression and/or death), 
55 (61%) in the MEDI-573 and AI arm, and 49 (60%) in the AI-only arm, had occurred by 
data cut-off for this analysis (15Oct2014). A median (PFS) of 12.6 months was observed in 
the MEDI573 and AI cohort compared with 11.0 months in the AI-only cohort.  The adjusted 
HR (stratified for Region and AI Type) was 0.95 (95% CI: 0.642, 1.408; P = 0.795). 
The objective response rate (ORR) for patients with measurable disease was 25.6 % (n = 23) 
for MEDI-573 and AI vs. 25.6 % (n = 22) for AI-only. The overall survival data were not 
mature at this time.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
18 of 113
No DLTs were observed in the Phase 1b portion of the study.  The most common AEs in 
patients who received MEDI-573 and AI were fatigue (47%), nausea (38%), arthralgia 
(31%), and back pain (30%), whereas the most common AEs in patients in the AI-alone arm 
were arthralgia (38%), hot flashes (34%), nausea (31%), and fatigue (30%).
Patients who received MEDI-573 and AI experienced a higher incidence of P Grade 3 AEs 
(n = 36 [36%] vs. n = 28 [32.6%]), serious AEs [SAEs] (n = 23 [23%] vs. n = 13 [15%]) and 
AEs leading to discontinuation of MEDI-573 and AI (n = 10 [10%] vs. n = 4 [4.7%]) 
compared with patients who received AI-only. The most common SAE in the MEDI-573 and 
AI arm was vomiting, reported by three (3%) patients. None led to discontinuation and all 
three patients recovered. All other SAEs in the MEDI-573 and AI arm were reported by no 
more than one patient. SAEs of supraventricular tachycardia and pleural effusion were 
reported by 2 patients each in the AI-only arm and remainder of the SAEs were reported by 
no more than 1 patient. There were 18 (18%) deaths reported in the MEDI-573 and AI arm 
and 18 (21%) deaths in the AI-alone arm. Majority of the deaths were due to disease 
progression (16 of 18 [89%] deaths in the MEDI-573 and AI arm and 17/18 (94%) deaths in 
the AI-only arm) and none of the deaths were attributable to study treatment in either arm.
Refer to the Investigator’s Brochure for further details.
1.3
Research Hypothesis
This study has 2 phases: a dose-evaluation phase (Phase 1b) and a randomization phase 
(Phase 2). The primary objective of the dose-evaluation phase is to evaluate the safety and 
tolerability of 3 doses of MEDI-573 in combination with an AI in subjects with HR+, 
HER2-negative MBC. The primary objective of the randomization phase is to evaluate the 
PFS of subjects with HR+, HER2-negative MBC treated with MEDI-573 and an AI versus 
treatment with an AI alone. Secondary objectives of the study include MEDI-573 safety and 
tolerability, antitumor activity, PK/pharmacodynamics, and IM.
The research hypothesis is that MEDI-573 will be able to be safely administered in 
combination with an AI and that MEDI-573 administered in combination with an AI will 
result in improved PFS in subjects with HR+, HER2-negative MBC compared to AI 
treatment alone.
1.4
Rationale for Study Conduct
Aberrant estrogen-receptor expression/functioning has been implicated in the development of 
over 70% of breast cancers (Riemsma et al, 2010). Many of these cancers respond to 
hormonal therapy, but a large number will ultimately develop resistance with long-term 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
19 of 113
treatment. There is evidence that peptide growth factors and their downstream effectors may 
interact with ER signaling to influence the sensitivity of breast cancer cells to endocrine 
therapy, and thus may be important targets for novel treatments (Leary and Dowsett, 2006; 
Johnston, 2010). Combining the most effective estrogen-deprivation therapies, including 
third-generation AIs, with new therapies that target estrogen-independent signaling pathways 
may increase the efficacy of breast cancer treatment. Expression of ER and associated genes 
characterizes the luminal breast cancers with luminal B having worse outcomes than luminal 
A. The association of increased IR-A:IR-B ratio with the luminal-B subtype suggests a 
rationale for targeting IR-A and suggests that these patients may benefit from treatment that 
targets both IGF-1R and IR-A. As the distinction between luminal A and luminal B tumors is 
somewhat difficult to achieve, Cheang et al have suggested that the Ki-67 index, which is a 
widely applicable, easily assessed marker of cell proliferation, can be used to identify the 
luminal B breast cancer subtype (Cheang et al, 2009).
1.5
Benefit-risk and Ethical Assessment
MEDI-573 has been shown to inhibit tumor growth in a wide range of human cancer models 
as a single agent. Nonclinical studies suggest that MEDI-573 has the potential to achieve 
broad anti-tumor efficacy owing to its ability to inhibit both IGF-1R and IR-A pathways. 
Furthermore, MEDI-573 has potential to achieve this without perturbing glucose 
homeostasis, which has been an endocrine liability of other investigational agents that target 
IGF-1R (Gao et al, 2011). In nonclinical safety studies, MEDI-573 was well tolerated with 
no evidence of test-article related toxicity. In all trials testing MEDI-573 to date, the AEs 
observed were consistent with the underlying diseases and associated therapies in the study 
populations, with the most common AEs being decreased appetite, fatigue, and 
gastrointestinal events such as nausea and diarrhea. No DLTs have been observed to date. 
Across the ongoing clinical studies, 3 subjects to date have experienced increased liver 
function test results that led to discontinuation of MEDI-573, with 1 subject experiencing 
increased ALT and increased AST considered to be related to MEDI-573.
Three major classes of therapeutic compounds that target the IGF axis are currently in 
development: (1) small molecule tyrosine kinase inhibitors (TKIs) that inhibit kinase 
activities of IGF-1R and IR, (2) antibodies that target IGF-1R, and (3) antibodies that target 
IGF ligands. Due to the high degree of homology among the kinase domains, the majority of 
IGF-1R-targeting TKIs inhibit not only IGF-1R but also IR-A and IR-B, thus impairing
glucose homeostasis and contributing to the transient hyperglycemia observed in clinical 
trials (Weroha and Haluska, 2008). Antibodies that target IGF-1R inhibit the binding of 
IGF to IGF-1R and are furthest along in clinical development. Many of these MAbs induce 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
20 of 113
IGF-1R internalization and degradation upon binding to the receptor. Although they do not 
bind to IR-A or IR-B, many of these MAbs partially modulate the activity of IGF-1R/IR-A or 
IGF-1R/IR-B hybrid receptors, which may contribute to the transient, treatment-related 
hyperglycemia observed in as many as 10-20% of subjects (Atzori et al, 2008). Although 
typically mild in nature, hyperglycemia has occasionally been dose-limiting and has
resulted in Grade 3-4 adverse events in various studies (Atzori et al, 2009; Gualberto and 
Pollak, 2009, Weroha and Haluska, 2008). 
If toxicities reported in studies of other investigational agents (mAbs as well as small 
molecules) that target the IGF axis are based on activity against IGF-1R, it is possible that 
hyperglycemia, anorexia, nausea, diarrhea, weight loss, elevated transaminases, 
anemia, thrombocytopenia, pruritus, rash, arthralgia, paresthesia, fatigue, autoantibody 
production, and infusion reactions might occur on Study CD-ON-MEDI-573-1030
(Weroha and Haluska, 2008). Based on published literature with similar therapies (ie, MAbs
targeting the IGF signaling pathway), observed AEs were generally mild (Grade 1 or 2) and 
included hyperglycemia, gastrointestinal disturbances, hypersensitivity reactions, pruritus, 
asthenia, and anemia (Haluska et al, 2007; Atzori et al, 2008). Other toxicities included
Grade 3/4 thrombocytopenia (Tolcher et al, 2008; Hidalgo et al, 2008), Grade 3
hyperglycemia (Higano et al, 2007), Grade 3 purpura (Atzori et al, 2008), Grade 4 uric acid
increase, and Grade 3 bilateral deep venous thrombosis (Olmos et al, 2008).
Limited data have been published from breast cancer studies testing MAbs that target the IGF 
axis in combination with AIs. The largest study published to date randomized 
156 postmenopausal women with HR+, metastatic or locally advanced breast cancer to 
AMG 479 (ganitumab) an IGF-1R targeting MAb plus exemestane or fulvestrant versus 
exemestane or fulvestrant alone. No unanticipated safety findings or improvement 
in PFS were reported for the combination of AMG 479 plus exemestane or fulvestrant versus 
exemestane or fulvestrant alone (Kaufman et al, 2010). Three other studies are currently 
testing IGF-targeting MAbs together with 1 of several different AIs (including anastrazole, 
letrozole, and/or exemestane) in the second-line breast cancer setting.
The proposed Phase 1b/2 study will characterize the safety and tolerability of MEDI-573, as 
well as evaluate the anti-tumor activity of MEDI-573 in combination with an AI, an 
approved treatment for patients with HR+ MBC, with the goal of more fully elucidating the 
benefit-risk profile of the combination. The proposed exclusion criteria, safety monitoring, 
starting dose, dose-escalation scheme, and stopping criteria are designed to minimize the 
potential risks for subjects participating in this clinical trial. Subjects will be carefully 
monitored for abnormal liver function test results given that elevated LFT results have led to 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
21 of 113
treatment discontinuation across the MEDI-573 studies. Based on the tolerability of 
MEDI-573, the benefit-risk profile is considered acceptable for the proposed clinical study.
2
STUDY OBJECTIVES
2.1
Primary Objective
The primary objective of the dose-evaluation phase (Phase 1b) of this study is to evaluate the 
safety and tolerability of 3 dose levels of MEDI-573 in combination with an AI in subjects 
with HR+, HER2-negative MBC.
The primary objective of the randomization phase (Phase 2) of this study is to evaluate the 
PFS of subjects with HR+, HER2-negative MBC treated with MEDI-573 and an AI versus 
treatment with an AI alone. 
2.2
Secondary Objectives
The secondary objectives of this study are:
•
To describe the safety and tolerability of MEDI-573 when used in combination with an 
AI 
•
To evaluate the antitumor activity of MEDI-573 when used in combination with an AI 
versus treatment with an AI alone 
•
To evaluate OS in subjects treated with MEDI-573 when used in combination with an AI 
versus treatment with an AI alone
•
To describe the PK of MEDI-573 in combination with an AI
•
To evaluate the pharmacodynamics of MEDI-573 in combination with an AI on 
circulating levels of IGF-I and IGF-II
•
To evaluate the IM of MEDI-573 in combination with an AI
2.3
Exploratory Objectives
 
 
 
.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
22 of 113
3
STUDY DESIGN
3.1
Overview of Study Design
This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, 
antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult 
subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-evaluation phase 
(Phase 1b) and a randomization phase (Phase 2).
3.1.1
Phase 1b (Dose-evaluation Phase)
In the Phase 1b portion of the study, 3 cohorts (Cohorts A, B, and C) will be examined. In 
Cohorts A, B, and C, 3 to 6 evaluable subjects will receive 
 
 MEDI 573, 
respectively, by IV infusion on Day 1 of each 21-day cycle. Subjects in each of the 3 cohorts 
will also be given an AI of the investigator’s choice (letrozole, anastrozole, or exemestane) 
orally once daily. Subjects will be treated until unacceptable toxicity, documentation of 
disease progression, or subject withdrawal for other reasons (see Section 4.2.3). Enrollment 
into Cohorts A, B, and C will be initiated sequentially.
Modifications of the MEDI-573 dosing schedule for toxicities other than DLTs are described 
in Section 4.5.8. Eligible subjects are considered evaluable if they receive 1 full cycle of 
MEDI-573 and are followed for safety through the DLT evaluation period (defined as 
21 days following the first dose of MEDI-573) or if the subject experiences a DLT, as 
defined in Section 4.5.8.1. Nonevaluable subjects will be replaced in the same dose cohort. 
Approximately 9 to 18 evaluable subjects will be required for the Phase 1b portion of this 
study. A study flow diagram for Phases 1b and 2 is shown in Figure 3.1.2-1. Up to 
20 investigational sites in North America may participate in the Phase 1b portion of the 
study.
3.1.2
Phase 2 (Randomization Phase)
Following evaluation of the safety of MEDI-573 at the 
 
 dose level in combination 
with an AI in Phase 1b, approximately 178 subjects with HR+, HER2-negative MBC will be 
randomized into the Phase 2 portion of the study in a 1:1 ratio to receive MEDI-573 at 
mg/kg and an AI (investigator’s choice of anastrozole, letrozole, or exemestane) (Arm 1) 
or an AI alone (Arm 2). A limit of approximately 30 subjects with metastases to bone-only
will be randomized to reflect the proportion of subjects with bone-only metastases in the 
target population. MEDI-573 will be administered via IV infusion on Day 1 of 21-day cycles. 
An AI will be given orally once daily. Subjects will be treated until unacceptable 
toxicity, documentation of disease progression, or other reasons for subject withdrawal (see 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
23 of 113
Section 4.2.3). Approximately 100 investigational sites worldwide will participate in 
the Phase 2 portion of the study. A study flow diagram for Phases 1b and 2 is shown in 
Figure 3.1.2-1.
Figure 3.1.2-1
Study Flow Diagram
AI = aromatase inhibitor; DLT = dose-limiting toxicity
Randomization will be stratified by geographic region (North America vs rest of world) and 
AI type (letrozole, anastrozole, or exemestane). The endpoints to be measured in this study 
are described in Section 7.3. All subjects will be followed every 9 weeks (three 21-day 
cycles) until disease progression and then followed for survival every 3 months until the end 
of the study as defined in Section 4.8.
3.2
Estimated Duration of Subject Participation
In both the Phase 1b and 2 portions of the study, subjects will be treated either with the 
combination of MEDI-573 and an AI or single-agent AI until PD, initiation of alternative 
anticancer treatment, unacceptable toxicity, or another reason to discontinue therapy, and will 
also be followed for survival until the end of the study as defined in Section 4.8.
Day 1      
Dose Cohort A
N = 3 to 6                                           
 MEDI-573 +      
AI orally once per day
Dose Cohort B
N = 3 to 6                                    
 MEDI-573 +      
AI orally once per day
Phase 1b
Phase 2
Arm 1
N = 89                                         
 MEDI-573 +      
AI orally once per day
Arm 2
N = 89                                         
AI orally once per day
MEDI-573
Safety Follow-up Period (through 60 days 
after final dose or until start of another 
anticancer therapy)
Survival Follow-up Period (Survival will 
be followed approximately every 3 
months until the end of the study)
MEDI-573 will be initiated on Day 1 of each 21-day cycle until progressive 
disease, unacceptable toxicity, or other reasons for subject withdrawal. AI will 
be administered daily.
Once daily AI will be administered until progressive disease, unacceptable 
toxicity, or other reasons for subject withdrawal.
21-Day Treatment Cycle
21-Day Treatment Cycle
21-Day Treatment Cycle
In Phase 1b, if 0 of 3 or only 1 of  6 subjects experiences a DLT in Cohort A,  B, 
or C, Phase 2 may begin
Dose Cohort C
N = 3 to 6                                   
      
AI orally once per day
21-Day Treatment Cycle


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
24 of 113
3.3
Study-stopping Criteria
If any of the following occur, administration of investigational product may be stopped and 
no additional subjects will be entered or randomized into the study:
1. Death in any subject in which the cause of death is assessed as related to investigational 
product 
2. Anaphylactic reaction to investigational product in any subject 
3. A cumulative rate of 30% or greater for DLT-like events that occur within the first cycle 
in all subjects treated within the study. A DLT-like event is one that otherwise meets the 
definition of DLT but occurs during Cycle 1 of the Phase 2 portion of the study, which 
does not have a formal DLT period
4. Other events that, in the judgment of the medical monitor, are deemed serious enough to 
warrant immediate review by the Safety Monitoring Committee (SMC) and/or Data 
Monitoring Committee (DMC)
If any of the above-listed events occur, a prompt cumulative review of safety data and the 
circumstances of the event in question will be conducted (see Section 6.5) to determine 
whether dosing and study entry/randomization should be stopped, remain stopped, or 
resumed (depending on the initial response to any of the above-listed events); whether the 
protocol will be modified; or whether the study will be discontinued permanently. Review 
and approval by the MedImmune SMC are required for resumption of the study in the event 
the study is interrupted because of one of the above-listed events. Where applicable, 
regulatory authorities and Institutional Review Boards (IRBs)/Independent Ethics 
Committees (IECs) will be notified of any actions taken with the study.
Any subjects who have already received investigational product and are currently in the 
study at the time study stopping criteria are met will continue to be followed by the 
investigator for safety. Decisions regarding ongoing treatment for other already enrolled 
subjects will be made on a case-by-case basis after discussion with the subject, investigator, 
sponsor, and the health authority.
Withdrawal criteria for individual subjects are provided in Section 4.2.3.
3.4
Rationale for Study Design, Doses, and Control Groups
A study design that constitutes an open-label dose-evaluation phase (Phase 1b) followed by a 
randomization phase (Phase 2) is common in early-phase oncology trials. Because some 
breast cancers respond to estrogen, lowering the estrogen level in postmenopausal women 
using AIs has been proven to be effective in breast cancer treatment. Aromatase inhibitors 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
25 of 113
are an approved standard of care for postmenopausal women with endocrine-responsive 
MBC and will be administered to all subjects in the study with or without MEDI-573.
In Amendment 2, the inclusion criterion for patients with MBC is being revised to limit the 
enrollment of subjects with bone-only metastases to approximately 30 subjects. This change 
is being made to ensure that the study population remains representative of the overall target 
population. The prevalence of bone-only metastases in studies reported by Paridaens and 
Nabholtz ranged from 12% to 20% (Paridaens et al, 2008; Nabholtz et al, 2000). To date, the 
current study has been enrolling a higher percentage of subjects with bone-only disease. This 
may bias the study results because subjects with bone-only disease generally have a better 
prognosis (Niikura et al, 2011). Accordingly, to limit enrollment to a more representative 
proportion of bone-only subjects and better predict efficacy in later-stage trials, enrollment 
will be capped at approximately 30 subjects.
The primary objective for the dose-evaluation phase is to assess the safety of MEDI-573 
when used in combination with an AI. Outcome measures include DLT identification and 
descriptions of AEs. As a result, the doses of MEDI-573 to be investigated in the Phase 1b 
clinical study will enable assessments on the safety, tolerability, PK, immunogenicity, and 
pharmacodynamics of the combination of MEDI-573 and an AI for proceeding to Phase 2.  
The primary endpoint for the randomization phase is PFS, which provides a direct measure 
of the effect of MEDI-573 on antitumor activity when used in combination with an AI. 
Progression-free survival has been used to assess potential clinical benefit in patients with 
MBC, and unlike OS, measurement of PFS is not confounded by subsequent antitumor 
therapies. Overall survival and ORR will both be collected as secondary endpoints to help in 
the evaluation of MEDI-573 as an antitumor therapy. Response and progression will be 
determined according to Response Evaluation Criteria in Solid Tumors, version 1.1
(RECIST 1.1) guidelines (Eisenhauer et al, 2009).
No unacceptable toxicities are anticipated based on the mechanisms of action and safety 
profiles of MEDI-573 and AIs. At present, evidence for quantitative translation of IGF-I and 
IGF-II suppression levels to clinical improvement in cancer patients is limited. Therefore, 
full suppression (> 90%) of IGF-I and IGF-II in the periphery is used to guide clinical dose 
selection. Dose selection for the Phase 2 portion of this study is based on the 
pharmacokinetic and pharmacodynamic profiles of MEDI-573 obtained from Phase 1 
(Study MI-CP184) and Phase 1b (Study CD-ON-MEDI-573-1030) studies. In these two 
trials, a wide range of MEDI-573 doses (
 once every week and 
 -
mg/kg 
Q3W) has been tested. No DLT has been observed to date at any dose level or schedule of 
MEDI-573 tested (either as monotherapy or in combination with an AI). Following weekly 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
26 of 113
dosing, MEDI-573 at dose levels greater than 
 resulted in complete and sustained 
suppression of plasma IGF-I and IGF-II over the entire dosing interval. In the case of 
 
 Q3Wk dosing, MEDI-573 was administered in conjunction with an AI on Study 
CD-ON-MEDI-573-1030. Following this 3-week dosing interval, 
 Q3Wk produced 
complete suppression of IGF-II in the plasma over the entire 3 weeks, while IGF-I in the 
plasma was only fully suppressed for about 7 days. MEDI-573 monotherapy administered at
 and 
 mg/kg Q3Wk has yielded complete suppression of IGF-I and II throughout the 
entire 3 week dosing interval. Given that the doses of 
and 
 mg/kg Q3Wk were well 
tolerated with no DLT, and in order to maximize tumor penetration of MEDI-573, the highest 
MEDI-573 dose tested 
 mg/kg Q3Wk) has been selected for administration in the Phase 2 
portion of the study. This Phase 2 dose will facilitate an evaluation of the relationship 
between MEDI-573 exposure and clinical efficacy as well as safety endpoints.
4
STUDY PROCEDURES
4.1
Subject Participation and Identification
Study participation begins once written informed consent is obtained (see Section 10.3 for 
details). Once informed consent is obtained, a subject identification (SID) number will be 
assigned by a central system (eg, an interactive web or voice response system [IXRS]), and 
the screening evaluations may begin to assess study eligibility (inclusion/exclusion) criteria. 
The SID number will be used to identify the subject during the screening process and 
throughout study participation, if applicable.
A master log of all consented subjects will be maintained at the site and will document all 
screening failures (ie, subjects who are consented but do not meet study eligibility criteria
and/or are not randomized), including the reason(s) for screening failure [see Section 9.1 for 
details]).
4.2
Subject Selection and Withdrawal
The subjects in this study will be postmenopausal women with HR+, HER2-negative MBC.
The investigator (physician) or qualified designee will discuss the study with a subject/the 
legal representative of a subject who is considered a potential candidate for the study and 
provide the subject/legal representative with the study-specific informed consent form(s) 
approved by the IRB/IEC. The investigator or designee will address any questions and/or 
concerns that the subject/legal representative may have and, if there is continued interest, will 
secure written informed consent for participation in the study. Written informed consent and 
any locally required authorization (eg, Health Insurance Portability and Accountability Act 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
27 of 113
[HIPAA] authorization in the US, European Union [EU] Data Privacy Directive 
authorization in the EU) will be obtained prior to conducting any protocol-specific 
procedures, including screening evaluations or medication washouts. See Section 10.3 for 
additional details concerning informed consent.
4.2.1
Inclusion Criteria
Subjects must meet all of the following criteria:
1. Subjects must have histologically-confirmed MBC not deemed amenable to curative 
surgery or curative radiation therapy
[
Subjects with metastases to bone only are eligible (enrollment of subjects with 
metastases to bone will be capped at approximately 30 subjects)
[
Subjects must be evaluated based on RECIST 1.1 guidelines
2. Tumors are positive for ER, PgR, or both (ie, 10% or more of infiltrating cancer cells 
exhibit nuclear staining for ER and/or PgR; positive biochemical test results are also 
acceptable). Expression can be ascertained on either primary or metastatic site. For 
subjects who have had the hormonal status of their tumor(s) assessed more than once 
over the course of their disease, the most recent assessment will determine eligibility.
3. Tumors must be negative for HER2 by fluorescence in situ hybridization (FISH),
chromogenic in situ hybridization (CISH), immunohistochemistry (IHC) used per local 
guidelines or manufacturer’s scoring criteria and instructions.
4. Female gender and age P 18 years (P 20 years for subjects enrolled in Japan) at time of 
study entry
5. Women must be postmenopausal as defined by 1 of the following:
a.
Bilateral oophorectomy 
b. P 55 years old with cessation of menses
c.
< 55 years old with:
4
Spontaneous amenorrhea > 1 year duration prior to randomization, except for 
patients having both ovaries removed, OR
4
Spontaneous menses within 1 year before randomization, but currently 
amenorrheic (eg, spontaneous or secondary to hysterectomy) and with 
postmenopausal gonadotropin levels (luteinizing hormone [LH] and follicle 
stimulating hormone [FSH] levels > 40 IU/L) or post-menopausal estradiol levels 
(< 5 ng/dL) within the postmenopausal range according to local guidelines OR
4
Radiation-induced menopause (P 3 months prior to randomization) OR
4
FSH levels in the postmenopausal range according to local guidelines prior to 
receipt of neo-adjuvant or adjuvant chemotherapy or radiation therapy OR
4
Women rendered amenorrheic by neoadjuvant or adjuvant chemotherapy who 
were premenopausal or perimenopausal prior to chemotherapy must be 
amenorrheic for at least 12 months prior to randomization and must have FSH 
levels in the postmenopausal range, with postmenopausal gonadotropin levels 
within the postmenopausal range, according to local guidelines.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
28 of 113
6. Karnofsky Performance Status (KPS) P 70 (Appendix 2)
7. Life expectancy of P 6 months
8. Subjects must have adequate organ and marrow function as defined below:
[
Hemoglobin (Hb) P 9 g/dL
[
Absolute neutrophil count P 1000/mm3
[
Platelet count P 75,000/mm3
[
Aspartate aminotransferase and ALT Y 2.5 × institutional upper limit of normal 
(ULN) in subjects without liver metastasis or Y 5 × ULN in subjects with liver 
metastasis
[
Bilirubin Y 1.5 × ULN
[
Creatinine Y 1.5 × ULN
9. Ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial 
procedures
10. Suitable candidate for AI therapy, including the ability to swallow and absorb oral agents
11. Subjects must consent to allow collection of available paraffin-embedded tumor tissue 
from either the primary or metastatic tumor site
12. Written informed consent and any locally-required authorization (eg, HIPAA in the US, 
EU Data Privacy Directive in the EU) obtained from the subject/legal representative prior 
to performing any protocol-related procedures, including screening evaluations
4.2.2
Exclusion Criteria
Any of the following would exclude the subject from participation in the study:
1. Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or 
biologic therapy for advanced or metastatic disease with the following exceptions:
[
Prior adjuvant therapy with an AI and/or tamoxifen is allowed, provided treatment 
ended at least 2 weeks prior to the first dose of MEDI-573
[
Prior neoadjuvant and/or adjuvant chemotherapy for breast cancer is allowed
2. Subject for whom endocrine therapy of breast cancer is not appropriate (ie, 
life-threatening or rapidly progressing metastatic disease) 
[
Subjects with extensive symptomatic visceral disease including hepatic involvement 
and pulmonary lymphangitic spread of tumor, or disease that is considered by the 
investigator to be rapidly progressing or life threatening (eg, subjects who are 
intended for chemotherapy).
3. Active brain metastases. 
[
Known brain metastases are only acceptable if they have been treated and subjects are 
asymptomatic, and there has been no evidence of central nervous system (CNS)
progression for at least 4 weeks before starting trial medication. If on dexamethasone, 
the subject must be on a stable or tapering dose for at least 4 weeks prior to starting 
trial medication. If on anti-epileptic therapy, the subject must be on a stable dose for 
at least 4 weeks prior to starting trial medication


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
29 of 113
4. Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis
[
Subjects with evidence (CT, MRI, or x-ray) of spinal canal involvement who are 
asymptomatic are allowed
5. Unresolved toxicities from prior therapy with the exception of alopecia that have not 
resolved to Y Grade 1 (by National Cancer Institute Common Terminology Criteria for 
Adverse Events [NCI CTCAE] version 4.0) at the time of starting study treatment 
[
An exception may be made in the case of a persistent, stable Y Grade 2 AE that, in the 
opinion of the investigator, would not interfere with evaluation of the investigational 
product, the interpretation of subject safety, or study results
6. Receipt of any investigational therapy within 30 days or 5 half-lives, whichever is longer, 
prior to receiving the first dose of study treatment
7. Previous treatment with an agent that targets IGF-1 or IGF-2 ligands or the IGF receptor
8. History of allergy or reaction attributed to compounds of chemical or biologic 
composition similar to those of MEDI-573 or AI
9. Use of immunosuppressive medication other than steroids within 7 days before the first 
dose of MEDI-573
10. History of another invasive malignancy within 5 years prior to starting study treatment 
except for curatively resected nonmelanoma skin cancer or carcinoma in situ of the 
cervix 
11. Poorly controlled diabetes mellitus as defined by investigator assessment 
12. History of cardiac disease including, but not limited to, congestive heart failure > Class II 
New York Heart Association (see Appendix 1); active coronary artery disease (eg, 
unstable angina pectoris), new onset angina pectoris, myocardial infarction within the 
past 6 months, ventricular arrhythmias requiring antiarrhythmic therapy, or uncontrolled 
hypertension within the last 6 months
13. Current active hepatic or biliary disease (with exception of subjects with Gilbert’s 
syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per 
investigator assessment)
14. Known human immunodeficiency virus or hepatitis B or C virus infection (either active, 
previously treated or both)
15. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection 
requiring parenteral antibiotics, or a psychiatric illness/social situations that would limit 
compliance with study requirement
16. Any condition that, in the opinion of the investigator, would interfere with evaluation of 
the investigational product or interpretation of subject safety or study results
17. Concurrent enrollment in another clinical study testing an investigational agent or 
intervention for cancer treatment or prevention
18. Subject directly involved with the conduct of the study or an immediate family member 
of any such individual
19. Any condition that compromises the subject’s ability to give informed consent


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
30 of 113
4.2.3
Withdrawal Criteria
An individual subject will not receive any further investigational product if any of the 
following occur in the subject in question:
1. Withdrawal of consent or lost to follow-up
2. Subject has met at least one exclusion criterion for study participation
3. Grade 3 or greater allergic or infusion reactions. Any allergic or infusion reaction that 
necessitates the use of systemic pressor agents will cause dose discontinuation in that 
subject
4. Infusion reactions P Grade 2 that do not respond to medical therapy or slowing the 
infusion rate and are not of limited duration 
5. Dose-limiting toxicity (see Section 4.5.8.1 for rules relating to dose escalation and 
DLTs), except for those DLTs that are considered to be controllable and allow for 
retreatment (see Section 4.5.8.1)
6. Grade 2 or higher toxicities that cause a cumulative delay of > 21 days in 3 consecutive 
cycles
7. Delay of cycle for > 21 days
8. Documentation of disease progression 
9. Adverse event that in the opinion of the investigator contraindicates further dosing
10. Significant subject noncompliance
11. Treatment with another investigational agent
12. Initiation of alternative anticancer therapy
13. Pregnancy or intent to become pregnant 
Withdrawal of consent: If consent is withdrawn, the subject will not receive any further 
investigational product or further study observation. Note that the subject may need to 
undergo additional tests or tapering of treatment to withdraw safely.
Lost to follow-up: Subjects will be considered lost to follow-up only if no contact has been 
established by the time the study is completed, such that there is insufficient information to 
determine the subject’s status through 30 days after the last dose of MEDI-573.
•
Note: Subjects refusing to return to the site or to continue participation in the study 
should be documented as “withdrawal of consent” rather than “lost to follow-up.” 
Investigators should document attempts to re-establish contact with missing subjects 
throughout the study period. If contact with a missing subject is re-established, the 
subject should not be considered lost-to-follow-up and any evaluations should resume 
according to the protocol.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
31 of 113
Permanent discontinuation of investigational product: Subjects who are permanently 
discontinued from further receipt of investigational product, regardless of the reason 
(withdrawal of consent, due to an AE, other), will be identified as having permanently 
discontinued treatment. Subjects who permanently discontinue treatment may either be
considered to have completed the study or not to have completed the study (see Section 4.7).
Subjects who are permanently discontinued from receiving investigational product will be 
followed for safety for 60 days after the last administration of investigational product, 
including the collection of any protocol-specified blood or urine specimens, unless consent is 
withdrawn, subject is lost to follow-up, subject has enrolled in another clinical study, or has 
initiated an alternative anticancer therapy. In addition, subjects will be followed for disease 
evaluation every 9 weeks until disease progression and then followed for survival every 
3 months until the end of the study, as defined in Section 4.8.
4.2.4
Replacement of Subjects
Nonevaluable subjects will be replaced in the same dose cohort in Phase 1b. Subjects will not 
be replaced in the Phase 2 portion of the study.
4.3
Treatment Assignment
For Phase 1b, each subject who meets the eligibility criteria will be assigned open-label 
investigational product and an AI. In Phase 2, each subject who meets the eligibility criteria 
will be assigned either open-label investigational product and an AI (investigator’s choice of 
anastrozole, letrozole, or exemestane) or an AI alone. Additional details on dosing are 
provided in Section 4.5.6.
An IXRS will be used for entry (Phase 1b)/randomization to a treatment arm (Phase 2) and 
assignment of unblinded investigational product and/or an AI (see Section 4.1). A subject is 
considered entered/randomized into the study when the investigator notifies the IXRS that 
the subject meets eligibility criteria and the IXRS provides the assignment of unblinded 
investigational product and/or AI to the subject.
In Phase 2 of the study, subjects will be randomized at a 1:1 ratio to receive either MEDI-573 
at
mg/kg and an AI or an AI alone. Please refer to Section 3.1.2 for randomization 
stratification factors.
The procedure for using IXRS is as follows:


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
32 of 113
•
The investigator or designee contacts the IXRS and provides the SID number and 
subject’s baseline characteristic(s) used to verify that it is the same subject
•
The IXRS assigns a cohort (Phase 1b) or treatment arm (Phase 2) and investigational 
product to the subject 
•
Confirmation of this information is sent to the investigator/designee who dispenses the 
investigational product to the subject per the communication and records the appropriate 
information in the subject’s medical records and investigational product accountability 
log
Investigational product (MEDI-573) must be administered within 24 hours of investigational 
product assignment. If there is a delay in the administration of investigational product such 
that it will not be administered within the specified timeframe, the study monitor must be 
notified immediately.
4.4
Blinding
This study is not blinded.
4.5
Study Treatment
4.5.1
Investigational Products 
Investigational product will be distributed to clinical sites using designated distribution 
centers. MedImmune will provide the investigator(s) with adequate quantities of 
investigational product. MEDI-573 must be stored at 2°C to 8°C (36°F to 46°F) in the 
original container and must not be frozen.
MEDI-573:
 
 
Diluent:
 
 
The investigator’s or site’s designated investigational product manager is required to 
maintain accurate investigational product accountability records. Upon completion of the 
study, copies of investigational product accountability records will be returned to 
MedImmune. All unused investigational product will be returned to a 
MedImmune-authorized depot or disposed of upon authorization by MedImmune.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
33 of 113
4.5.2
Other Study Medications
Subjects will receive an AI during this study. The AI will be purchased locally from a 
supplier chosen by the site, with reimbursement by MedImmune as appropriate. If 
reimbursement is required, MedImmune will reimburse up to the end of study as defined in 
Section 4.8. Labeling information for the AI should be kept on file. The 3 AIs (anastrozole, 
letrozole, and exemestane) that will serve as standard background therapy options are 
commercially available and are supplied as oral formulations. The AIs are supplied in tablet 
form for oral administration. Standard practice and local prescribing information should be 
followed. Subjects will be provided with a diary in which to record their intake of AI (an 
example of the diary is provided in Appendix 3). This information will be recorded in the 
case report form.
4.5.3
Treatment Regimens
4.5.3.1
Phase 1b………
In Phase 1b, all subjects will be treated with MEDI-573 at doses of 
 (as a 60-minute 
IV infusion),
or 
(as a 90 minute IV infusion) on Day 1 in combination 
with an AI of the investigator’s choice orally once daily. MEDI-573 will be administered at 
an every 21-day treatment cycle along with daily AI until unacceptable 
toxicity, documentation of disease progression, or other reasons for subject withdrawal (see 
Section 4.2.3). Rules for dose evaluation are described in Section 4.5.6. Dose modification 
for toxicities will be allowed as described in Section 4.5.8. Nonevaluable subjects, as defined 
in Section 4.5.8.1, will be replaced in the same dose cohort. A summary of dose cohorts is 
provided in Table 4.5.3.1-1. 
Table 4.5.3.1-1
Summary of Dose Cohorts
Dose Cohort
Number of Subjects
MEDI-573 Dose
A
3-6
 as a 60-minute (+ 20-minute)
IV infusion on Day 1
B
3-6
 as a 90-minute (+ 20-minute)
IV infusion on Day 1
C
3-6
 as a 90-minute (+ 20-minute)
IV infusion on Day 1
4.5.3.2
Phase 2……..
Following Phase 1b as described in Section 4.5.6, approximately 178 subjects with MBC will 
be randomly assigned to receive either MEDI-573 and an AI or single-agent AI. Subjects in 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
34 of 113
Phase 2 will be treated with one of the following regimens, depending on treatment 
assignment (see Section 4.5.6 for dose evaluation rules):
Arm 1: MEDI-573 
 mg/kg IV infusion on Day 1 of each 21-day cycle
AI (investigator’s choice) orally once daily
Arm 2: AI (investigator’s choice) orally once daily
Subjects will be treated with the assigned regimen until documentation of PD, initiation of 
alternative anticancer therapy, unacceptable toxicity, or another reason for treatment 
discontinuation (see Section 4.5.8) is observed.
Each new cycle will begin 21 days after the first day of the previous cycle. Subjects who do 
not receive the required dose of MEDI-573 (Arm 1) within a cycle will not advance to the 
next cycle of MEDI-573 and will be removed from treatment with MEDI-573. In Phases 1b 
and 2 of the study, all visits during Cycle 2 and subsequent visits may occur in a ± 2-day 
window to accommodate schedule changes, but doses of MEDI-573 must not occur more 
frequently than every 21 days.
4.5.3.3
Investigational Product Preparation 
The dose of investigational product for administration must be prepared by the Investigator’s 
or site’s designated investigational product manager using aseptic technique. The 
 
drug product within each MEDI-573 vial will be reconstituted 
 
for injection. To reconstitute the 
, slowly add 
 for 
injection to the vial. The vial should be tilted slightly and gently rotated or swirled for 
30 seconds or until dissolution is complete. Do not shake or vigorously agitate the vial. This 
is a critical step to avoid prolonged foaming. Reconstituted MEDI-573 should stand 
undisturbed at room temperature for a minimum of 2 minutes until the solution clarifies.
Total in-use storage time from reconstitution of MEDI-573 to the start of administration 
should not exceed 4 hours at room temperature. If in-use storage time exceeds this limit, a 
new dose must be prepared from a new vial or vials. MEDI-573 does not contain any 
preservatives, so any unused portion must be discarded.
MEDI-573 is compatible with an IV bag composed of polyolefin (ethylene and propylene) 
that is polyvinyl chloride (PVC)-free and di(2-ethylhexyl)phthalate (DEHP)-free; IV tubing 
composed of PVC that is DEHP-free; and a 0.2-Wm in-line filter composed of 
polyethersulfone.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
35 of 113
The dose of investigational product for IV administration must be prepared using aseptic 
technique. The volume (dose) of MEDI-573 will be calculated based on the subject’s body 
weight (kg) (obtained prior to the administration of MEDI-573 on Day 1 of each treatment 
cycle) and the subject’s dose level (mg). The dose volume of MEDI-573 will be calculated 
using the following formula:
Dose Volume (mL) = Dose Level (mg/kg) × Subject Weight (kg) ÷ Concentration 
(mg/mL)
 
 
 
MEDI-573 is prepared for administration by dilution into the appropriate volume of normal 
saline to a final volume of 
 
 depending on 
the dose level. To prepare the IV bag, the volume of normal saline equivalent to the 
calculated dose volume of MEDI-573 is removed from the IV bag, and then the calculated 
MEDI-573 dose volume is added to the IV bag containing the remaining saline.
4.5.4
Treatment Administration
The day of receipt of the first dose of investigational product is considered Day 1.
MEDI-573:
MEDI-573 should be administered as a 60-minute (+ 20-minutes for 
potential overfill; for
) or 90-minute (+ 20-minutes for 
potential overfill; for
 and 
 mg/kg doses) IV infusion. After the 
contents of the IV bag are fully administered, the IV line should be flushed 
with a volume of normal saline equal to the priming volume of the 
infusion set used. Subjects will be monitored during and after infusion 
with assessment of vital signs at the beginning of the infusion, at every 
30 minutes (± 5 minutes) during the MEDI-573 infusion, at the end of 
infusion (± 10 minutes) and 30 minutes (± 5 minutes) and 60 minutes 
(± 5 minutes) after the end of infusion.
Since the compatibility of MEDI-573 with other IV medications and solutions, 
 
, is not known, the MEDI-573 solution 
should not be infused through an IV line in which other solutions or medications are being 
administered. The date, start time, and completion time of MEDI-573 administration must be 
recorded in the source documents.
e.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
36 of 113
Aromatase Inhibitor of Investigator’s Choice: Letrozole, anastrozole, or exemestane will 
be dispensed per investigator’s choice. Standard practice and local prescribing information 
should be followed. Letrozole, anastrozole, and exemestane are commercially available and 
are supplied in tablet form for oral administration.
4.5.5
Monitoring of Dose Administration 
All subjects in Phases 1b and 2 will be monitored during and after infusion with assessment 
of vital signs (temperature, respiratory rate, pulse, and blood pressure) at the start of 
MEDI-573 infusion, at every 30 minutes (± 5 minutes) during the MEDI-573 infusion, at the 
completion of the infusion (± 10 minutes), and 30 and 60 minutes (± 5 minutes) after 
completion of the MEDI-573 infusion.
As with any antibody, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylactic reactions must be 
immediately available, and study personnel must be trained to recognize and treat 
anaphylaxis.
In the event of an infusion-related reaction, the infusion of MEDI-573 may be decreased by 
50% or interrupted until resolution of the event (up to 4 hours) and re-initiated at 50% of the 
initial rate until completion of the infusion. Acetaminophen 650 mg and/or an antihistamine 
(eg, diphenhydramine 50 mg) or equivalent medications per institutional standard may be 
administered. Alternatively, or in addition, the rate of infusion of MEDI-573 may be 
diminished at the discretion of the investigator. Any such activities must be recorded 
appropriately. If the infusion reaction is severe or prolonged, methylprednisolone 100 mg 
(or the equivalent) should be administered as well.
For subsequent infusions in subjects who experience an infusion reaction and do not require 
discontinuation of MEDI-573, acetaminophen 650 mg and/or an antihistamine (eg, 
diphenhydramine 50 mg) or equivalent medications per institutional standard will be 
administered prior to all subsequent infusions with MEDI-573. If the infusion reaction is 
severe or prolonged, glucocorticoids (methylprednisolone 100 mg [or the equivalent]) should 
be administered 30 minutes prior to the initiation of MEDI-573 infusion, or by standard 
institutional practice.
At the discretion of the investigator, appropriate medical therapy may also be administered 
per institutional standard for management of allergic or infusion reactions.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
37 of 113
4.5.6
Phase 1b (Dose-evaluation Phase)
Three dose levels of MEDI-573 will be evaluated in combination with AI during Phase 1b. 
Rules for dose evaluation are as follows:
1. Dosing will be administered according to the standard 3 + 3 design, beginning with the 
 group (Cohort A) and followed by the 
g (Cohort B) and 
 
(Cohort C) groups sequentially. Dosing in each group will occur every 21 days. If no 
DLTs are observed in the initial 3 evaluable subjects, dose evaluation will continue with 
the next cohort.
2. If 1 of 3 subjects within a cohort experiences a DLT, that cohort will be expanded to a 
total of 6 subjects. If no additional subjects in a cohort experience a DLT through the first 
21 days of administration of MEDI-573 and an AI, dose evaluation will continue with the 
next cohort.
3. If P 2 subjects within a specific dose cohort experience a DLT during the DLT evaluation 
period, the MTD will be exceeded and study enrollment will temporarily stop. 
Pharmacokinetic and response data of subjects treated at representative dose levels will 
be analyzed to determine if a lower MEDI-573 dose may achieve target serum 
concentrations and/or if a weekly dosing schedule would be appropriate. Three to 6 
additional subjects may be enrolled to explore this alternate dose and/or schedule.
4. If 0 of 3 or no more than 1 of 6 subjects in any cohort experiences a DLT through the first 
21 days of administration of MEDI-573 and an AI, enrollment into Phase 2 may begin. 
Dosing in Phase 2 will begin simultaneously in both treatment arms.
A study-specific safety committee will provide ongoing safety surveillance throughout the 
study, with regularly scheduled reviews of safety and other relevant data. This committee 
will be responsible for decisions regarding the initiation of the randomization phase and 
making recommendations regarding further conduct of the study. This committee will also 
review data at other time points in response to AEs assessed as medically relevant by the 
medical monitor, and will communicate outcomes and decisions to the MedImmune SMC. 
Safety outcomes will be evaluated on a quarterly basis by the SMC to identify any nascent 
safety concerns.
4.5.7
Phase 2 (Randomization Phase)
Following Phase 1b, 178 subjects with HR+, HER2-negative MBC will be randomized to 
one of 2 arms to receive either the combination of MEDI-573 at 
mg/kg with an AI, or an 
AI alone, in order to evaluate in more detail the safety profile and antitumor activity of the 
combination.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
38 of 113
4.5.8
Management of Toxicities, Dose Reductions and Dose Delays
No dose modification is allowed for MEDI-573. Following the DLT period (Phase 1b) and 
starting with Cycle 2 in Phase 2, dosing of MEDI-573 may be delayed or discontinued based 
on hematologic and nonhematologic toxicities observed during each subsequent cycle of 
treatment as described in Table 4.5.8-1. Both hematologic and nonhematologic toxicities will 
be graded according to the NCI CTCAE v4.0. Standard practice and local prescribing 
information should be followed to manage AI-related toxicities.
Adverse events for which a cause other than MEDI-573 or the AI can be clearly attributed 
(such as an accident) will not require a dose delay.
Subjects with allergic or infusion reactions of Grade 3 or higher will permanently discontinue 
MEDI-573. Allergic or infusion reactions at or below Grade 2 that respond to medical 
therapy or slowing the infusion rate and are of limited duration will not necessitate dose 
interruption or discontinuation; however, any such events that necessitate the use of systemic 
pressor agents will result in dose discontinuation. Dosing will not be interrupted or 
discontinued for a Grade 2 laboratory toxicity that does not represent deterioration since 
study entry.
Table 4.5.8-1
MEDI-573 Dose Delays or Discontinuation for Toxicity 
Hematologic or 
Nonhematologic Toxicity
Schedule Adjustment
Grade 1
•
No change (resume MEDI-573 at the current dose level)
Grade 2 a
•
If resolution to Y Grade 1 or baseline occurs within 21 days of the 
previous dose, resume MEDI-573 at the current dose level.
•
If resolution to Y Grade 1 or baseline does not occur within 21 days of 
previous dose, MEDI-573 will be discontinued unless toxicity is clearly 
attributable to another cause.
•
Grade 2 laboratory toxicities that do not have clinical significance may 
not require dose delay. The medical monitor should be consulted in the 
event of Grade 2 laboratory toxicities that are deemed clinically 
insignificant to determine if dosing may continue.
•
If toxicities cause a cumulative delay of P 21 days in 3 consecutive 
cycles, MEDI-573 will be discontinued.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
39 of 113
Table 4.5.8-1
MEDI-573 Dose Delays or Discontinuation for Toxicity 
Hematologic or 
Nonhematologic Toxicity
Schedule Adjustment
Grade 3 or 4 b
•
If resolution to Y Grade 1 or baseline occurs within 21 days of the 
previous dose, resume MEDI-573 at the current dose level.
•
If resolution to Y Grade 1 or baseline does not occur within 21 days of 
the previous dose, MEDI-573 will be discontinued.
•
If resolution to Y Grade 1 or baseline occurs within 21 days of the 
previous dose and the subject has not achieved some degree of clinical 
benefit while on MEDI-573 therapy, MEDI-573 will be discontinued.
a
Allergic or infusion reactions at or below Grade 2 that respond to medical therapy or slowing the infusion 
rate and are of limited duration will not necessitate dose interruption or discontinuation; however, any 
such events that necessitate the use of systemic pressor agents will result in dose discontinuation. Dosing 
will not be interrupted or discontinued for a Grade 2 laboratory toxicity that does not represent 
deterioration since study entry. 
b
Subjects with allergic or infusion reactions of Grade 3 or higher will permanently discontinue MEDI-573.
4.5.8.1
Dose-limiting Toxicity
The period for evaluating DLTs in Phase 1b will be defined as Cycle 1, Day 1 through 
Day 21. Subjects who do not receive 1 full cycle of MEDI-573 for reasons other than DLT 
will be replaced at the same dose level. Grading of DLTs will be according to the NCI 
CTCAE v4.0 (Appendix 5).
All AEs that are suspected of having a causal relationship to MEDI-573 and are P Grade 3 in 
severity are considered DLTs. In the absence of clinical abnormality, repeat laboratory 
testing will be conducted to confirm significant laboratory findings prior to designation as a 
DLT. Any such events occurring during Cycle 1 of Phase 2 will be considered to be DLT-
like events and will contribute to the study-stopping rule described in Section 3.3.
4.5.9
Treatment Compliance
Investigational product (MEDI-573) is administered by study site personnel who will 
monitor compliance.
4.6
Concomitant Medications
4.6.1
Permitted Concomitant Medications
Investigators may prescribe concomitant medications or treatments deemed necessary to 
provide adequate supportive care. 
Bisphosphonate, denosumab or calcitonin treatment established 2 weeks or more prior to 
randomization is allowed for the management of hypercalcemia, bone pain and/or 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
40 of 113
osteoporosis. After Cycle 1, Day 21, such therapy may be initiated for the management of 
hypercalcemia, bone pain and/or osteoporosis, but not for the prevention of bone metastasis. 
Palliative radiotherapy for bone pain is acceptable, provided that the radiated area does not 
overlap with that of the target lesions.
Ongoing ovarian suppression with a depot luteinizing hormone-releasing hormone agonist is 
allowed if initiated 2 weeks prior to entry into the study. Subjects who have been treated 
previously with depot luteinizing hormone-releasing hormone analogues must have received 
their last dose P 12 months prior to randomization.
All concomitant medications given to the subject from the time the subject signs the 
informed consent form through 60 days after the last study treatment will be recorded on the 
source document. The sponsor must be notified if any subject receives any prohibited 
concomitant medications as outlined above or in Section 4.2.2.
4.6.2
Excluded Concomitant Medications
Subjects may receive medications as supportive care or to treat AEs as deemed necessary by 
the investigator or the subject’s physician. 
4.7
Subject Completion
An individual subject will be considered to have completed the study if the subject was 
followed until the end of the study as defined in Section 4.8, regardless of the number of 
doses of investigational product received.
Subjects will be considered not to have completed the study if consent was withdrawn or the 
subject was lost to follow-up (see Section 4.2.3).
4.8
End of the Study
The end of the study (“study completion”) is defined as the date of the last protocol-specified 
visit/assessment (including telephone contact) for the last subject in the study. Per the 
original protocol, this date was to be up to 36 months from the date the last subject was 
entered into the trial or earlier at the discretion of the sponsor. As of 10Jul2016, this 
milestone will have been met. All follow-up for any subjects that have discontinued 
treatment by 10Jul2016 (whether or not they have progressed), will end, as per the original 
protocol, 36 months after the last subject was entered into the study. However, as of 
Amendment 3, subjects still on treatment at that time will be allowed to continue treatment 
until they meet one of the criteria for treatment discontinuation. Once treatment discontinues, 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
41 of 113
the subject will be followed for 60 days as described in Section 5.1.4. The end of the study 
will therefore be when the last subject still on treatment as of 10Jul2016 finishes the 60-day 
(+/- 3 days) safety follow-up following treatment discontinuation.
All materials or supplies provided by the sponsor will be returned to the sponsor or designee 
upon study completion, as directed by the site monitor. The investigator will notify the 
IRB/IEC when the study has been completed.
5
STUDY PROCEDURES
5.1
Schedule of Study Procedures
All subjects who are assigned an SID number and receive any investigational product will be 
followed according to the protocol regardless of the number of doses received, unless consent 
is withdrawn. The investigator must notify the sponsor or designee of deviations from 
protocol visits or evaluations and these evaluations, if applicable, must be rescheduled or 
performed at the nearest possible time to the original schedule. Protocol deviations will be 
recorded on the source document with an explanation for the deviation. The investigator must 
comply with the applicable requirements related to the reporting of protocol deviations to the 
IRB/IEC.
Subjects/legal representatives will be instructed to call study personnel to report any 
abnormalities during the intervals between study visits and to come or to bring the subject to 
the study site if medical evaluation is needed and the urgency of the situation permits. For 
emergency and other unscheduled visits to a medical facility other than the study site, 
medical records will be obtained by the investigator and made available to the sponsor or 
designee during monitoring visits.
The schedules of study procedures for the screening and treatment periods are provided in 
Table 5.1-1 and Table 5.1-2, and those for the follow-up period are provided in Table 5.1-3
and Table 5.1-4. A description of the study procedures is provided in Section 5.2. 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
42 of 113
Table 5.1-1
Schedule of Subject Evaluations: Screening and Treatment Periods - All Subjects Unless 
Otherwise Specified (not applicable for subjects continuing on treatment under Amendment 3)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(-7 days) through 
24 months post 
study entry
Every 6 
months 
(± 7 Days) > 24
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 2 days)
Written Informed Consent 
and HIPAA (where 
applicable)
X
Assignment of SID 
number
X
Medical History
X
 
 
X
Protocol/Safety Evaluations
 
X
X
X
X
Serum KHCG
X
Urine or Serum pregnancy 
test
X
X
X
Physical Examination
X
X
X
X
Height
X
Weight (-2 days is 
acceptable)
X
X
X
X
Vital Signs
X
X
X
`
X
12-lead ECG
X
X
X
X
AE/SAE Assessment
X
X
X
X
X
X
X
X
X
Concomitant Medications
X
X
X
X
X
X
X
X
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
43 of 113
Table 5.1-1
Schedule of Subject Evaluations: Screening and Treatment Periods - All Subjects Unless 
Otherwise Specified (not applicable for subjects continuing on treatment under Amendment 3)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(-7 days) through 
24 months post 
study entry
Every 6 
months 
(± 7 Days) > 24
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 2 days)
Karnofsky Performance 
Status
X
X
X
X
 
X
X
X
X
Study Entry (Phase 1b)/Randomization (Phase 2) and Treatment
Verify Eligibility Criteria
X
X
Study Entry (Phase 1b)/
Randomization (Phase 2)
X
MEDI-573 Administration
(Phase 1b and Phase 2; 
Arm 1. Dose interval no 
shorter than 
21 days)
X
X
AI Administration
(Once daily throughout 
treatment period)
X
X 
X
X
X
X
X
Laboratory Evaluations
Hematology
X
X
X
X
X
X
Hemoglobin A1c
X
X
Serum Chemistry
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
MEDI-573 serum 
concentration (Phase 1b 
and Phase 2; Arm 1)
X
X
X
X
X
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
44 of 113
Table 5.1-1
Schedule of Subject Evaluations: Screening and Treatment Periods - All Subjects Unless 
Otherwise Specified (not applicable for subjects continuing on treatment under Amendment 3)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(-7 days) through 
24 months post 
study entry
Every 6 
months 
(± 7 Days) > 24
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 2 days)
Anti-MEDI-573
Antibodies (Phase 1b and 
Phase 2; Arm 1)
X
X
X
X
X
X
X
X
 
X
X
X
X
X
 
X
X
X
X
X
X
X
X
X
DNA Sample (optional)
X
Archived Tumor Sample, 
if available (consent 
required)
X
Tumor Measurements
CXR, CT or MRI Scans  
(see Section 5.2.6.1 for 
detailed evaluation
schedule)
X
X
X
X
AE = adverse event; AI = aromatase inhibitor; KhCG = beta human chorionic gonadotropin; CT = computed tomography; CXR = chest x-ray; 
ECG = electrocardiogram; 
; HIPAA = Health 
Insurance Portability and Accountability Act; IGF = insulin-like growth factor; MRI = magnetic resonance imaging; SAE= serious adverse event; SID = subject 
identification 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
45 of 113
Table 5.1-2
Schedule of Subject Evaluations: Screening and Treatment (Subjects continuing treatment 
under Amendment 3 only)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(± 7 days) post 
study entry
Every 6 
months 
(± 7 Days) > 24 
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 5 days)
Written Informed Consent 
and HIPAA (where 
applicable)
X
Assignment of SID 
number
X
Medical History
X
 
X
Protocol/Safety Evaluations
 
X
X
Serum KHCG
X
Urine or Serum pregnancy 
test
X
X
X
Physical Examination
X
X
X
X
Height
X
Weight (-2 days is 
acceptable)
X
X
X
X
Vital Signs
X
X
X
`
X
12-lead ECG
X
X
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
46 of 113
Table 5.1-2
Schedule of Subject Evaluations: Screening and Treatment (Subjects continuing treatment 
under Amendment 3 only)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(± 7 days) post 
study entry
Every 6 
months 
(± 7 Days) > 24 
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 5 days)
AE/SAE Assessment
X
X
X
X
X
X
X
Concomitant Medications
X
X
X
X
X
X
X
Karnofsky Performance 
Status
X
X
X
X
 
X
X
Study Entry (Phase 1b)/Randomization (Phase 2) and Treatment
Verify Eligibility Criteria
X
X
Study Entry (Phase 1b)/
Randomization (Phase 2)
X
MEDI-573 Administration
(Phase 1b and Phase 2; 
Arm 1. Dose interval no 
shorter than 
21 days)
X
X
AI Administration
(Once daily throughout 
treatment period)
X
X 
X
X
X
Laboratory Evaluations
Hematology
X
X
X
X
X
X
Hemoglobin A1c
X
Serum Chemistry
X
X
X
X
X
X
Urinalysis
X
X
X
X
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
47 of 113
Table 5.1-2
Schedule of Subject Evaluations: Screening and Treatment (Subjects continuing treatment 
under Amendment 3 only)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(± 7 days) post 
study entry
Every 6 
months 
(± 7 Days) > 24 
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 5 days)
MEDI-573 serum 
concentration (Phase 1b 
and Phase 2; Arm 1)
X
X
X
X
Anti-MEDI-573
Antibodies (Phase 1b and 
Phase 2; Arm 1)
X
X
X
X
 
X
X
X
 
X
X
X
ls
X
X
DNA Sample (optional)
X
Archived Tumor Sample, 
if available (consent 
required)
X
Tumor Measurements
CXR, CT or MRI Scans  
(see Section 5.2.6.1 for 
detailed evaluation
schedule)
X
X
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
48 of 113
Table 5.1-2
Schedule of Subject Evaluations: Screening and Treatment (Subjects continuing treatment 
under Amendment 3 only)
Evaluation
Screening
Cycle 1
Cycle 2 and 
Every Cycle 
Thereafter
Every 9 Weeks
(± 7 days) post 
study entry
Every 6 
months 
(± 7 Days) > 24 
months post 
study entry
End of 
Treatment
Day -30 
through 
Day -1 
Day 
1
Day 2
(Phase 
1b only)
Day 8
Day 15
(± 2 
days)
Day 1
(± 5 days)
AE = adverse event; AI = aromatase inhibitor; KhCG = beta human chorionic gonadotropin; CT = computed tomography; CXR = chest x-ray; 
ECG = electrocardiogram; 
 HIPAA = Health 
Insurance Portability and Accountability Act; IGF = insulin-like growth factor; MRI = magnetic resonance imaging; SAE= serious adverse event; SID = subject 
identification 
Table 5.1-3
Schedule of Study Procedures: Follow-up Period- All Subjects Unless Otherwise Specified (not 
applicable for subjects continuing on treatment under Amendment 3)
All Treatment Arms
Follow-up/Posttherapy
30 Days Post Last Dose (± 3 
days)and
60 Days Post Last Dose (± 5 days)
Every 9 weeks (± 7 Days) Post Last 
Dose for Subjects Without PD
through 24 months posttreatment
Every 3 months
Post Last 
Dose(± 7 Days)
Every 6 months Post 
Last Dose (± 7 Days)
> 24 months
posttreatment for 
Subjects Without PD
Physical examination
X
X
Vital signs
X
12-lead ECG
X (30 days post visit only)
Weight 
X
Hematology
X
Serum chemistry
X
Urinalysis
X
AE/SAE assessment
X
Concomitant medications
X


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
49 of 113
Table 5.1-3
Schedule of Study Procedures: Follow-up Period- All Subjects Unless Otherwise Specified (not 
applicable for subjects continuing on treatment under Amendment 3)
All Treatment Arms
Follow-up/Posttherapy
30 Days Post Last Dose (± 3 
days)and
60 Days Post Last Dose (± 5 days)
Every 9 weeks (± 7 Days) Post Last 
Dose for Subjects Without PD
through 24 months posttreatment
Every 3 months
Post Last 
Dose(± 7 Days)
Every 6 months Post 
Last Dose (± 7 Days)
> 24 months
posttreatment for 
Subjects Without PD
Subsequent anticancer 
therapy
X
X
Karnofsky Performance 
Status
X
X
Survival status
X
X
MEDI-573 Serum 
Concentration (Phase 1b and 
Phase 2; Arm 1)
X
X (first 3-month 
visit only)
Anti-MEDI-573 antibodies 
(Phase 1b and Phase 2; Arm 
1)
X
X (first 3-month 
visit only)
 
X
  
X
CXR, CT or MRI Scans (see 
Section 5.2.6.1 for detailed 
long term follow up 
schedule)
X
X
AE = adverse event; CT = computed tomography; CXR = chest x-ray; ECG = electrocardiogram; IGF = insulin-like growth factor; MRI = magnetic resonance 
imaging; PD = progressive disease


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
50 of 113
Table 5.1-4
Schedule of Study Procedures: Follow-up Period (Subjects 
continuing treatment under Amendment 3 only)
All Treatment Arms
Follow-up/Posttherapy
30 Days Post Last Dose (± 3 days)and
60 Days Post Last Dose (± 5 days)
Physical examination
X
Vital signs
X
12-lead ECG
X (30 days post visit only)
Weight 
X
Hematology
X
Serum chemistry
X
Urinalysis
X (30 days post visit only)
AE/SAE assessment
X
Concomitant medications
X
Subsequent anticancer therapy
X
Karnofsky Performance Status
X
Survival status
MEDI-573 Serum Concentration (Phase 1b and Phase 
2; Arm 1)
X
Anti-MEDI-573 antibodies (Phase 1b and Phase 2; 
Arm 1)
X
 
  (see Section 7.3.3)
CXR, CT or MRI Scans (see Section 5.2.6.1 for 
detailed long term follow up schedule)
AE = adverse event; CT = computed tomography; CXR = chest x-ray; ECG = electrocardiogram; IGF = insulin-
like growth factor; MRI = magnetic resonance imaging; PD = progressive disease
5.1.1
Screening (All Subjects Unless Otherwise Specified)
All screening procedures must be performed within 30 days before study 
entry/randomization, unless otherwise specified. The screening evaluations may be carried 
out over more than one visit. Written informed consent and any locally required authorization 
(eg, HIPAA in the US, EU Data Privacy Directive authorization in the EU) must be obtained 
prior to performing any protocol-specific procedures, including screening evaluations. 
1. Obtain written informed consent and appropriate privacy act document authorization 
2. Assign an SID number via IXRS
3. Verify eligibility criteria, including review of lab results
4.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
51 of 113
b.
 
5. Obtain medical history
6. Perform a complete physical examination
7. Record height
8. Record weight
9. Record vital signs
10. Assess KPS
11. Obtain 12-lead electrocardiogram (ECG) as described in Section 5.2.1.
12. Collect blood for screening samples:
[
Serum chemistry
[
Hematology
[
Hemoglobin A1c 
[
Beta human chorionic gonadotropin (KhCG) serum pregnancy test (women of 
childbearing potential)
[
[
[
13. Collect urinalysis sample
14. Collect archive tumor sample, where available
15.
16. Perform chest x-ray (CXR), computed tomography (CT), or magnetic resonance imaging 
(MRI) scan
17. Assess for AEs and serious adverse events (SAEs)
18. Record concomitant medications
5.1.2
Treatment Period
5.1.2.1
Cycle 1, Day 1 (All Subjects Unless Otherwise Specified)
Note that any assessments performed within 24 hours prior to dosing may be used for Cycle 
1, Day 1 assessments.
1. Verify eligibility criteria, including review of lab results
2. Study entry (Phase 1b)/randomization (Phase 2) in IXRS 
3.
 
a.
b.
4. Perform directed physical examination
5. Record weight


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
52 of 113
6. Record pretreatment vital signs
7. Assess KPS
8. Update concomitant medications
9. Collect urine or serum for pregnancy test (women of childbearing potential); ensure result 
is negative pretreatment
10. Collect urinalysis sample
11. Collect blood for baseline samples prior to treatment:
[
Serum chemistry
[
Hematology
[
MEDI-573 serum concentration (Phase 1b and Phase 2; Arm 1)
[
Anti-drug antibodies (Phase 1b and Phase 2; Arm 1)
[
[
[
[
12. Perform 12-lead ECG prior to treatment as described in Section 5.2.1 (Phase 1b and 
Phase 2, Arm 1)
13. Infuse MEDI-573 (Phase 1b and Phase 2; Arm 1)
14. Collect blood after infusion of MEDI-573 (Phase 1b and Phase 2; Arm 1)
[
MEDI-573 serum concentration (immediately postinfusion [± 5 minutes])
[
15. Record posttreatment vital signs (Phase 1b and Phase 2; Arm 1)
[
30 minutes [± 5 minutes] after the start of MEDI-573 infusion
[
60 minutes [± 5 minutes] after the start of MEDI-573 infusion 
[
At the end of infusion [±10 minutes] 
[
30 minutes [± 5 minutes] postinfusion
[
60 minutes [± 5 minutes] postinfusion
16. Perform 12-lead posttreatment ECG (Phase 1b and Phase 2, Arm 1) as described in 
Section 5.2.1
17. Start daily AI treatment, continued throughout the treatment period.
18. Assess for AEs and SAEs throughout the treatment period 
19. Update concomitant medications, as needed
5.1.2.2
Cycle 1, Day 2 (For Phase 1b only)
1. Continue daily AI administration throughout treatment period
2. Collect blood 
[
MEDI-573 serum concentration (24 ± 2 hours post-Day 1 infusion)
3. Assess for AEs and SAEs 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
53 of 113
4. Update concomitant medications 
5.1.2.3
Cycle 1, Day 8 (All Subjects Unless Otherwise Specified)
1. Collect urinalysis sample
2. Collect blood
[
Serum chemistry
[
Hematology
[
MEDI-573 serum concentration (Phase 1b and Phase 2; Arm 1)
[
[
[
[
3. Assess for AEs and SAEs 
4. Update concomitant medications 
5. Continue daily AI administration throughout treatment period
5.1.2.4
Cycle 1, Day 15 (Plus/Minus 2 Days, All Subjects Unless Otherwise 
Specified)
1. Assess for AEs and SAEs
2. Update concomitant medications
3. Collect blood
[
Serum chemistry
[
Hematology
[
MEDI-573 serum concentration (Phase 1b and Phase 2 Arm 1)
[
 (see Section 7.3.3)
4. Continue daily AI administration throughout the treatment period
5.1.2.5
Cycle 2 and Every Cycle Thereafter, Day 1 (Plus/Minus 2 Days, All 
Subjects Unless Otherwise Specified)
For subjects continuing on treatment under Amendment 3, please refer to Section 5.1.2.5.1
for applicable study related procedures.
Note that any assessments performed within 24 hours prior to dosing may be used for Cycle 
1, Day 1 assessments.
1.
 
a.
b.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
54 of 113
2. Perform directed physical examination
3. Record weight
4. Record pretreatment vital signs
5. Assess KPS
6. Collect urine or serum for pregnancy test (women of childbearing potential); ensure result 
is negative pretreatment
7. Collect urinalysis sample
8. Perform 12-lead ECG prior to treatment (Phase 1b and Phase 2, Arm 1) as described in 
Section 5.2.1
9. Collect pretreatment blood samples:
[
Serum chemistry
[
Hematology
[
MEDI-573 serum concentration (Phase 1b and Phase 2 Arm 1)
[
Anti-drug antibodies (Phase 1b and Phase 2 Arm 1)
[
 
[
 (see Section 7.3.3)
[
[
10. Infuse MEDI-573 (Phase 1b and Phase 2 Arm 1)
11. Collect blood after infusion of MEDI-573 (Phase 1b and Phase 2; Arm 1)
[
MEDI-573 serum concentration (immediately postinfusion [± 5 minutes])
[
 
12. Record posttreatment vital signs (Phase 1b and Phase 2: Arm 1)
[
30 minutes [± 5 minutes] after the start of MEDI-573 infusion
[
60 minutes [± 5 minutes] after the start of MEDI-573 infusion 
[
At the end of infusion [± 10 minutes] 
[
30 minutes [± 5 minutes] postinfusion
[
60 minutes [± 5 minutes] postinfusion
13. Perform 12-lead ECG post-dose (Phase 1b and Phase 2, Arm 1)
14. Continue daily AI treatment
15. Assess for AEs and SAEs
16. Update concomitant medications, as needed
5.1.2.5.1
Every Cycle, Day 1 (± 5 Days) (For subjects continuing on treatment 
under Amendment 3 only)
1. Perform symptom-directed physical examination
2. Record weight
3. Record pretreatment vital signs
4. Infuse MEDI-573 (Phase 1b and Phase 2 Arm 1) every cycle (Q21D)


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
55 of 113
5. Record posttreatment vital signs (Phase 1b and Phase 2: Arm 1)
a.
30 minutes [± 5 minutes] after the start of MEDI-573 infusion
b. 60 minutes [± 5 minutes] after the start of MEDI-573 infusion 
c.
At the end of infusion [± 10 minutes] 
d. 30 minutes [± 5 minutes] postinfusion
e.
60 minutes [± 5 minutes] postinfusion
6. Continue daily AI treatment 
7. Assess for AEs and SAEs 
8. Update concomitant medications, as needed
9. Assess KPS
5.1.2.6
Every 9 Weeks Minus 7 Days (All Subjects) Through 24 Months Post Study 
Entry
For subjects continuing on treatment under Amendment 3, please refer to Section 5.1.2.6.1
for applicable study related procedures.
1. Assess for AEs and SAEs 
2. Update concomitant medications
3. Perform CXR, CT, or MRI scan (complete within 7 days prior to start of next cycle, see 
Section 5.2.6.1 for detailed schedule)
4. Continue daily AI treatment
5.1.2.6.1
Every 9 Weeks (± 7 Days) Post Study Entry unless otherwise specified 
(For subjects continuing on treatment under Amendment 3 only)
1. Collect pretreatment blood samples (continue until End of Treatment):
a.
Serum chemistry
b. Hematology
2. Collect urine or serum for pregnancy test (women of childbearing potential); ensure result 
is negative pretreatment (continue until End of Treatment)
3. Collect urinalysis sample
5.1.2.7
Every 6 Months Plus/Minus 7 Days, Beginning > 24 Months Post Study 
Entry (All Subjects)
For subjects continuing on treatment under Amendment 3, please refer to Section 5.1.2.7.1
for applicable study related procedures.
1. Assess for AEs and SAEs 
2. Update concomitant medications


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
56 of 113
3. Perform CXR, CT, or MRI scan (complete within 7 days prior to start of next cycle, see 
Section 5.2.6.1 for detailed schedule)
4. Continue daily AI treatment
5.1.2.7.1
Every 6 Months (± 7 Days), Beginning > 24 Months Post Study Entry 
(For subjects continuing on treatment under Amendment 3 only)
1. Perform CXR, CT, or MRI scan (complete within 7 days prior to start of next cycle, see 
Section 5.2.6.1 for detailed schedule)
5.1.3
End-of-Treatment Visit (All Subjects Unless Otherwise Specified)
For subjects continuing on treatment under Amendment 3, please refer to Section 5.1.3.1 for 
applicable study related procedures.
1.
a.
b.
2. Perform a complete physical exam
3. Record weight
4. Record vital signs
5. Assess KPS
6. Obtain 12-lead ECG as described in Section 5.2.1
7. Collect blood
[
Serum chemistry
[
Hematology
[
Hemoglobin A1c 
[
MEDI-573 serum concentration (Phase 1b and Phase 2 Arm 1)
[
Anti-drug antibodies (Phase 1b and Phase 2 Arm 1)
[
[
 
[
[
8. Collect urine or serum for pregnancy test (women of childbearing potential)
9. Collect urinalysis sample
10. Assess for AEs and SAEs
11. Update concomitant medications
12. Perform CXR, CT, or MRI scan (unless it has been performed within 14 days of 
treatment discontinuation)


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
57 of 113
5.1.3.1
End-of-Treatment Visit (For subjects continuing on treatment under 
Amendment 3 only)
1. Perform a symptom-directed physical exam
2. Record weight
3. Record vital signs
4. Obtain 12-lead ECG as described in Section 5.2.1
5. Collect blood
a.
Serum chemistry
b. Hematology
6. Collect urine or serum for pregnancy test (women of childbearing potential)
7. Collect urinalysis sample
8. Assess for AEs and SAEs
9. Update concomitant medications
10. Assess KPS
11. Perform CXR, CT, or MRI scan (complete within 7 days prior to start of next cycle, see 
Section 5.2.6.1 for detailed schedule)
5.1.4
Posttreatment Follow-up Period
The reporting period for AEs/SAEs is the period immediately following the time that written 
informed consent is obtained through 60 days after the last dose of MEDI-573 or until the 
subject begins another anticancer therapy, whichever occurs first. New (nonserious) AEs that 
start after the reporting period will not be collected. All AEs/SAEs will be followed to 
resolution through the end of subject participation in the study, even if the date extends 
beyond the reporting period.
5.1.4.1
30 Days (Plus/Minus 3 Days) and 60 Days (Plus/Minus 5 Days) 
Posttreatment (All Subjects Unless Otherwise Specified)
For subjects continuing on treatment under Amendment 3, please refer to Section for 
5.1.4.1.1 applicable study related procedures.
1. Perform directed physical exam
2. Record weight
3. Record vital signs
4. Assess KPS
5. Perform 12-lead ECG (at 30 days after visit only) as described in Section 5.2.1
6. Collect blood
[
Serum chemistry
[
Hematology


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
58 of 113
[
MEDI-573 serum concentration (Phase 1b and Phase 2 Arm 1)
[
Anti-MEDI-573 antibodies (Phase 1b and Phase 2 Arm 1)
[
[
7. Collect urinalysis sample
8. Assess for AEs and SAEs
9. Update concomitant medications
5.1.4.1.1
30 Days (± 3 Days) and 60 Days (± 5 Days) Posttreatment (For subjects 
continuing on treatment under Amendment 3 only)
1. Perform directed physical exam
2. Record weight
3. Record vital signs
4. Collect blood
a.
Serum chemistry
b. Hematology
c.
MEDI-573 serum concentration (Phase 1b and Phase 2, Arm 1)
5. Collect urinalysis sample (at 30 Days Post Last Dose visit only)
6. Obtain 12-lead ECG as described in Section 5.2.1 (30 day posttreatment visit only)
7. Record any subsequent anticancer therapy
8. Anti-MEDI-573 antibodies (Phase 1b and Phase 2, Arm 1)
9. Assess for AEs and SAEs
10. Assess KPS
11. Update concomitant medications
5.1.4.2
Every 9 Weeks (Plus/Minus 7 Days) Posttreatment for Subjects Without 
Progressive Disease Through 24 Months Posttreatment
For subjects continuing on treatment under Amendment 3, there will be no additional 
assessments beyond those indicated at the 60 days posttreatment visit. 
1. Perform directed physical exam
2. Assess KPS
3. Record subsequent anticancer therapy
4. Record survival status
5. Perform CXR, CT, or MRI scan (see Section 5.2.6.1 for detailed schedule)


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
59 of 113
5.1.4.3
Every 3 Months (Plus/Minus 7 Days) Posttreatment
For subjects continuing on treatment under Amendment 3, there will be no additional 
assessments beyond those indicated at the 60 days posttreatment visit. 
1. Record subsequent anticancer therapy
2. Record survival status
3. Collect blood (first 3-month posttreatment visit only)
[
MEDI-573 serum concentration (performed only at first 3-month posttreatment visit;
Phase 1b and Phase 2 Arm 1) 
[
Anti-MEDI-573 antibodies (performed only at first 3-month posttreatment visit;
Phase 1b and Phase 2 Arm 1)
5.1.4.4
Every 6 Months (Plus/Minus 7 Days) Posttreatment Beginning > 24 Months
Post Study Entry For Subjects Without PD
For subjects continuing on treatment under Amendment 3, there will be no additional 
assessments beyond those indicated at the 60 days posttreatment visit. 
1. Perform CXR, CT, or MRI scan (see Section 5.2.6.1 for detailed schedule)
5.2
Description of Study Procedures
A Laboratory Manual will be provided to the sites that specifies the procedures for 
collection, processing, storage, and shipment of samples, as well as laboratory contact 
information.
5.2.1
Medical History, Physical Examination, Electrocardiogram, Weight 
and Vital Signs
A medical history will be recorded at Screening.
Complete physical examinations will be performed by a licensed independent healthcare 
provider (ie, physician, physician’s assistant, or licensed nurse practitioner) as described in 
Table 5.1-1, Table 5.1-2, Table 5.1-3 and Table 5.1-4. Physical examinations will include an 
assessment of head, eyes, ears, nose and throat (HEENT), respiratory, cardiovascular, 
gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological, 
hematologic/lymphatic, and endocrine systems; and height (screening only). A directed 
physical exam will include assessment of only specific organ systems as appropriate based 
on the subject’s complaints/symptoms and should be performed at the time points specified 
in Section 5.1.2. 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
60 of 113
Findings from medical history and physical exam shall be given a baseline grade according 
to the procedure for AEs. Increases in severity of pre-existing conditions during the study 
will be considered AEs, with resolution occurring when the grade returns to or below the 
pre-study grade (baseline).
A 12-lead ECG will be obtained for all subjects at screening, end of treatment, and 30 days 
posttreatment and for subjects enrolled in Phase 1b and Phase 2, Arm 1 only on Day 1 of 
each cycle (see Table 5.1-1, Table 5.1-2, Table 5.1-3 and Table 5.1-4). Prior to Amendment 
3, the specific ECG collection times on Day 1 of each cycle for subjects enrolled in Phase 1b 
and Phase 2, Arm 1 are as follows:  prior to infusion, at the time of completion of infusion (± 
10 minutes), and 2 hours (± 15 minutes) post completion of infusion. For all subjects 
continuing treatment under Amendment 3, ECGs will no longer be collected during treatment 
but will still be collected at end of treatment and 30 days posttreatment. All ECGs should be 
done prior to PK draw for the corresponding time point. Electrocardiogram equipment, with 
instant print-out and electronic transmission capabilities, and training will be provided to all 
study sites. All ECGs performed during the study will be obtained in triplicate (ie, 3 ECGs 
should be obtained within a 5 minute time period). The ECGs will be transmitted and 
interpreted by a central vendor selected by the sponsor.
Vital signs will be collected as described in Table 5.1-1, Table 5.1-2, Table 5.1-3 and 
Table 5.1-4. Vital signs include temperature, blood pressure (seated), pulse rate, respiratory 
rate, and weight (where indicated). For subjects enrolled in Phase 1b and Phase 2, Arm 1, 
vital sign collection times are specified in Sections 5.1.1 and 5.1.2.
5.2.2
Clinical Laboratory Tests
Clinical laboratory safety tests for all study visits will be performed in a licensed clinical 
laboratory. Urine or serum pregnancy tests on Day 1 of each dosing period prior to 
MEDI-573 administration will be performed in the clinic using a licensed test for females of 
childbearing potential. Abnormal laboratory results that are deemed clinically significant by 
the investigator should be repeated as soon as possible (preferably within 24 to 48 hours).
The following clinical laboratory tests will be performed (see Table 5.1-1 and Table 5.1-2 for 
the schedule of assessment for the Screening and Treatment Phases, Table 5.1-3 and 
Table 5.1-4 for the Follow-up Phase):


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
61 of 113
Serum Chemistry
•
Calcium
•
Blood urea nitrogen 
•
Chloride
•
Uric acid
•
Magnesium
•
Creatinine
•
Potassium
•
Total bilirubin
•
Sodium
•
Glucose
•
Aspartate transaminase
•
Albumin
•
Alanine transaminase
•
Total protein
•
Alkaline phosphatase
•
Triglycerides
•
Gamma glutamyl transferase 
•
Cholesterol
•
Lactate dehydrogenase 
Hematology
•
White blood cell count with differential
•
Platelet count
•
Red blood cell count
•
Mean corpuscular volume 
•
Hematocrit
•
Mean corpuscular Hb concentration 
•
Hemoglobin
•
Hemoglobin A1c - performed only at Screening 
and End-of-Treatment visits
Urinalysis
•
Color
•
Glucose
•
Appearance
•
Ketones
•
Specific gravity
•
Blood
•
pH
•
Bilirubin
•
Protein
•
Microscopy including white blood cell/high-
power field, red blood cell/high-power field
Pregnancy Test 
•
Urine human chorionic gonadotropin 
•
Serum KhCG (required at screening visit only. Serum KhCG or urine pregnancy test permitted at 
postscreening visits)
5.2.3
Pharmacokinetic Evaluation and Methods
An electrochemiluminescence (ECL) assay using a Meso Scale Discovery® (MSD) platform 
will be used for the quantitative determination of MEDI-573 in human serum. Blood 
samples for assessment of MEDI-573 serum concentrations will be collected as described in 
Section 5.1.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
62 of 113
5.2.4
Immunogenicity Evaluation and Methods
 
 
 
. Confirmed positive samples will be evaluated for the titer of ADA and will be 
archived for future testing in a neutralizing ADA assay. For all subjects receiving MEDI-573, 
the presence of anti-MEDI-573 antibodies will be assessed at the intervals specified in 
Section 5.1.
5.2.5
Biomarker Evaluation and Methods
 
 
 
 
 
 
 
 
 
 
, 
 
 
 
 
 
 
 
 
 
 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
63 of 113
 
 
 
 
 
5.2.6
Disease Evaluation and Methods
5.2.6.1
Tumor Assessments and Response Criteria
Tumor measurements and assessments will be based on RECIST 1.1 and will be performed 
as specified in Section 5.1. Additional tumor measurements may be performed at the 
discretion of the investigator or according to institutional practice. In subjects who achieve a 
complete response (CR) or partial response (PR) to treatment, tumor measurements will be 
repeated for confirmation at least 4 weeks later using the same imaging tests. The 
confirmatory scan may be conducted at least 4 weeks later or at the regularly scheduled 
response assessments that occur every 9 weeks for subjects on treatment, or at 9 weeks after 
the last dose for subjects without PD. The same tumor assessment method should be used 
throughout the study.
Tumor measurements must be recorded in metric notation by use of a ruler or calipers, and
the same method/technique of tumor assessment must be used throughout the study. 
Imaging-based evaluation is preferred to evaluation by clinical examination when both 
methods have been used to assess the antitumor effect of the treatment. All scans will be 
reviewed locally. Decisions regarding management of individual subjects will be based on 
local interpretation of the imaging data. All scans will be collected and stored for possible 
future central analysis by a third party vendor.
Tumor assessments may include the following evaluations: physical examination, CXR, CT,
or MRI scan of the chest, abdomen, and pelvis, and CT or MRI scan of the brain. Computed 
tomography or MRI scan of the brain will be performed if the subject is neurologically 
symptomatic. The same method must be used for all subsequent tumor assessments. Imaging 
will be completed every 9 weeks, per the schedule of subject evaluations, through 24 months 
post study entry. Imaging will then be completed every 6 months beginning after 24 months 
post study entry through the End of Study.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
64 of 113
•
Physical examination. Lesions detected by physical examination will only be considered 
measurable if superficial, eg, skin nodules and palpable lymph nodes. Documentation by 
color photography including ruler is recommended for estimating the size of skin lesions.
•
Chest x-ray. Lesions considered acceptable for measurement on CXR should be clearly 
defined and surrounded by aerated lung. However, CT is preferable.
•
Computed tomography scans of the chest, abdomen, and pelvis. Computed 
tomography scans should be performed with contiguous cuts in slice thickness of 10 mm 
or less. Spiral CT should be performed using a 5-mm contiguous reconstruction 
algorithm.
•
Magnetic resonance imaging scans. Magnetic resonance imaging is acceptable for 
measurement of lesions provided that the same anatomical plane is used for serial 
assessments. If possible, the same imaging device should be used for serial evaluations. 
In case of MRI, measurements will be preferably performed in the axial (transverse) 
plane on contrast enhanced T1-weighted images. However, there are no specific sequence 
recommendations.
Measurability of Tumor Lesions 
Tumor lesions will be categorized as follows:
•
Measurable Lesions - Must be accurately measured by at least 1 dimension (longest 
diameter in the plane of measurement is to be recorded) with a minimum size of: 
[
10 mm by CT scan (irrespective of scanner type) or MRI (no less than double the 
slice thickness and a minimum of 10 mm) 
[
10 mm caliper measurement by clinical exam (when superficial)
[
20 mm by CXR (if clearly defined and surrounded by aerated lung)
[
Malignant lymph nodes are considered pathologically enlarged and measurable, a 
lymph node must be P 15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).
•
Nonmeasurable Lesions - Nonmeasurable lesions are defined as all other lesions (or 
sites of disease), including small lesions (longest diameter < 20 mm with conventional 
techniques or < 10 mm using spiral CT scan). Lesions considered truly nonmeasurable 
include the following: leptomeningeal disease, ascites, pleural/pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, and abdominal 
masses/abdominal organomegaly identified by physical exam that is not measurable by 
reproducible imaging techniques.
•
Target Lesions - All lesions up to a maximum of 5 lesions total (and a maximum of two 
lesions per organ) representative of all involved organs should be identified as target 
lesions. It may be the case that, on occasion, the largest lesion does not lend itself to 
reproducible measurement in which circumstance the next largest lesion which can be 
measured reproducibly should be selected.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
65 of 113
•
Nontarget Lesions - It is possible to record multiple nontarget lesions involving the 
same organ as a single item on the case record form (eg, “multiple enlarged pelvic lymph 
nodes” or “multiple liver metastases”)
Response Criteria
Evaluation of Target Lesions
•
Complete Response - Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to < 10 mm (the sum may 
not be “0” if there are target nodes). 
•
Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters.
•
Progressive Disease- At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more 
new lesions is also considered progression).
•
Stable Disease - Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters while on study.
Evaluation of Nontarget Lesions
•
Complete Response - Disappearance of all nontarget lesions and normalization of tumor 
marker level. All lymph nodes must be nonpathological in size (< 10 mm short axis). 
•
Non-CR/Non-PD - Persistence of 1 or more nontarget lesion(s) and/or maintenance of 
tumor marker level above the normal limits.
•
Progressive Disease - Unequivocal progression of existing nontarget lesions will be 
defined as the overall level of substantial worsening in nontarget disease such that, even 
in the presence of stable disease (SD) or PR in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therapy. In the absence of 
measurable disease, change in nonmeasurable disease comparable in magnitude to the 
increase that would be required to declare PD for measurable disease. Examples include 
an increase in a pleural effusion from ‘trace’ to ‘large’, an increase in lymphangitic 
disease from localized to widespread.
Evaluation of Overall Response
Table 5.2.6.1-1 provides overall responses for all possible combinations of tumor responses 
in target and nontarget lesions with or without the appearance of new lesions.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
66 of 113
Table 5.2.6.1-1
Evaluation of Overall Response
Target Lesions (T)
Nontarget Lesions (NT)
New Lesions
Overall Response
CR
CR
No
CR
No-T b
CR
No
CR
CR
NE a
No
PR
CR
Non-CR/Non-PD
No
PR
PR
Non-PD and NE a
No
PR
SD
Non-PD and NE a
No
SD
Not all evaluated
Non-PD
No
NE
No-T b
Not all evaluated
No
NE
No-T b
Non-CR/Non-PD
No
Non-CR/Non-PD
PD
Any
Yes/No
PD
Any
PD
Yes/No
PD
Any
Any
Yes
PD
No-T b
Unequivocal PD
Yes or No
PD
No-T b
Any
Yes
PD
CR = complete response; NE = not evaluable; PR = partial response; SD = stable disease; PD = progressive 
disease
a
Not evaluable is defined as either when no or only a subset of lesion measurements are made at an 
assessment.
b
No-T is defined as no target lesions at baseline.
Overall Survival Outcomes
Survival will be followed approximately every 3 months by clinic visit or telephone until the 
end of the study.
5.2.6.2
 
 
 
 
.
 
 
 
 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
67 of 113
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.7
Estimate of Volume of Blood to Be Collected 
In Phase 1b, the estimated volume of blood to be collected for screening for each subject is 
40 mL. The estimated volume of blood to be collected during the first treatment cycle is 
130 mL and during every other cycle is 60 mL. In Phase 2, the estimated volume of blood to 
be collected during the first treatment cycle is 125 mL and during every other cycle is 60 mL. 
The total volume of blood to be collected for all subjects will depend on the number of cycles 
administered and the length of follow-up.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
68 of 113
6
ASSESSMENT OF SAFETY
6.1
Safety Parameters
6.1.1
Adverse Events
The International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice 
(GCP) E6(R1) defines an AE as:
•
Any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
An AE includes, but is not limited to, any clinically significant worsening of a subject’s 
pre-existing condition. An abnormal laboratory finding (including ECG finding) that requires 
an action or intervention by the investigator, or a finding judged by the investigator to 
represent a change beyond the range of normal physiologic fluctuation, should be reported as 
an AE.
Adverse events may be treatment-emergent (ie, occurring after initial receipt of 
investigational product) or nontreatment-emergent. A nontreatment-emergent AE is any new 
sign or symptom, disease, or other untoward medical event that begins after written informed 
consent has been obtained but before the subject has received investigational product.
Elective or preplanned (ie, scheduled prior to the subject being enrolled into the study) 
treatments or surgeries for documented pre-existing conditions are not considered AEs 
(serious or nonserious) if deemed unrelated to MEDI-573.
6.1.2
Serious Adverse Events
An SAE is any AE that:
•
Results in death
•
Is immediately life-threatening. This term refers to an event in which the subject was at 
risk of death at the time of the event; it does not refer to an event that may have led to 
death.
•
Requires inpatient hospitalization or prolongation of existing hospitalization. In general, 
hospitalization signifies that the subject has been detained (usually involving at least an 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
69 of 113
overnight stay) at the hospital or emergency ward for observation and/or treatment that 
would not have been appropriate in an outpatient setting. 
•
Results in persistent or significant disability/incapacity. The term disability means a 
substantial disruption of a person’s ability to conduct normal life functions. 
•
Is a congenital anomaly/birth defect in offspring of the subject
•
Is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above. Medical or scientific judgment 
should be exercised in deciding whether expedited reporting is appropriate in this 
situation. Examples of medically important events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions 
that do not result in hospitalizations; or development of drug dependency or drug abuse.
6.2
Assessment of Safety Parameters
6.2.1
Assessment of Severity
Assessment of severity is one of the responsibilities of the investigator in the evaluation of 
AEs and SAEs. Severity will be graded according to the NCI CTCAE v4.0 as provided in 
Appendix 5. The determination of severity for all other events not listed in the NCI CTCAE 
should be made by the investigator based upon medical judgment and the severity categories 
of Grade 1 to 5 as defined below.
Grade 1 (mild)
An event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not 
generally interfere with usual activities of daily living.
Grade 2 (moderate)
An event that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities 
of daily living, causing discomfort, but poses no significant or 
permanent risk of harm to the subject.
Grade 3 (severe)
An event that requires intensive therapeutic intervention. The 
event interrupts usual activities of daily living, or significantly 
affects the clinical status of the subject.
Grade 4 (life threatening) An event, and/or its immediate sequelae, that is associated with an 
imminent risk of death or with physical or mental disabilities that 
affect or limit the ability of the subject to perform activities of 
daily living (eg, eating, ambulation, toileting, etc).
Grade 5 (fatal)
Death (loss of life) as a result of an event.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
70 of 113
It is important to distinguish between serious criteria and severity of an AE. Severity is a 
measure of intensity whereas seriousness is defined by the criteria in Section 6.1.2. A Grade 
3 AE need not necessarily be considered an SAE. For example, a Grade 3 headache that 
persists for several hours may not meet the regulatory definition of an SAE and would be 
considered a nonserious event, whereas a Grade 2 seizure resulting in a hospital admission 
would be considered an SAE.
6.2.2
Assessment of Relationship
6.2.2.1
Relationship to Investigational Product
The investigator is required to provide an assessment of relationship of AEs and SAEs to the 
investigational product.
An event will be considered “not related” to use of the investigational product if any of the 
following tests are met:
•
An unreasonable temporal relationship between administration of the investigational 
product and the onset of the event (eg, the event occurred either before or too long after 
administration of the investigational product for it to be considered product-related)
•
A causal relationship between the investigational product and the event is biologically 
implausible (eg, death as a passenger in an automobile accident)
•
A clearly more likely alternative explanation for the event is present (eg, typical adverse 
reaction to a concomitant drug and/or typical disease-related event)
Individual AE/SAE reports will be considered “related” to use of the investigational product 
if the “not related” criteria are not met. 
“Associated with the use of the drug” means that there is a “reasonable possibility” that the 
event may have been caused by the product under investigation (ie, there are facts, evidence, 
or arguments to suggest possible causation).
6.2.2.2
Relationship to Protocol Procedures
The investigator is also required to provide an assessment of relationship of SAEs to protocol 
procedures on the SAE Report Form. This includes nontreatment-emergent SAEs (ie, SAEs 
that occur prior to the administration of investigational product) as well as treatment-
emergent SAEs. A protocol-related SAE may occur as a result of a procedure or intervention 
required during the study (eg, blood collection, washout of an existing medication). The 
following guidelines should be used by investigators to assess the relationship of SAEs to the 
protocol:


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
71 of 113
Protocol-related:
The event occurred due to a procedure/intervention that was described 
in the protocol for which there is no alternative etiology present in the 
subject’s medical record.
Not protocol-related: The event is related to an etiology other than the procedure/ 
intervention that was described in the protocol (the alternative etiology 
must be documented in the study subject’s medical record).
6.3
Recording of Safety Parameters
6.3.1
Recording of Adverse Events and Serious Adverse Events
Adverse events will be recorded on the CRF using a recognized medical term or diagnosis 
that accurately reflects the event. Adverse events will be assessed by the investigator for 
severity, relationship to the investigational product, possible etiologies, and whether the 
event meets the criteria of an SAE and therefore requires immediate notification to 
MedImmune Patient Safety. See Section 6.1.2 for the definition of SAEs, and Section 6.2.1
and Section 6.2.2 for guidelines for assessment of severity and relationship, respectively. If 
an AE evolves into a condition that meets the regulatory definition of “serious,” it will be 
reported on the SAE Report Form.
6.4
Reporting Requirements for Safety Parameters
6.4.1
Study Reporting Period and Follow-up for Adverse Events
The reporting period for AEs is the period immediately following the time that written 
informed consent is obtained through 60 days after the subject’s last dose of MEDI-573 or 
until the subject begins another anticancer therapy, whichever occurs first. New (nonserious) 
AEs that start after the reporting period will not be collected. All AEs will be followed to 
resolution through the end of subject participation in the study, even if the date extends 
beyond the reporting period.
6.4.2
Reporting of Serious Adverse Events
6.4.2.1
Study Reporting Period and Follow-up for Serious Adverse Events
The reporting period for SAEs is the period immediately following the time that written 
informed consent is obtained through 60 days after the subject’s last dose of treatment or 
until the subject begins another anticancer therapy, whichever occurs first. The reporting 
period for protocol-related SAEs (see Section 6.1.2) is the period immediately following the 
time that written informed consent is obtained through the end of subject participation in the 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
72 of 113
study. After submitting an initial SAE report for a subject (to MedImmune Patient Safety), 
the investigator is required to follow the subject proactively and provide further information 
on the subject’s condition to MedImmune Patient Safety.
At any time after completion of the study, if an investigator or qualified designee becomes 
aware of an SAE that is suspected by the investigator or qualified designee to be related to 
investigational product, the event must be reported to MedImmune Patient Safety.
The investigator is responsible for following all SAEs until resolution, until the subject 
returns to baseline status, or until the condition has stabilized with the expectation that it will 
remain chronic, even if this extends beyond study participation. 
6.4.2.2
Notifying the Sponsor of Serious Adverse Events
Within 24 hours of identifying an SAE, regardless of the presumed relationship to the 
investigational product, the investigator or qualified designee must complete the SAE 
Report Form and fax it to MedImmune Patient Safety.
MedImmune contact information: 
Patient Safety 
MedImmune
One MedImmune Way
Gaithersburg, MD 20878
Fax: +1 301 398 4205
Note: Sites outside of North America should use the international fax number indicated on 
the SAE form.
The sponsor is responsible for reporting certain SAEs as expedited safety reports to 
applicable regulatory authorities, ethics committees, and participating investigators, in 
accordance with ICH Guidelines and/or local regulatory requirements (see Section 6.4.2.3). 
The sponsor may be required to report certain SAEs to regulatory authorities within 
7 calendar days of being notified about the event; therefore, it is important that investigators 
submit additional information requested by the sponsor as soon as it becomes available.
Investigators should provide all available information at the time of SAE Report Form 
completion. Investigators should not wait to collect additional information to fully document 
the event before notifying MedImmune Patient Safety of an SAE. When additional 
information becomes available, investigators should submit a follow-up SAE Report Form 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
73 of 113
(separate from the initial report form) with the new information. Any follow-up information 
to an SAE also needs to be provided to MedImmune Patient Safety within 24 hours of 
learning of the new information.
6.4.2.3
Safety Reporting to Investigators, Institutional Review Boards or 
Independent Ethics Committees, and Regulatory Authorities
The sponsor is responsible for reporting all applicable SAEs to regulatory authorities, 
investigators, and IRBs/IECs, as applicable, in accordance with national regulations in the 
countries where the study is conducted. The sponsor will also prepare an expedited report for 
other safety issues where these might materially alter the current benefit-risk assessment of 
an investigational product or that would be sufficient to consider changes in the 
administration of the investigational product or in the overall conduct of the study.
For all investigators located in the European Economic Area, the sponsor will be responsible 
for reporting suspected unexpected serious adverse reactions and any other applicable SAEs 
to regulatory authorities including the European Medicines Agency, investigators, and 
IRBs/IECs, as applicable, in accordance with national regulations in the countries where the 
study is conducted. Suspected unexpected serious adverse reactions will be submitted within 
7 days for fatal and life-threatening events and within 15 days for other serious events, unless 
otherwise required by national regulations.
For all other investigators, the sponsor will prepare an expedited report for all SAEs that are 
unexpected and potentially related to the investigational product, and copies will be 
distributed to all concerned regulatory authorities, investigator(s), and IRBs/IECs according 
to applicable laws and regulations. The investigational site also will forward a copy of all 
expedited reports to the site’s applicable IRB/IEC. Investigators must also submit safety 
information provided by the sponsor to the IRB/IEC as detailed in Section 10.1 and 
Section 10.2.
6.4.3
Other Events Requiring Immediate Reporting
6.4.3.1
Overdose
An overdose is defined as a subject receiving a dose of investigational product in excess of 
that specified in the Investigator’s Brochure, unless otherwise specified in this protocol.
Any overdose of a study subject with the investigational product, with or without associated 
AEs/SAEs, is required to be reported within 24 hours of knowledge of the event to 
MedImmune Patient Safety using the Fax Notification Form (see Section 6.4.2.2 for contact 
information). If the overdose results in an AE, the AE must also be recorded on the AE CRF 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
74 of 113
(see Section 6.3.1). Overdose does not automatically make an AE serious, but if the 
consequences of the overdose are serious, eg, death or hospitalization, the event is serious 
and must be reported as an SAE (see Section 6.3.1 and Section 6.4.2).
6.4.3.2
Pregnancy
Pregnancy in a female subject who has received investigational product is required to be 
reported within 24 hours of knowledge of the event to MedImmune Patient Safety using the 
Fax Notification Form (see Section 6.4.2.2 for contact information).
Subjects who become pregnant during the study period must not receive additional doses of 
investigational product but will not be withdrawn from the study. After obtaining the 
subject’s consent, the pregnancy will be followed for outcome of the mother and child 
(including any premature terminations) and should be reported to MedImmune Patient Safety
after outcome.
6.4.3.3
Events Meeting Study Stopping Criteria
Events that meet any of the study stopping criteria (Section 3.3), with or without associated 
AEs or SAEs, are required to be reported within 24 hours of knowledge of the event to 
MedImmune Patient Safety using the Safety Fax Notification Form (see Section 6.4.2.2 for 
contact information). The occurrence of these events does not automatically make an AE 
serious, but if the consequences of the event are serious, eg, death or hospitalization, the 
event is serious and must be reported as an SAE (see Section 6.3.1 and Section 6.4.2).
6.5
Safety Management During the Study
The medical monitor has primary responsibility for the ongoing medical review of safety 
data throughout the study. This includes review of SAEs and timely review of AEs and 
“other events” reported during the study. MedImmune Patient Safety is responsible for the 
receipt, immediate medical/clinical review, investigation, and follow-up of SAEs and other 
immediately reportable events (eg, overdose and pregnancies) from the clinical study sites.
The MedImmune SMC will regularly review safety data and the decisions of the medical 
monitor regarding dose escalation throughout the study and make recommendations 
regarding further conduct of the study if required. At any time during the study, the 
MedImmune SMC will also review safety data assessed by the medical monitor as medically 
relevant.
A study-specific safety committee will provide ongoing safety surveillance of the study, with 
regularly scheduled reviews of safety and other relevant data. This committee will be 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
75 of 113
responsible for dose-escalation decisions and recommendations regarding further conduct of 
the study. This committee will also review data at other time points in response to AEs 
assessed as medically relevant by the medical monitor and will communicate outcomes and 
decisions to the MedImmune SMC. 
A formal data monitoring committee (DMC) consisting of a biostatistician and multiple 
clinicians who have appropriate expertise will be established to monitor the safety of subjects 
in this study. The DMC will consist of external advisory members, who are not MedImmune 
employees, must be independent of study sites, and must have no financial or other conflict 
of interest in accordance with the DMC Charter. The DMC, in accordance with its Charter, 
will review data in response to AEs felt to be medically significant by the medical monitor, 
or in accordance with Section 3.3 and Section 4.5.8.1. The DMC will also review safety data 
on a periodic basis throughout the study. The DMC is advisory to the MedImmune SMC.
7
STATISTICAL CONSIDERATIONS
7.1
General Considerations
Data will be provided in data listings sorted by treatment group and subject number. Tabular 
summaries will be presented by treatment group. Categorical data will be summarized by the 
number and percentage of subjects in each category. Continuous variables will be 
summarized by descriptive statistics, including mean, standard deviation, median, minimum, 
and maximum. Confidence intervals will be 2-sided, unless otherwise stated. Details of 
endpoint analyses will be described in the statistical analysis plan.
7.2
Analysis Populations
The Intent-to-Treat Population includes all subjects who are enrolled in the Phase 1b portion 
or randomized into the Phase 2 portion of the study. The treatment arm in the Phase 2 portion 
will be assigned according to the initial randomization, regardless of whether subjects receive 
any investigational product or receive an investigational product different from that to which 
they were randomized.
The Evaluable Population for Phase 1b includes all subjects enrolled in the Phase 1b who 
receive at least 1 full cycle of MEDI-573 and complete the safety follow-up through the DLT 
evaluation period (defined in Section 4.5.8.1) or experience any DLT during the DLT 
evaluation period.
The Per-Protocol Population includes all subjects who are in the randomization phase of the 
study, receive any investigational product, have at least one postbaseline tumor assessment, 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
76 of 113
and have no major protocol violations. The Per-Protocol Population will be identified prior to 
database lock.
The Safety Population includes all subjects who receive any investigational product.
For the Evaluable Population for Phase 1b, the Safety Population, and the Per-Protocol 
Population, treatment arm will be assigned according to the investigational product that is 
actually received.
7.3
Endpoints
7.3.1
Primary Endpoints
The endpoints related to the primary objectives are described in the sections below.
7.3.1.1
Primary Safety Endpoint
The primary safety endpoints are the following:
•
Adverse events and SAEs occurring during the protocol-specified reporting period (as 
defined in Section 6.4)
•
Dose-limiting toxicities occurring during the DLT period in the Phase 1b portion of this 
study 
Adverse events, treatment-related AEs and SAEs will be summarized by system organ class
and MedDRA preferred term, severity, and relationship to investigational product. The safety 
analysis will be descriptive with no formal statistical comparisons.
The number and percentage of subjects with DLT in the Evaluable Population for Phase 1b 
of this study will be summarized.
7.3.1.2
Primary Efficacy Endpoint
Progression-free survival is the primary endpoint for assessing antitumor activity and will be 
measured from randomization until the documentation of disease progression or death due to 
any cause, whichever occurs first. Disease progression is defined according to RECIST 1.1 
guidelines. Progression-free survival will be censored on the date of the last tumor 
assessment documenting absence of tumor progression for subjects who have no documented
progression and are still alive prior to data cutoff, dropout, or the initiation of alternate 
anticancer treatment. Subjects having no tumor assessments after randomization will have 
PFS censored on the date of randomization.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
77 of 113
Progression-free survival will be evaluated using the Kaplan-Meier method and comparisons 
among the treatment groups will be performed using the log-rank test. Progression-free 
survival will be summarized based on the Intent-to-Treat Population in the randomization 
phase of the study as the primary analysis. Several sensitivity analyses may be conducted 
based on different analysis populations, tumor response determined by different reviewers, 
different methods of handling of missing data, or other statistical analysis methods. The 
details of the sensitivity analyses will be described in the statistical analysis plan.
7.3.2
Secondary Endpoints
The secondary endpoints related to safety and tolerability of MEDI-573 when used in 
combination with an AI, PK/pharmacodynamic assessments, IM of MEDI-573, and 
antitumor activities are presented below.
7.3.2.1
Safety and Tolerability of MEDI-573 in Phase 2
The safety endpoints include AEs, SAEs, and changes in clinical laboratory evaluations from 
baseline. These will be summarized using the same method as stated in Section 7.3.1.1.
7.3.2.2
Pharmacokinetic Endpoint
Individual MEDI-573 concentrations will be tabulated by dose cohort along with descriptive 
statistics. Noncompartmental PK data analysis will be performed for data obtained from each 
dose cohort with scheduled PK sample collection. Descriptive statistics of noncompartmental 
PK parameters (AUC, Cmax, systemic clearance, half-life) will be provided.
7.3.2.3
Pharmacodynamic Endpoints
Circulating IGF-I and IGF-II levels will be summarized by dose cohort and descriptive 
statistics will be used. The time course of circulating IGF will be graphed based on dose 
group. Exposure-response analysis will be conducted to explore the relationship between 
MEDI-573 exposure and circulating biomarkers (such as IGF-I and IGF-II).
7.3.2.4
Immunogenicity of MEDI-573
Immunogenicity results will be assessed by summarizing the number and percentage of 
subjects who develop detectable anti-MEDI-573 antibodies for all subjects entered in 
Phase 1b and Phase 2 (Arm 1 and Arm 2). The ADA titer will be reported for samples 
confirmed positive for the presence of anti-MEDI-573 antibodies. The effect of ADA on PK, 
pharmacodynamics, and safety will be evaluated.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
78 of 113
7.3.2.5
Secondary Efficacy Endpoints
The secondary endpoints for assessing antitumor activity include ORR, time to response, 
duration of response (DR), time to progression (TTP), and OS and change in tumor size. 
Response Evaluation Criteria in Solid Tumors v1.1 guidelines will be used to evaluate tumor 
response.
•
Objective response rate is defined as the proportion of subjects with confirmed CR or 
confirmed PR according to RECIST 1.1 guidelines. Confirmed responses are those that 
persist on repeat imaging study P 4 weeks after the initial documentation of response.
•
Time to response will be measured from randomization to the first documentation of 
objective response and will only be assessed in subjects who have achieved objective 
response.
•
Duration of response will be defined as the duration from the first documentation of 
objective response to the first documented disease progression. The DR will be censored 
on the date of last tumor assessment documenting absence of disease progression for 
subjects who have no documented progression prior to data cutoff, dropout, or the 
initiation of alternate anticancer treatment. The DR will only be evaluated for the 
subgroup of subjects with an objective response.
•
Time to progression will be measured from randomization until the documentation of 
disease progression. Disease progression is defined according to RECIST 1.1 guidelines. 
The TTP will be censored on the date of last tumor assessment documenting absence of 
tumor progression for subjects who have no documented progression prior to data cutoff, 
dropout, or the initiation of alternate anticancer treatment. Subjects having no tumor 
assessments after randomization will have TTP censored on the date of randomization. 
•
Overall survival will be determined as the time from randomization until death due to any 
cause. For subjects who are alive at the end of study or lost to follow-up, OS will be 
censored on the last date when subjects are known to be alive. 
•
Change in tumor size will be summarized by the percent change of the sum of the longest 
diameters for target tumor(s) from baseline.
The time-to-event data, including time to response, DR, TTP, and OS, will be evaluated 
using Kaplan-Meier methods. The ORR will be summarized by study arm and compared 
using Fisher's exact test between three study arms. The 95% confidence interval of the ORR 
for each study arm will be calculated based on an exact probability method. The change in 
tumor size will be analyzed using appropriate statistical methods.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
79 of 113
7.3.3
Exploratory Endpoints
 
 
•
•
 
 
•
 
 
•
 
 
•
 
 
•
 
 
.
•
 
 
7.4
Planned Analysis
Two formal analyses are planned for the study. The primary analysis of PFS and safety will 
be performed after 122 PFS events have occurred. The final analysis of OS and safety will be 
performed at the end of study as defined in Section 4.8.
7.5
Sample Size and Power Calculations
In the Phase 1b portion of the study, a minimum of 9 evaluable subjects (3 each at the 
MEDI-573 
 mg/kg dose levels) will be required to evaluate the safety and 
tolerability of 3 doses of MEDI-573 in combination with an AI. Up to 18 evaluable subjects 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
80 of 113
(6 subjects each at 3 dose levels) may be needed if DLT occurs. A subject will be considered 
evaluable if the subject receives 1 full cycle of MEDI-573 and is followed for safety through 
the DLT evaluation period (as defined in Section 4.5.8.1) or if the subject experiences a DLT 
in the DLT evaluation period. Any nonevaluable subject will be replaced.
In the Phase 2 portion of the study, the primary objective is to compare PFS among subjects 
treated at
 mg/kg MEDI-573 and an AI versus subjects treated with single-agent AI 
alone. The assumed median PFS for subjects with single-agent AI alone is 9.4 months 
(Mouridsen et al, 2001) and the expected median PFS for subjects receiving the 
mg/kg 
dose of MEDI-573 plus an AI is 13.4 months, which represents an improvement in PFS of 
42.6% and corresponds to a hazard ratio (HR) of 0.7. Based on these assumptions, a total of 
122 events (ie, subjects with disease progression or death) are required to provide 75% power 
for the log-rank test at a 2-sided significance level of 0.2. With a planned accrual period of 
12 months and a minimum follow-up period of 14 months, it is estimated that a total of 
approximately 178 subjects are needed to observe 122 PFS events by the end of the 
minimum follow-up period. The primary analysis (log-rank test) will be performed after 122 
PFS events have occurred.  If the expected median PFS in MEDI-573 arm is 13.8 or 14.4 
months (corresponding to HR of 0.68 or 0.653), the power will change to 80% or 85%, 
respectively, with 122 PFS events.
8
DIRECT ACCESS TO SOURCE DOCUMENTS
The study will be monitored by the sponsor on a regular basis throughout the study period. 
During monitoring visits, the investigator will provide direct access to all source 
documentation relevant to the subject’s participation in the study. Source documentation 
includes, but is not limited to, the subject’s clinic and/or office chart, hospital chart, informed 
consent forms, treatment notes, laboratory reports, pharmacy records, radiographs, recorded 
data from automated instruments, and any other records maintained to conduct and evaluate 
the clinical study. The investigator must also ensure that direct access to study documents be 
made available for study-related audits, IRB/IEC review, or regulatory inspection.
9
QUALITY CONTROL AND QUALITY ASSURANCE
9.1
Data Collection
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate and accurate case histories for the subjects treated under this protocol. 
Case histories include CRFs and supporting data including, but not limited to, signed and 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
81 of 113
dated informed consent forms, progress notes, hospital charts, nurse’s notes, diary cards, 
laboratory reports, ECG strips, etc.
Subject demographics and key/essential disease baseline characteristics thought to affect 
outcome, ie, stratification variables and other prognostic factors, will be collected, as 
available, for all subjects who provide written informed consent. For subjects who provide 
informed consent and were not entered/randomized into the study, the reason the subject was 
not entered/randomized, ie, did not meet one or more inclusion criteria, met one or more 
exclusion criteria, or other (eg, lost to follow-up, consent withdrawn), will also be collected.
9.2
Study Monitoring
The primary source document for this study will be the subject’s medical record. If separate 
research records are maintained by the investigator(s), both the medical record and the 
research records will be monitored/audited for the purposes of the study.
The investigator and institutions involved in the study will permit study-related monitoring 
and provide direct access to all study records and facilities. Adequate time and space for 
monitoring visits should be made by the investigator or other investigator site staff.
The monitor will visit study facilities at periodic intervals, in addition to maintaining 
necessary contact through telephone, e-mail, and letter. The monitor will assess subject 
enrollment and informed consent procedures; investigational product storage, dispensing, 
administration and accountability; compliance with protocol procedures; completeness and 
accuracy of data entered onto validated data collection instruments (paper CRF or electronic 
data screen) against original source documents; and the occurrence of AEs/SAEs. All aspects 
of the study will be carefully monitored for compliance with the protocol, applicable 
regulatory requirements, GCP, and the site’s standard operating procedures.
The monitor will discuss the conduct and progress of the study with the investigator and 
other site staff. The investigator must cooperate with the monitor to ensure that corrective 
action is taken to resolve any problems noted in the course of the monitoring, and that the 
preventative measures are put into place to prevent recurrence of issues. In cases where 
compliance is not achieved, shipment(s) of investigational product to the investigator will be 
discontinued and study participation by that investigator will be terminated.
9.3
Audit and Inspection of the Study
During the conduct of the study, the sponsor or its representative may conduct audits of any 
data and any facility participating in the study. The investigator and institutions involved in 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
82 of 113
the study will permit such study-related audits and provide direct access to all study records 
and facilities. The investigator must maintain a comprehensive and centralized filing system 
of all study-related documentation that is suitable for inspection by the sponsor or its 
designated monitors, auditors, or regulatory agency representatives. The investigator agrees 
to participate in audits conducted at a convenient time in a reasonable manner.
Government regulatory authorities may also perform inspections either during or after the 
study. In the event of an inspection by any regulatory authority, the investigator should 
promptly notify the sponsor. The investigator agrees to cooperate fully with inspections 
conducted by regulatory authorities and to allow representatives of the regulatory authority 
access to all study records. The investigator will forward to the sponsor a copy of any 
inspection records received.
10 ETHICS
10.1
Regulatory Considerations
The study will be conducted in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with the ICH guidelines on GCP, any applicable 
laws and requirements, and any conditions required by a regulatory authority and/or IRB/IEC 
that approves this study to be conducted in its territory. Good clinical practice is defined as a 
standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and 
reporting of clinical studies in a way that provides assurance that the data and reported results 
are credible and accurate, and that the rights, safety, and well-being of study subjects are 
protected.
Per GCP, the protocol will be reviewed and approved by the IRB or IEC of each participating 
center prior to study initiation. Serious adverse events, regardless of causality, will be 
reported to MedImmune Patient Safety, and the investigator will keep the IRB/IEC informed 
as to the progress of the study.
The investigator will explain the nature of the study and will inform the subject/legal 
representative that participation is voluntary and that the subject can withdraw or be 
withdrawn from the study at any time. Written informed consent will be obtained from each 
subject/legal representative prior to the screening procedures to determine if study eligibility 
criteria are met. A copy of the signed consent form will be given to every subject/legal 
representative, and the original will be maintained with the subject’s records.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
83 of 113
10.2
Institutional Review Board or Independent Ethics Committee
A list of IRB/IEC members or a Statement of GCP Compliance should be obtained by the 
investigator and provided to the sponsor.
Any documents that the IRB/IEC may need to fulfill its responsibilities, such as protocol 
amendments, and information concerning subject recruitment, payment, or compensation 
procedures, or information from the sponsor will be submitted to the IRB/IEC. The 
IRB/IEC’s written unconditional approval of the study protocol, the informed consent 
form(s), and any other written materials to be provided to subjects will be in the possession 
of the investigator and the sponsor before the study is initiated. The IRB/IEC’s unconditional 
approval statement will be transmitted by the investigator to the sponsor prior to shipment of 
investigational product supplies to the site. This approval must refer to the study by exact 
protocol title and number, and should identify the documents reviewed and the date of 
review.
Protocol modifications or changes may not be initiated without prior written IRB/IEC 
approval except when necessary to eliminate immediate hazards to the subjects or when the 
change(s) involves only logistical or administrative aspects of the study. Such modifications 
will be submitted to the IRB/IEC and written verification that the modification was submitted 
should be obtained.
The IRB/IEC must be informed by the investigator of informed consent form changes or 
revisions of other documents originally submitted for review; serious and/or unexpected 
adverse experiences occurring during the study; new information that may affect adversely 
the safety of the subjects or the conduct of the study; an annual update and/or request for 
re-approval; and when the study has been completed.
10.3
Informed Consent
Freely given informed consent will be obtained and documented for all subjects under this 
protocol (or a subject’s legal representative, if the subject is unable to provide informed 
consent) in accordance with ethical principles that have their origin in the Declaration of 
Helsinki and are consistent with the ICH guidelines on GCP, any applicable laws and 
requirements, and any conditions required by a regulatory authority and/or IRB/IEC.
Information should be given in both oral and written form, and subjects or their legal 
representatives must be given ample opportunity to inquire about details of the study. 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
84 of 113
The consent form(s) generated by the investigator must be approved by the IRB/IEC and be 
acceptable to the sponsor. Consent forms must be written so as to be understood by the 
prospective subject/legal representative. Informed consent will be documented by the use of 
a written consent form(s) approved by the IRB/IEC and signed and dated by the subject or 
the subject’s legal representative, and by the person who conducted the informed consent 
discussion. The signature confirms the consent is based on information that has been 
understood. Each subject’s signed informed consent form(s) must be kept on file by the 
investigator for possible inspection by the sponsor or its designated monitors, auditors, or 
regulatory agency representatives. The subject or the subject’s legal representative should 
receive a copy of the signed and dated written informed consent form(s) and any other 
written information provided to the subject, and should receive copies of any signed and 
dated consent form updates and any amendments to the written information provided to 
subjects. 
10.4
Withdrawal of Consent for Continued Study Participation
Data and Samples Obtained for the Main Study
Study data are protected by the use of a SID number, which is a number specific to the 
subject. The investigator is in control of the information that is needed to connect a study 
sample to a subject. A subject’s consent to the use of data does not have a specific expiration 
date, but the subject may withdraw consent at any time by notifying the investigator. If 
consent is withdrawn, any data collected prior to that time may still be given to and used by 
the sponsor but no new data or samples will be collected unless specifically required to 
monitor safety of the subject.
Samples Obtained for Genetic Research or Future Research
Samples obtained for genetic research or future research will be labeled with a sample 
identification number but will not be labeled with personal identifiers such as the subject’s 
name. A file linking this sample identification number with the SID number will be kept in a 
secure place at the sponsor with restricted access. If the subject withdraws consent for 
participating in the genetic research or future research, this link will allow the sponsor to 
locate the subject’s sample and destroy it. The coding of samples and results is to ensure that 
these research results are kept confidential by keeping the subject’s identity and these results 
separate.
If the subject consents to have his/her samples used for genetic research or future research, 
this additional research may not start immediately and may start at any time during the 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
85 of 113
storage period. The subject’s sample(s) including any specimens of extracted DNA will be 
stored by the sponsor with similar samples from other subjects at MedImmune. The subject’s 
samples will not be kept for more than 25 years after the end of the study in which they were 
collected. If the subject chooses not to allow his/her study samples to be used for genetic 
research or future research, the samples will be destroyed by the sponsor at the conclusion of 
the main study.
If consent is withdrawn after a sample has been taken but before the subject’s sample is sent 
to the sponsor for genetic research or future research, the investigator will arrange to have it 
destroyed. If consent is withdrawn after the subject’s sample(s) have been sent to the sponsor 
for genetic research or future research, the sponsor and the investigator will ensure that these 
sample(s) are destroyed unless the sample identification number has been removed and the 
subject can no longer be linked to any sample(s). However, if the subject’s samples have 
already been used for research, the sponsor is not required to destroy results of this research. 
In this case, only the remaining sample(s) will be destroyed.
11 DATA HANDLING AND RECORD KEEPING
To maintain confidentiality, all laboratory specimens, evaluation forms, reports, and other 
records transmitted outside the clinical site will be identified by a SID or coded number. All 
study records, source medical records, and code sheets or logs linking a subject’s name to an 
SID number will be kept in a secure location. Study records such as CRFs may be maintained 
electronically and require the same security and confidentiality as paper. Clinical information 
will not be released without written permission of the subject/legal representative, except as 
specified in the informed consent form(s) (eg, necessary for monitoring by regulatory 
authorities or the sponsor of the clinical study). The investigator must also comply with all 
applicable privacy regulations (eg, HIPAA 1996, EU Data Protection Directive 95/46/EC).
Study documents (including subject records, copies of data submitted to the sponsor, study 
notebook, and pharmacy records) must be kept secured in accordance with the specific data 
retention periods that are described in the clinical study site agreement and based upon local 
requirements. Study documents must not be destroyed without prior written approval of the 
sponsor.
12 FINANCING AND INSURANCE
Financing and insurance are addressed in the individual site contracts.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
86 of 113
13 PUBLICATION POLICY
Publication by the site of any data from this study must be carried out in accordance with the 
clinical study site agreement.
14 REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument 
for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-
76.
Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, et al. A phase I, 
pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an 
insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) 
with advanced solid tumors. American Society of Clinical Oncology 2008 Annual Meeting. 
30May-03Jun2008; Chicago, Illinois. Abstract 3519.
Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Exp Opin 
Ther Targets. 2005 Aug;9(4):753-68.
Baserga R. The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res. 2009 Mar 
10;315(5):727-32.
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin 
receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 
2009 Oct;30:586-623.
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, 
and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009 May 
20;101(10):736-50.
Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact 
of new chemotherapeutic and hormone agents on survival in a population-based cohort of 
women with metastatic breast cancer. Cancer. 2007 Sep 1;110(5):973-9.
Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like 
growth factor receptor pathway. Clin Cancer Res. 2008 Oct 15;14(20):6364-70.
Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient’s 
experience. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6236s-642s.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
87 of 113
De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays. 2004 
Dec;26(12):1351-62.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J 
Cancer. 2009 Jan;45(2):228-47.
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, et al. The role of insulin 
receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008 
Feb;114(1):23-7.
Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. 
Dual IGF-I/II–neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor 
growth. Cancer Res. 2011 Feb 1;71(3):1029-40.
Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of 
advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007 Jan 
24;(1):CD003370.
Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-
receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2008
Dec;112 Suppl 1:53-66.
Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor 
receptor in oncology. Curr Drug Targets. 2009 Oct;10(10):923-36.
Gueth U, Huang DJ, Schoetzau A, Holzgreve W, Wight E. Systemic therapy of metastatic 
breast cancer: the truth beyond the clinical trials. Oncology. 2009;76(4):247-53.
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR et al. Phase I dose 
escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-
751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007 Oct 1;13(19):5834-
40.
Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 
receptor-targeted therapy. Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40.
Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn GL, et al. A phase I 
study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor 
receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. American 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
88 of 113
Society of Clinical Oncology 2008 Annual Meeting. 30May-03Jun2008; Chicago, Illinois. 
Abstract 3520.
Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F, et al. A phase I, first in 
man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 
monoclonal antibody, in patients with advanced solid tumors. American Society of Clinical 
Oncology 2007 Annual Meeting. Chicago, Illinois. Abstract 3505.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and 
mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907.
Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 
2010 Apr 1;16(7):1979-87.
Kaufman B, Wu Y, Amonkar MM, Sherrill B, Bachelot T, Salazar V, et al. Impact of 
lapatinib monotherapy on QOL and pain symptoms in patients with HER+ relapsed or 
refractory inflammatory breast cancer. Curr Med Res Opin. 2010 May;26(5):1065-73.
Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, et al. A 
randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane 
(E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) 
metastatic (M) or locally advanced (LA) breast cancer (BC). San Antonio Breast Cancer 
Symposium 2010 Annual Meeting. 8-12Dec2010; San Antonio, Texas. Abstract S1-4.
Leary A, Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast 
cancer treatment? Br J Cancer. 2006 Sep 18;95(6):661-6.
Martin M, Mahillo E, Llombart-Cussac A, Lluch A, Munarriz B, Pastor M, et al. The “El 
Alamo” project (1990-1997): two consecutive hospital-based studies of breast cancer 
outcomes in Spain. Clin Transl Oncol. 2006 Jul;8(7):508-18.
Montazeri A. Health-related quality of life in breast cancer patients: A bibliographic review 
of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008 Aug 29;27:32.
Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior 
efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with 
advanced breast cancer: results of a phase III study of the International Letrozole Breast 
Cancer Group. J Clin Oncol. 2001 May 15;19(10):2596-606.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
89 of 113
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is 
superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal 
women: results of a North American multicenter randomized trial. J Clin Oncol. 2000 Nov 
15;18(22):3758-67.
Nagel GC, Schmidt S, Strauss BM, Katenkamp D. 
 
 
.
Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN. Treatment outcome and 
prognostic factors for patients with bone-only metastases of breast cancer: a single-institution 
retrospective analysis. The Oncologist. 2011;16:155-64.
Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, et al. Safety, 
pharmacokinetics and preliminary activity of the anti-IGF-1R antibody CP-751,871 in 
patients with sarcoma. American Society of Clinical Oncology 2008 Annual Meeting. 
30May-03Jun2008; Chicago, Illinois. Abstract 10501.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study 
comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast 
cancer in postmenopausal women: the European organisation for research and treatment of 
cancer breast cancer cooperative group. J Clin Oncol. 2008 Oct 20;26(30):4883-90.
Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH. Phase II study of gemcitabine in 
combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic 
breast cancer. Invest New Drugs. 2010 Oct;28(5):659-69.
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer.
2008 Dec;8(12):915-28.
Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, et al. 
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive 
advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):9-24.
Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004 
Dec;11(4):643-58.
Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a 
therapeutic target in cancer. Oncologist. 2008 Jan;13(1):16-24.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
Y
90 of 113
Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer 
therapy. Mol Cancer Ther. 2007 Jan;6(1):1-12.
Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor 
activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. 
Oncogene. 1999 Apr 15;18(15):2471-9.
Seidman AD, Portenoy R, Yao TJ, Lepore M, Mont EK, Kortmansky J, et al. Quality of life 
in phase II trials: a study of methodology and predictive value in patients with advanced 
breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl
Cancer Inst. 1995 Sep 6;87(17):1316-22.
Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol. 2006
Feb;33 (1 Suppl 2):S2-5.
Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y. Quality of life in women 
with metastatic breast cancer during 9 months after randomization in the TEX trial 
(epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat. 2010 Oct;123(3):785-
93.
Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like 
growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat Clin Pract Oncol. 
2007 Oct;4(10):591-602.
Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, et al. A phase I 
study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 
receptor) antagonist, in patients (pts) with advanced solid tumor (ST). American Society of 
Clinical Oncology 2008 Annual Meeting. 30May-03Jun2008; Chicago, Illinois. Abstract 
3582.
Wardley A, Davidson N, Barret-Lee P, Hong A, Mansi J, Dodwell D, et al. Zoledronic acid 
significantly improves pain scores and quality of life in breast cancer patients with bone 
metastases: a randomised, crossover study of community vs hospital bisphosphonate 
administration. Br J Cancer. 2005 May 23;92(10):1869-76.
Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary 
Gland Biol Neoplasia. 2008 Dec;13(4):471-83.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
91 of 113
Wu JS, Beaton D, Smith PM, Hagen NA. Patterns of pain and interference in patients with 
painful bone metastases: a brief pain inventory validation study. J Pain Symptom Manage.
2010 Feb;39(2):230-40.
Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a 
treatment for cancer. Expert Opin Ther Targets. 2008 May;12(5):589-603.
Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor 
receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007
Jan;67(1):391-7.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
92 of 113
15 SUMMARY OF PROTOCOL AMENDMENTS AND 
ADMINISTRATIVE CHANGES TO THE PROTOCOL
Protocol Amendment 1, 07Feb2012
The following changes were made:
1. Cover Page: The name of the CRO for the study was added.
2. Study Abstract: Updated to be consistent with the changes made to the body of the 
protocol.
3. Section 1.2.1 Product Derivation: the word “fully” was removed from the description of 
MEDI-573’s human derivation.
4. Section 1.2.3 Clinical Experience with MEDI-573:
[
The text was updated to specify that MEDI-573 has been administered at the 
mg/kg dose level once every 21 days.
[
The text was updated to include current information on subject exposure to 
MEDI-573.
[
The text was updated to include current safety findings in MI-CP184. 
5. Section 1.3 Research Hypothesis:
[
The number of dose levels to be tested in the current study was changed from 2 to 3.
[
Last sentence of section, added “with HR+, HER2-negative MBC” for consistency. 
6. Section 1.5: Benefit-risk and Ethical Assessment:  
[
The text was modified to account for the fact that MEDI-573 has been administered 
to subjects in more than one clinical trial.
[
Discussion of potential adverse reactions based on sequestering IGF ligands in 
contrast to current knowledge of adverse reactions resulting from inhibition of other 
molecular targets within the IGF signaling pathway was added.
7. Section 2.1: Primary Objective: The number of dose levels to be tested in the current 
study was changed from 2 to 3.
8. Section 3.1.1 Phase 1b (Dose-evaluation Phase): 
[
The text was modified to account for the addition of a 
 mg/kg plus AI treatment 
arm.
[
The text referring to the number of subjects to be evaluated in the study was changed 
to state: “Approximately 9 to 18” and the number of investigational sites was changed 
to 20 in North America. 
9. Section 3.1.2: Phase 2 (Randomization Phase): Phase 2 was changed to a 2-arm 
structure to test 
mg/kg MEDI-573 plus AI versus AI alone. The text and study flow 
diagram were updated to account for the change.
10. Section 3.3 Study-stopping Criteria: added DMC to bullet 4.
11. Section 3.4: Rationale for Study Design, Doses, and Control Groups: Rationale for 
the dosing schedule was provided, including the addition of a 
mg/kg arm in Phase 1b 
and Phase 2, based on PK and pharmacodynamic experience.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
93 of 113
12. Section 4.2.1 Inclusion Criteria: 
[
Inclusion Criterion 1 added “Subjects with metastases to bone only are eligible
[
Inclusion Criterion 3 was clarified to specify that HER2 negativity will be assessed 
by FISH or CISH assay will be used according to local guidelines or manufacturer’s 
scoring criteria.
[
Text was added to Inclusion Criterion 4 indicating that subjects enrolled in Japan 
must be P 20 years of age at study entry.
[
Text was added to Inclusion Criterion 5 to clarify the definition of postmenopausal.
13. Section 4.2.2 Exclusion Criteria:
[
The required washout period following tamoxifen or an AI prior to receiving the first 
dose of MEDI-573 was changed to 2 weeks.
[
Eligibility was extended to subjects with bone-only metastases.
[
Text was added to clarify the exclusion of subjects with active brain metastases.
[
The text regarding the exclusion of subjects with known CNS metastases and 
leptomeningeal carcinomatosis was edited to exclude subjects with spinal cord 
compression or leptomeningeal carcinomatosis.
[
Text was added to exclude subjects with a history of allergy or reaction attributed to 
compounds of chemical or biologic composition similar to those of MEDI-573 or AI.
[
The text referring to the exclusion of subjects with a history of another primary 
malignancy within 5 years prior to starting study treatment was modified to exclude 
subjects with a history of another invasive malignancy.
[
The text referring to exclusion of subjects with poorly controlled diabetes mellitus 
was edited to remove the hemoglobin test requirement. 
14. Section 4.3 Treatment Assignment: 
[
The text was modified to specify that an IXRS will be used for entry (Phase 
1b)/randomization to a treatment arm (Phase 2) and assignment of unblinded 
investigational product and/or an AI.
[
The text was modified to specify that in Phase 2 of the study, subjects will be 
randomized at a 1:1 ratio to receive either MEDI-573 at 
mg/kg and an AI or an AI 
alone.
15. Section 4.5.1 Investigational Products: Reference to the Investigational Product 
Manual was removed.
16. Section 4.5.2 Other Study Medications: 
[
The text stating that manufacturer and batch numbers should be recorded in the drug 
accountability log was deleted.
[
The following text was added: “Subjects will be provided with a diary in which to 
record their intake of AI (an example of the diary is provided in Appendix 3). This 
information will be recorded in the case report form”. A new appendix containing the 
subject diary of AI usage was added. 
17. Section 4.5.3.1 Phase 1b: The text was modified to account for the addition of a 
mg/kg MEDI-573 dose cohort. 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
94 of 113
18. Section 4.5.3.2 Phase 2: The text was modified to account for the change in the Phase 2 
dose structure to 
 mg/kg MEDI-573 plus AI versus AI alone. 
19. Section 4.5.3.3 Investigational Product Preparation:  
[
Reference to the Investigational Product Manual was deleted.
[
Information of the compatibility of MEDI-573 with IV bags and tubing was updated.
20. Section 4.5.4 Treatment Administration:
[
The text was modified to clarify that the infusion time for 
 MEDI-573 
recipients will be 60 minutes whereas that for the 
and 
 MEDI-573 
recipients will be 90 minutes. 
[
Removed “Subjects are to continue with an AI initially assigned to them for the 
duration of their treatment on the study” in response to investigator feedback.
21. Section 4.5.6 Dose Evaluation Phase: The text was modified to account for the addition 
of a 
 MEDI-573 dose cohort.
22. Section 4.5.7 Phase 2 (Randomization Phase): The text was modified to account for the 
addition of a 
 MEDI-573 arm and the number of subjects to be randomized into 
Phase 2 was changed to 178.
23. Section 4.5.8 Management of Toxicities, Dose Reductions and Dose Delays: Text was 
added to specify that dosing will not be interrupted or discontinued for a Grade 2 
laboratory toxicity that does not represent deterioration since study entry.
24. Section 4.6.1 Permitted Concomitant Medications:  Text on the permitted use of 
concomitant bisphosphonate or denosumab treatment was added. 
25. Section 5.1 Schedule of Study Procedures: 
[
Text was added to the schedule of assessments to specify that the Cycle 1, Day 2 
assessments are only required for Phase 1b.
[
A -2 day window for weight determination prior to dosing was added to the schedule 
of assessments.
[
Text was added in the schedule of assessments table to specify that the dose interval 
for the Cycle 2 (and subsequent cycles), Day 1 infusion should be no shorter than 21 
days.
[
The row header text in the schedules of study procedures was modified where 
appropriate to account for the change in structure of Phase 2 to include a 
 mg/kg 
MEDI-573 plus AI arm and an AI alone arm.
[
The visit descriptions in Section 5.1.1 through Section 5.1.4.3 were modified 
according to the changes described above.
[
Text was added in the schedule of assessment table to reference Section 5.2.6.1 for 
detailed schedule for CXR, CT, or MRI scans.
26. Section 5.2.1 Medical History and Physical Examination: Additional physical 
examination details were added and the title was edited to include ECG, weight, and vital 
signs. 
27. Section 5.2.2 Clinical Laboratory Tests: Text was added to clarify that only abnormal 
laboratory tests that are deemed clinically significant by the investigator will be repeated.
28. Section 5.2.5 Biomarker Evaluation and Methods: 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
95 of 113
[
/
 
.
[
The corresponding changes were made to Section 7.3.3 Exploratory Endpoints. 
29. Section 5.2.6.1 Tumor Assessments and Response Criteria:  
[
Text added to define plans for archived images.
[
Text added to clarify the imaging requirements throughout the study.
30. Section 6.5 Safety Management During the Study: Text describing the DMC and its 
role in safety management was added.
31. Section 7.3.1.2 Primary Efficacy Endpoint:
[
The text stating that blinded central independent imaging review of response and 
disease progression will be the basis for the primary analysis was removed because 
the primary endpoint will be based on investigator assessment.
[
The text was modified to specify that sensitivity analyses may be conducted based on 
different analysis populations, tumor response determined by reviewers’ different 
handling of missing data, or other statistical analysis methods.
32. Section 7.4 Planned Analyses: The text was changed to specify that the primary analysis 
of PFS and safety would be performed after 122 PFS events have occurred. 
33. Section 7.5 Sample Size and Power Calculations: 
[
The required number of evaluable subjects to determine the safety and tolerability of 
MEDI-573 was changed to 9 and the text was modified to state that up to 
18 evaluable subjects may be needed if DLT occurs.
[
The primary objective of the Phase 2 portion of the study is now to compare PFS 
among subjects treated at 
 MEDI-573 and an AI versus subjects treated with 
single-agent AI alone; the text was modified accordingly. 
[
Additional edits were made to the text describing the number of subjects required to 
observe an adequate number of PFS events for study powering based on the changes 
in study design as described above.
34. Other minor text edits and corrections were incorporated into the document. 
35. Corresponding edits based on the above changes were made in the study synopsis.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
96 of 113
Protocol Amendment 2, 05Dec2012
The protocol was updated to incorporate changes described in Administrative Change 1 and 
Administrative Change 2, and to make other changes where possible to streamline study 
conduct and decrease subject burden. In addition, a limit of approximately 30 subjects with 
bone metastases only was added to reflect the proportion of subjects with bone-only 
metastases in the target population. The following changes were made:
1. Cover page: The medical monitor was updated.
2. Study Abstract: The abstract was updated to be consistent with changes made in the 
body of the protocol.
3. Section 3.1.2, Phase 2 (Randomization Phase): A statement was added to indicate that 
a limit of approximately 30 subjects with bone-only disease will be randomized to reflect 
the proportion of subjects with bone-only metastases in the target population.
4. Section 3.4, Rationale for Study Design, Doses, and Control Groups: The rationale 
for the limit of 30 subjects with bone-only metastases was added.
5. Section 4.2.1, Inclusion Criteria: 
a.
It was clarified that subjects with metastases to bone only will be capped at 
approximately 30 subjects, and that subjects must be evaluated for inclusion based on 
RECIST criterion 1.1.
b. Immunohistochemistry was added as a method of determining HER2 status because 
some locations do not have access to FISH or CISH.
6. Section 4.2.2, Exclusion Criteria:
a.
It was clarified that prior adjuvant therapy with an AI and/or tamoxifen is allowed.
b. It was clarified that subjects with evidence of spinal canal involvement who are 
asymptomatic of spinal cord compression or leptomeningeal carcinomatosis are 
allowed to enroll.
7. Section 4.5.3.1, Phase 1b; and Section 4.5.4, Treatment Administration: A window of 
+ 20 minutes was added to infusion times to account for potential overfill.
8. Section 4.5.4, Treatment Administration: Windows for collection of vital signs during 
and after MEDI-573 infusion were added.
9. Section 4.6.1, Permitted Concomitant Medications: It was clarified that 
bisphosphonate, denosumab, or calcitonin treatment may be initiated after Cycle 1, Day 
21 for the management of hypercalcemia, bone pain, and/or osteoporosis.
10. Section 4.6.2, Excluded Concomitant Medications: The statement regarding recording 
of concomitant medications was deleted for redundancy with the prior section.
11. Section 5.1, Schedule of Study Procedures: 
[
Table 5.1-1: A urine or serum pregnancy test was added at Cycle 2 (and every cycle 
thereafter), Day 1.
[
Table 5.1-1: It was clarified that the column for evaluations to be conducted every 9 
weeks is to be followed until 24 months post study entry.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
97 of 113
[
Table 5.1-1: A column was added for evaluations to be conducted every 6 months 
beginning > 24 months post-randomization, primarily to reduce the radiation 
exposure that would result in continued tumor evaluations every 9 weeks.
[
Table 5.1-1: The archival tumor biopsy was changed from mandatory to “if 
available”, as per Administrative Change 1.
[
Table 5.1-2: It was clarified that the column for evaluations to be conducted every 9 
weeks is to be followed until 24 months post study entry.
[
Table 5.1-2: A column was added for evaluations to be conducted every 6 months 
beginning > 24 months post-randomization to reduce the radiation exposure that 
would result in continued tumor evaluations every 9 weeks.
12. Section 5.1.1, Screening (All Subjects Unless Otherwise Specified): Text was added to 
Item #3 to clarify that verification of eligibility criteria should include review of 
laboratory results. Item #12 was clarified to indicate that pregnancy tests are required for 
women of childbearing potential only. Item #14 was modified to indicate that archival 
tumor samples are not mandatory, but will be collected if available, as outlined in 
Administrative Change 1. 
13. Section 5.1.2.1, Cycle 1, Day 1 (All Subjects Unless Otherwise Specified): A statement 
was added to indicate that any assessments performed within 24 hours prior to dosing 
may be used for Cycle 1, Day 1 assessments. Text was added to Item #1 to clarify that 
verification of eligibility criteria should include review of laboratory results. The window 
for the end of infusion vital signs was increased to 10 minutes to allow sufficient time for 
completion of all end of infusion assessments. It was clarified that the 12-lead 
posttreatment ECG is required only for subjects enrolled in Phase 1b and Phase 2, Arm 1.
Item #9 was clarified to indicate that pregnancy tests are required for women of 
childbearing potential only. 
14. Section 5.1.2.5, Cycle 2 and Every Cycle Thereafter, Day 1 (Plus/Minus 2 Days, All 
Subjects Unless Otherwise Specified): A urine or serum pregnancy test and post-dose 
12-lead ECG were added to this visit. These were inadvertently omitted from the 
previous version of the protocol.
15. Section 5.1.2.6, Every 9 Weeks Minus 7 Days, Starting with Cycle 4 (All Subjects) 
Through 24 Months Post Study Entry: The title of this section was edited to indicate 
that these evaluations are conducted through 24 months post study entry.
16. Section 5.1.2.7, Every 6 Months Plus/Minus 7 Days, beginning > 24 Months Post 
Study Entry: This section was added to describe the assessments required after 2 years 
on study for subjects who remain on study drug. This change was made to decrease 
radiation exposure, as tumor assessments will decrease from every 9 weeks to every 6 
months after 2 years on study.
17. Section 5.1.3, End-of-Treatment Visit (All Subjects Unless Otherwise Specified): It 
was clarified that the pregnancy test is to be conducted in women of childbearing 
potential only.
18. Section 5.1.4.2, Every 9 Weeks (Plus/Minus 7 Days) Posttreatment for Subjects 
Without Progressive Disease Through 24 Months Post Study Entry: The title of this 
section was changed to indicate that the assessments should be done only through 24 
months post study entry.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
98 of 113
19. Section 5.1.4.4, Every 6 Months (Plus/Minus 7 Days) Beginning > 24 Months Post 
Study Entry: This section was added to describe the assessments required after 2 years 
on study for subjects who have discontinued study drug. This change was made to 
decrease radiation exposure, as tumor assessments will decrease from every 9 weeks to 
every 6 months after 2 years on study.
20. Section 5.2.1, Medical History, Physical Examination, Electrocardiogram, Weight 
and Vital Signs: Language was added to clarify which subjects receive ECGs at each 
timepoint. The window for completion of the ECG at the end of infusion was increased to 
10 minutes. The ECG at 6 hours post-infusion was deleted as per Administrative Change 
1. Language was added to clarify the times at which vital signs are collected for subjects 
enrolled in Phase 1b and Phase 2, Arm 1.
21. Section 5.2.5, Biomarker Evaluation and Methods: Language was changed to indicate 
that IGF-1R signaling proteins will be evaluated for their expression levels on archived 
tissue samples where available, as outlined in Administrative Change 1.
22. Section 5.2.6.1, Tumor Assessments and Response Criteria: Clarification that the scan 
to confirm CR or PR may be completed at the regularly scheduled response assessments 
that occur every 9 weeks was added as described in Administrative Change 2.
23. Other minor text edits and corrections were incorporated into the document.
Protocol Amendment 3, 25Jul2016
The following changes were made:
1. Cover page: The name and contact information of the medical monitor was updated.
2. Study Abstract: The study abstract was updated to be consistent with changes made in 
the body of the protocol.
3. Section 1.2.3 Clinical Experience with MEDI-573: Language has been updated to 
include the results from the completed FTIH study (CP-184) and the primary analysis of 
CD-ON-MEDI-573-1030 study.
4. Section 4.8 End of Study: The language was updated to clarify the follow-up procedures 
for patients that have discontinued treatment. Additionally, text was added to specify that 
patients still on treatment at the end of 36 months will be allowed to continue treatment 
until they meet the criteria for treatment discontinuation.
5. Section 5.1 Schedule of Study Procedures: Language was updated to clarify and 
simplify required procedures for subjects continuing treatment with Amendment 3 
approval, given primary analysis of the study is completed.
[
Table 5.1-2, Schedule of Subject Evaluations: Screening and Treatment Periods – All 
subjects unless otherwise specified (Subjects continuing treatment under Amendment 
3 only) and Table 5.1-4, Schedule of Study Procedures: Follow-up Period (Subjects 
continuing treatment under Amendment 3 only): Tables were added to include 
subjects continuing treatment under Amendment 3 only.
[
Table 5.1.3, Schedule of Study Procedures: Follow-up Period (All Subjects Unless 
Otherwise Specified): The table number and title were updated.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
99 of 113
6. Section 5.1.2.5.1 Cycle 2 and Every cycle Thereafter, Day 1 (Plus/Minus 5 days): 
Section was added to clarify follow-up evaluations for the subjects on treatment at the 
time of Amendment 3.
7. Section 5.1.2.6.1 Every 9 Weeks (± 7 Days) Post Study Entry unless otherwise specified 
(For subjects continuing on treatment under Amendment 3 only): Section was added to 
clarify evaluations for the subjects on treatment at the time of Amendment 3.
8.
Section 5.1.2.7.1 Every 6 Months (± 7 Days), Beginning > 24 Months Post Study Entry 
(For subjects continuing on treatment under Amendment 3 only): Section was added to 
clarify evaluations for the subjects on treatment at the time of Amendment 3.
9.
Section 5.1.3.1 End-of-Treatment Visit (For subjects continuing on treatment under 
Amendment 3 only): Section was added to clarify evaluations for the subjects on 
treatment at the time of Amendment 3.
10. Section 5.1.4.1.1 30 Days (± 3 Days) and 60 Days (± 5 Days) Posttreatment (For subjects 
continuing on treatment under Amendment 3 only): Section was added to clarify 
follow-up evaluations for the subjects on treatment at the time of Amendment 3.
11. Section 5.2.1 Medical History, Physical Examination, Electrocardiogram, Weight 
and Vital Signs: Language was updated to be consistent with the Schedule of Study 
Procedures.
12. Section 5.2.6.1 Tumor Assessments and Response Criteria: Language was added to 
clarify the management of subject imaging data.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
100 of 113
Appendix 1
Signatures


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
101 of 113
Sponsor Signature(s)
 
 


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
102 of 113
 
 
 
 
 
 
 
 
 
 
 
 
 
:  
 
  
 
This document contains confidential information, which should not be copied, referred to, released, or published 
without written approval from MedImmune or AstraZeneca. Investigators are cautioned that the information in 
this protocol may be subject to change and revision.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
103 of 113
Appendix 2
Karnofsky Performance Status Scale
Karnofsky Performance Status Scale
Score
Description
100
Normal; no complaints; no evidence of disease
90
Able to carry on normal activity; minor signs or symptoms of disease
80
Normal activity with effort; some signs or symptoms of disease
70
Cares for self; unable to carry on normal activity or to do active work
60
Requires occasional assistance, but is able to care for most of his needs
50
Requires considerable assistance and frequent medical care
40
Disabled; requires special care and assistance
30
Severely disabled; hospitalization is indicated although death not imminent
20
Very sick; hospitalization necessary; active support treatment necessary
10
Moribund; fatal processes progressing rapidly
0
Dead
Source: Adapted from Karnofsky D, Abelman W, Craver L, Burchenal J. The use of nitrogen mustards in the 
palliative treatment of carcinoma. Cancer. 1948;1:634-56.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
104 of 113
Appendix 3
Aromatase Inhibitor Subject Diary


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
105 of 113


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
106 of 113
Appendix 4
New York Heart Association Cardiac Performance 
Status Assessment Function Scale
New York Heart Association Cardiac Performance Status Assessment Function Scale
Class
Description
I
Patients with cardiac disease but without resulting limitation of physical activity. Ordinary 
physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
II
Patients with cardiac disease resulting in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal 
pain.
III
Patients with cardiac disease resulting in marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.
IV
Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort increases. 
Source: The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis 
of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-6.


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
107 of 113
Appendix 5
National Cancer Institute Common Terminology 
Criteria for Adverse Events Version 4.0 (NCI CTCAE 
V4.0)
The NCI CTCAE V4.0 can be downloaded from the Cancer Therapy Evaluation Program
homepage (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_8.5x11.pdf).


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
108 of 113


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
109 of 113


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
110 of 113
Appendix 7


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
111 of 113


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
112 of 113


MedImmune 
Protocol CD-ON-MEDI-573-1030 Amendment 3
MEDI-573
25Jul2016; Final
113 of 113


                                                                                                                                          
DOCUMENT ID:
VERSION LABEL:
                                  
   
                                   
   
                                   
   
                                
ELECTRONIC SIGNATURES
Signed by
Meaning of Signature
Server Date
(dd-MMM-yyyy HH:mm ‘GMT’Z)
$3KDVHE5DQGRPL]HG6WXG\RI0(',LQ&RPELQDWLRQZLWKDQ$URPDWDVH
,QKLELWRU$,9HUVXV$,$ORQHLQ:RPHQZLWK0HWDVWDWLF%UHDVW&DQFHU0%&
'RF,'

$SSURYHG
&855(17
/$7(67

SAP_001.pdf: 
0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
67$7,67,&$/$1$/<6,63/$1

Protocol Number: &'210(',2ULJLQDO3URWRFRO

$3KDVHE5DQGRPL]HG6WXG\RI0(',LQ&RPELQDWLRQZLWKDQ$URPDWDVH,QKLELWRU
$,9HUVXV$,$ORQHLQ:RPHQZLWK0HWDVWDWLF%UHDVW&DQFHU0%&










0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
7DEOHRI&RQWHQWV
1 
Introduction............................................................................................... 7 
2 
Background................................................................................................ 7 
 6WXG\2YHUYLHZ 
 5DQGRPL]DWLRQDQG%OLQGLQJ 
 6FKHGXOHRI(YDOXDWLRQV 
 6DPSOH6L]H&RQVLGHUDWLRQV 
3 
Statistical Methods.................................................................................. 10 
 *HQHUDO&RQVLGHUDWLRQV 
 6XEMHFW3RSXODWLRQV 
 6XEMHFW'LVSRVLWLRQ 
 %DVHOLQH&KDUDFWHULVWLFV 
 6WXG\'UXJ([SRVXUH 
 6XPPDULHVWR6XSSRUWWKH3ULPDU\2EMHFWLYHV 
 3ULPDU\(QGSRLQWVRI6DIHW\LQ3KDVHE 
 3ULPDU\(QGSRLQWRI(IILFDF\LQ3KDVH 
 
3ULPDU\$QDO\VLVRI3)6 
 
6XSSRUWLYH$QDO\VLVRI3)6 
 6XPPDULHVWR6XSSRUWWKH6HFRQGDU\2EMHFWLYHV 
 6HFRQGDU\(QGSRLQWVRI6DIHW\DQG7ROHUDELOLW\ 
 6HFRQGDU\(IILFDF\(QGSRLQWV 
 ,PPXQRJHQLFLW\RI0(', 
 3KDUPDFRORJ\DQG3KDUPDFRG\QDPLFVRI0(', 
 ([SORUDWRU\6XPPDULHV 


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
 ([SORUDWRU\$QDO\VHVRI%LRPDUNHUV 
 ([SORUDWRU\$QDO\VLV
 
 
 
 
 
4 
Interim Analyses...................................................................................... 27 
5 
References ................................................................................................ 27 


















0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI

/LVWRI,QWH[W7DEOHV
7DEOH
6XEMHFW'LVSRVLWLRQWREH6XPPDUL]HG
7DEOH
%DVHOLQH&KDUDFWHULVWLFVWREH6XPPDUL]HG
7DEOH
6XEJURXSVRI,QWHUHVW
7DEOH
6WXG\'UXJ([SRVXUH
7DEOH
'HILQLWLRQDQG&HQVRULQJ,QIRUPDWLRQIRU3)6
7DEOH
'HILQLWLRQDQG&HQVRULQJ,QIRUPDWLRQIRU3)6%DVHGRQ%,&5
7DEOH
'HILQLWLRQDQGFHQVRULQJLQIRUPDWLRQIRU3)63)6(YHQWV2QO\
7DEOH
'HILQLWLRQDQG&HQVRULQJ,QIRUPDWLRQIRU3)68QLIRUP3URJUHVVLRQ
DQG$VVHVVPHQW'DWHV
7DEOH
7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
7DEOH
(&*3DUDPHWHUV
7DEOH
.DUQRIVN\3HUIRUPDQFH3DUDPHWHUV
7DEOH
/DERUDWRU\3DUDPHWHUVWREH6XPPDUL]HG
7DEOH
9LWDO6LJQV
7DEOH
'HILQLWLRQDQG&HQVRULQJ,QIRUPDWLRQIRU'5
7DEOH
'HILQLWLRQDQGFHQVRULQJLQIRUPDWLRQIRU773




0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
/LVWRI$EEUHYLDWLRQV
Abbreviation or 
Specialized Term 
Definition 
$'$
$QWLGUXJ$QWLERG\
$(
$GYHUVH(YHQW
$,
$URPDWDVH,QKLELWRU


&,
&RQILGHQFH,QWHUYDO
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULD)RU$GYHUVH(YHQWV
&5
&RPSOHWH5HVSRQVH
&7
&RPSXWHG7RPRJUDSK\
'/7
'RVH/LPLWLQJ7R[LFLW\
'5
'XUDWLRQRI5HVSRQVH
(&*
(OHFWURFDUGLRJUDP



+5
+RUPRQH5HFHSWRU3RVLWLYH
+(5
+XPDQ(SLGHUPDO*URZWK)DFWRU5HFHSWRU
,*),,,
,QVXOLQ/LNH*URZWK)DFWRU,,,
,0
,PPXQRJHQLFLW\
,77
,QWHQWWR7UHDW
.36
.DUQRIVN\3HUIRUPDQFH6WDWXV
0%&
0HWDVWDWLF%UHDVW&DQFHU
6$(
6HULRXV$GYHUVH(YHQW
7($(
7UHDWPHQW(PHUJHQW$GYHUVH(YHQW
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
1&,
1DWLRQDO&DQFHU,QVWLWXWH
26
2YHUDOO6XUYLYDO
25
2EMHFWLYH5HVSRQVH
255
2EMHFWLYH5HVSRQVH5DWH
5(&,67
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV
3'
3URJUHVVLRQ'LVHDVH
3.
3KDUPDFRNLQHWLFV


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Abbreviation or 
Specialized Term 
Definition 
352
3DWLHQW5HSRUWHG2XWFRPH
3)6
3URJUHVVLRQ)UHH6XUYLYDO
35
3DUWLDO5HVSRQVH
6'
6WDEOH'LVHDVH
633
6WDWLVWLFDO3URJUDPPLQJ3ODQ
775
7LPHWR5HVSRQVH
773
7LPHWR3URJUHVVLRQ



0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI

,QWURGXFWLRQ
7KLVGRFXPHQWGHVFULEHVWKHVWDWLVWLFDOPHWKRGRORJ\DQGVXPPDULHVIRUSURWRFRO&'21
0(',DVWXG\RI0(',LQFRPELQDWLRQZLWKDQDURPDWDVHLQKLELWRU$,
YHUVXV$,DORQHLQZRPHQZLWKPHWDVWDWLFEUHDVWFDQFHU0%&$VEDFNJURXQGLQIRUPDWLRQ
DQRYHUYLHZRIWKHVWXG\GHVLJQLVSURYLGHG7KHPDLQSRUWLRQRIWKLVGRFXPHQWGHWDLOVWKH
VWDWLVWLFDOVXPPDULHVUHODWLQJWRHDFKVWXG\REMHFWLYHDVZHOODVWKHJHQHUDOFRQYHQWLRQVDQG
GHILQLWLRQVWKDWZLOOEHXVHG
,QDGGLWLRQDVHWRIWDEOHWHPSODWHVDQGVSHFLILFDWLRQVDUHSODQQHGWREHFUHDWHGLQDVWDWLVWLFDO
SURJUDPPLQJSODQ633WRFRPSOHPHQWWKLVGRFXPHQW

%DFNJURXQG

6WXG\2YHUYLHZ
7KLVLVD3KDVHEPXOWLFHQWHURSHQODEHOVWXG\WRHYDOXDWHWKHVDIHW\WROHUDELOLW\
DQWLWXPRUDFWLYLW\DQGSKDUPDFRORJ\RI0(',LQFRPELQDWLRQZLWKDQ$,LQDGXOW
VXEMHFWVZLWK+5+(5QHJDWLYH0%&7KLVVWXG\KDVSKDVHVDGRVHHYDOXDWLRQSKDVH
3KDVHEDQGDUDQGRPL]DWLRQSKDVH3KDVH
,QWKH3KDVHESRUWLRQRIWKHVWXG\FRKRUWVZLOOEHH[DPLQHG,QHDFKFRKRUWWR
HYDOXDEOHVXEMHFWVZLOOHDFKUHFHLYH0(',DWGRVHVRI
&RKRUWV$RU

&RKRUWV%E\,9LQIXVLRQRQ'D\RIHDFKGD\F\FOH$Q$,RIWKHLQYHVWLJDWRU¶V
FKRLFHDQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQHZLOOEHJLYHQRUDOO\RQFHGDLO\(QUROOPHQWLQWR
&RKRUWV$DQG%ZLOOEHLQLWLDWHGVHTXHQWLDOO\
$SSUR[LPDWHO\VXEMHFWVZLWK+5+(5QHJDWLYH0%&ZLOOEHUDQGRPL]HGLQWRWKH
3KDVHSRUWLRQRIWKHVWXG\LQDUDWLRWRUHFHLYH0(',
DQGDQ$,
LQYHVWLJDWRU¶VFKRLFH$UP0(',
DQGDQ$,$UPRUDQ$,DORQH
$UP0(',ZLOOEHDGPLQLVWHUHGYLD,9LQIXVLRQRQ'D\RIGD\F\FOHV$Q$,
ZLOOEHJLYHQRUDOO\RQFHGDLO\5DQGRPL]DWLRQZLOOEHVWUDWLILHGE\JHRJUDSKLFUHJLRQ1RUWK
$PHULFDYVUHVWRIZRUOGDQG$,W\SH$OOVXEMHFWVZLOOEHIROORZHGHYHU\ZHHNVWKUHH
GD\F\FOHVXQWLOGLVHDVHSURJUHVVLRQDQGWKHQIROORZHGIRUVXUYLYDOHYHU\PRQWKVXQWLOWKH
HQGRIWKHVWXG\DVGHILQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
6XEMHFWVZLOOEHWUHDWHGXQWLOXQDFFHSWDEOHWR[LFLW\GRFXPHQWDWLRQRIGLVHDVHSURJUHVVLRQRU
RWKHUUHDVRQVIRUVXEMHFWZLWKGUDZDOVHH6HFWLRQRIWKHVWXG\SURWRFRO$SSUR[LPDWHO\
LQYHVWLJDWLRQDOVLWHVLQ1RUWK$PHULFDDQG(XURSHZLOOSDUWLFLSDWHLQWKH3KDVHESRUWLRQ
RIWKHVWXG\DQGDSSUR[LPDWHO\LQYHVWLJDWLRQDOVLWHVZRUOGZLGHZLOOSDUWLFLSDWHLQWKH
3KDVHSRUWLRQRIWKHVWXG\7XPRUPHDVXUHPHQWVDQGDVVHVVPHQWVZLOOEHEDVHGRQ
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV5(&,67JXLGHOLQHV
7KHSULPDU\REMHFWLYHRIWKHGRVHHYDOXDWLRQSKDVH3KDVHERIWKLVVWXG\LVWRHYDOXDWHWKH
VDIHW\DQGWROHUDELOLW\RIGRVHOHYHOVRI0(',LQFRPELQDWLRQZLWKDQ$,LQVXEMHFWV
ZLWK+5+(5QHJDWLYH0%&
7KHSULPDU\REMHFWLYHRIWKHUDQGRPL]DWLRQSKDVH3KDVHRIWKLVVWXG\LVWRHYDOXDWHWKH
3)6RIVXEMHFWVZLWK+5+(5QHJDWLYH0%&WUHDWHGZLWK0(',DQGDQ$,YHUVXV
WUHDWPHQWZLWKDQ$,DORQH
7KHVHFRQGDU\REMHFWLYHVRIWKLVVWXG\DUH
x 7RGHVFULEHWKHVDIHW\DQGWROHUDELOLW\RI0(',ZKHQXVHGLQFRPELQDWLRQZLWK
DQ$,
x 7RHYDOXDWHWKHDQWLWXPRUDFWLYLW\RI0(',ZKHQXVHGLQFRPELQDWLRQZLWKDQ$,
YHUVXVWUHDWPHQWZLWKDQ$,DORQH
x 7RHYDOXDWH26LQVXEMHFWVWUHDWHGZLWK0(',ZKHQXVHGLQFRPELQDWLRQZLWKDQ
$,YHUVXVWUHDWPHQWZLWKDQ$,DORQH
x 7RGHVFULEHWKH3.RI0(',LQFRPELQDWLRQZLWKDQ$,
x 7RGHWHUPLQHWKHSKDUPDFRG\QDPLFVRI0(',LQFRPELQDWLRQZLWKDQ$,RQ
FLUFXODWLQJOHYHOVRI,*),DQG,*),,
x 7RGHWHUPLQHWKH,0RI0(',LQFRPELQDWLRQZLWKDQ$,
7KHH[SORUDWRU\REMHFWLYHVRIWKLVVWXG\DUH
x 7RHYDOXDWHELRPDUNHUVUHODWHGWR0(',WUHDWPHQW
x 7RLQYHVWLJDWHWKHHIIHFWVRI0(',RQSDWLHQWUHSRUWHGRXWFRPHV352V


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI

5DQGRPL]DWLRQDQG%OLQGLQJ
7KLVLVDQRSHQODEHOVWXG\%OLQGLQJLVQRWDSSOLFDEOHWRWKLVVWXG\'HWDLOVRIWUHDWPHQW
DVVLJQPHQWDQGUDQGRPL]DWLRQDUHGHVFULEHGLQ6HFWLRQRIWKHVWXG\SURWRFRO

6FKHGXOHRI(YDOXDWLRQV
7KHVFKHGXOHRIHYDOXDWLRQVLVRXWOLQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO

6DPSOH6L]H&RQVLGHUDWLRQV
,QWKH3KDVHESRUWLRQRIWKHVWXG\DPLQLPXPRIHYDOXDEOHVXEMHFWVHDFKDWWKH0(',

GRVHOHYHOVZLOOEHUHTXLUHGWRGHWHUPLQHWKHVDIHW\DQGWROHUDELOLW\RI
GRVHVRI0(',LQFRPELQDWLRQZLWKDQ$,8SWRHYDOXDEOHVXEMHFWVVXEMHFWV
HDFKDWWKH0(',
GRVHOHYHOVPD\EHQHHGHGLIGRVHOLPLWLQJWR[LFLW\
'/7RFFXUV$VXEMHFWZLOOEHFRQVLGHUHGHYDOXDEOHLIWKHVXEMHFWUHFHLYHVIXOOF\FOHRI
0(',DQGLVIROORZHGIRUVDIHW\WKURXJKWKH'/7HYDOXDWLRQSHULRGDVGHILQHGLQ
6HFWLRQRIWKHVWXG\SURWRFRORULIWKHVXEMHFWH[SHULHQFHVD'/7LQWKH'/7
HYDOXDWLRQSHULRG$Q\QRQHYDOXDEOHVXEMHFWZLOOEHUHSODFHG
,QWKH3KDVHSRUWLRQRIWKHVWXG\WKHSULPDU\REMHFWLYHLVWRFRPSDUHGRVHOHYHOVRI
0(',DQGDQ$,WRVLQJOHDJHQW$,DORQHLQWHUPVRI3)6LQRUGHUWRVHOHFWRQHGRVHIRU
SRWHQWLDOIXUWKHUGHYHORSPHQW$VVXPLQJWKDWWKHPHGLDQ3)6IRUVXEMHFWVZLWKVLQJOHDJHQW
$,DORQHLVPRQWKV0RXULGVHQHWDODQGWKDWWKHPHGLDQ3)6IRUVXEMHFWV
UHFHLYLQJWKH
GRVHVRI0(',SOXVDQ$,ZLOOHDFKEHPRQWKVDQ
LPSURYHPHQWLQ3)6RIZRXOGEHDFKLHYHGFRUUHVSRQGLQJWRDKD]DUGUDWLRRI
%DVHGRQWKHVHDVVXPSWLRQVDQGVLPXODWLRQVDWRWDORIHYHQWVVXEMHFWVZLWKGLVHDVH
SURJUHVVLRQRUGHDWKDUHUHTXLUHGWRSURYLGHSRZHUIRUWZRORJUDQNWHVWVRQHIRUHDFK
GRVHYVFRQWURODWDQRYHUDOOVLGHGW\SH,HUURURIDGMXVWLQJIRUFRPSDULVRQV
DVVRFLDWHGZLWK0(',DUPVEHLQJFRPSDUHGWRWKH$,DORQHDUP,IWKHPHGLDQ3)6LQ
RIWKH0(',SOXV$,DUPVLVDVVXPHGWREHPRQWKVDQGWKHPHGLDQ3)6LQWKH
RWKHUDUPLVRUPRQWKVWKHSRZHUZLOOFKDQJHWRRUUHVSHFWLYHO\$WRWDO
VDPSOHVL]HRIVXEMHFWVLVUHTXLUHGJLYHQWKDWVXEMHFWVZLOOEHIROORZHGXQWLO
DSSUR[LPDWHO\KDYH3)6HYHQWVDWWKHWLPHRI3)6DQDO\VLV:LWKDSODQQHGDFFUXDO
SHULRGRIPRQWKVWKHHVWLPDWHGIROORZXSSHULRGDIWHUWKHODVWVXEMHFWLVUDQGRPL]HGLQWR


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
WKHVWXG\ZRXOGEHDSSUR[LPDWHO\PRQWKV7KHSULPDU\DQDO\VLVORJUDQNWHVWZLOOEH
SHUIRUPHGDIWHU3)6HYHQWVKDYHRFFXUUHG

6WDWLVWLFDO0HWKRGV

*HQHUDO&RQVLGHUDWLRQV
$OOGDWDZLOOEHSURYLGHGLQGDWDOLVWLQJVDQGVRUWHGE\WUHDWPHQWJURXSDQGVXEMHFWQXPEHU
$OOWDEXODUVXPPDULHVZLOOEHSUHVHQWHGE\WUHDWPHQWJURXSDQGDOOVXEMHFWVFRPELQHG
&DWHJRULFDOGDWDZLOOEHVXPPDUL]HGE\WKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIDOOLQJZLWKLQ
HDFKFDWHJRU\,QJHQHUDOFRQWLQXRXVYDULDEOHVZLOOEHVXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFV
LQFOXGLQJPHDQVWDQGDUGGHYLDWLRQPHGLDQPLQLPXPDQGPD[LPXP$OODYDLODEOHGDWDZLOO
EHXVHGDQGWKXVPLVVLQJGDWDZLOOQRWEHLPSXWHGIRUWKHSULPDU\DQDO\VLV&RQILGHQFH
LQWHUYDOVZKHQHYHUVSHFLILHGZLOOEHSURGXFHGDWWRDOLJQZLWKWKHQRPLQDOVLJQLILFDQFH
OHYHOIRUWKLVVWXG\DQGDOVRDWIRUFRQYHQLHQFHRIFRPSDULVRQZLWKWUDGLWLRQDO
&,LQOLWHUDWXUH
6XEMHFWVZLWKPLVVLQJGDWDIRUDSDUDPHWHUZLOOEHH[FOXGHGIURPWKHVXPPDU\RIWKLV
SDUDPHWHU7KLVUXOHLVDSSOLFDEOHIRUWKHVXPPDULHVRIGHPRJUDSKLFVDQGEDVHOLQH
FKDUDFWHULVWLFVODERUDWRU\HOHFWURFDUGLRJUDP(&*DQG.DUQRIVN\3HUIRUPDQFH6WDWXV
.36
7KHGDWDDQDO\VHVZLOOEHFRQGXFWHGXVLQJWKH6$66\VWHP9HUVLRQ6$6,QVWLWXWH
,QF&DU\1&LQD81,;HQYLURQPHQW$OO6$6SURJUDPVXVHGWRJHQHUDWHDQDO\WLFDOUHVXOWV
ZLOOEHGHYHORSHGDQGYDOLGDWHGDFFRUGLQJWR0HG,PPXQH6$6SURJUDPPLQJVWDQGDUGVDQG
0HG,PPXQH6$6YDOLGDWLRQSURFHGXUHV

6XEMHFW3RSXODWLRQV
7KHIROORZLQJVXEMHFWSRSXODWLRQVZLOOEHXVHGZKHQVXPPDUL]LQJGDWD
x ,QWHQWWR7UHDW,773RSXODWLRQLQFOXGHVDOOVXEMHFWVZKRDUHHQWHUHGLQWRWKH3KDVH
ESRUWLRQRUUDQGRPL]HGLQWRWKH3KDVHSRUWLRQRIWKHVWXG\7KHWUHDWPHQWDUPLQ
WKH3KDVHSRUWLRQZLOOEHDVVLJQHGDFFRUGLQJWRWKHLQLWLDOUDQGRPL]DWLRQUHJDUGOHVV
RIZKHWKHUVXEMHFWVUHFHLYHDQ\VWXG\WUHDWPHQWRUUHFHLYHDVWXG\WUHDWPHQWGLIIHUHQW
IURPWKDWWRZKLFKWKH\ZHUHUDQGRPL]HG


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
x (YDOXDEOH3RSXODWLRQIRU3KDVHELQFOXGHVDOOVXEMHFWVHQWHUHGLQWKH3KDVHEZKR
UHFHLYHDWOHDVWIXOOF\FOHRI0(',DQGFRPSOHWHWKHVDIHW\IROORZXSWKURXJK
WKH'/7HYDOXDWLRQSHULRGZKLFKLVGHILQHGDV&\FOH'D\WKURXJK'D\RU
H[SHULHQFHDQ\'/7GXULQJWKH'/7HYDOXDWLRQSHULRG
x 6DIHW\3RSXODWLRQLQFOXGHVDOOVXEMHFWVZKRUHFHLYHDQ\VWXG\WUHDWPHQW
x 3HU3URWRFRO3RSXODWLRQLQFOXGHVDOOVXEMHFWVZKRDUHLQWKHUDQGRPL]DWLRQSKDVHRI
WKHVWXG\UHFHLYHDQ\VWXG\WUHDWPHQWKDYHDWOHDVWRQHSRVWEDVHOLQHWXPRU
DVVHVVPHQWDQGKDYHQRPDMRUSURWRFROYLRODWLRQV7KH3HU3URWRFRO3RSXODWLRQZLOO
EHLGHQWLILHGSULRUWRGDWDEDVHORFN
)RUWKH(YDOXDEOH3RSXODWLRQIRU3KDVHEWKH3HU3URWRFRO3RSXODWLRQDQGWKH6DIHW\
3RSXODWLRQWKHWUHDWPHQWDUPZLOOEHDVVLJQHGDFFRUGLQJWRWKHVWXG\WUHDWPHQWWKDWLV
DFWXDOO\UHFHLYHGDWWKHILUVWGRVH
7KHQXPEHUDQGSHUFHQWRIVXEMHFWVLQHDFKVXEMHFWSRSXODWLRQIRUHYDOXDWLRQZLOOEH
VXPPDUL]HGE\WUHDWPHQWDUPDQGDOOVXEMHFWVFRPELQHG

6XEMHFW'LVSRVLWLRQ
7DEOHSUHVHQWVWKHVXPPDULHVWKDWZLOOEHSUHSDUHGIRUVXEMHFWGLVSRVLWLRQ6XPPDULHV
ZLOOEHSUHSDUHGE\WUHDWPHQWDUPDQGDOOVXEMHFWVFRPELQHGEDVHGRQWKH,77SRSXODWLRQ
Table 3.3-1 
Subject Disposition to be Summarized 
Summary 
Population 
1XPEHURI6XEMHFWV(QUROOHG5DQGRPL]HGE\6LWH
,77
6XEMHFW6WDWXVDWWKH(QGRI6WXG\WUHDWPHQW
,77
6XEMHFW6WDWXVDWWKH(QGRI6WXG\DQG0RUWDOLW\6XPPDU\
,77
6XPPDULHVRIWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVHQUROOHGUDQGRPL]HGE\VLWHZLOOEH
SURYLGHG
7KHVXPPDU\RIVXEMHFWVWDWXVDWWKHHQGRIVWXG\WUHDWPHQWZLOOLQFOXGHDIUHTXHQF\
GLVWULEXWLRQRIUHDVRQIRUWUHDWPHQWGLVFRQWLQXDWLRQIRUWKHIROORZLQJFDWHJRULHVORVWWR
IROORZXSZLWKGUDZDORIFRQVHQWGHDWKDGYHUVHHYHQWGLVHDVHSURJUHVVLRQLQYHVWLJDWRU
GLVFUHWLRQRURWKHU


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
6XEMHFWVWDWXVDWWKHHQGRIVWXG\ZLOOEHVXPPDUL]HGLQWHUPVRIWKHQXPEHUDQGSHUFHQWDJH
RIVXEMHFWVZKRFRPSOHWHGWKHVWXG\)RUWKRVHZKRGLGQRWFRPSOHWHWKHVWXG\DVXPPDU\
WDEOHZLOOEHSURYLGHGZLWKWKHIROORZLQJUHDVRQVORVWWRIROORZXSZLWKGUDZDORIFRQVHQW
GHDWKRURWKHU)RUVXEMHFWVZKRGLHE\WKHHQGRIWKHVWXG\WKHFDXVHRIGHDWKGXHWR
GLVHDVHYVQRWGXHWRGLVHDVHDQGWKHUHODWLRQVKLSWRVWXG\WUHDWPHQWUHODWHGYVQRWUHODWHG
DQG0(',UHODWHGYVQRWUHODWHGZLOOEHVXPPDUL]HG)RUWKRVHVXEMHFWVZKRGLHGRQ
VWXG\ZKLFKLVGHILQHGDVDGHDWKZLWKLQGD\VIURPWKHODVWGRVHGDWHWKHFDXVHRIGHDWK
DQGWKHUHODWLRQVKLSWRVWXG\WUHDWPHQWDQG0(',ZLOODOVREHVXPPDUL]HG

%DVHOLQH&KDUDFWHULVWLFV
6XPPDULHVRIGHPRJUDSKLFVGLVHDVHKLVWRU\VXEJURXSVRILQWHUHVWDWEDVHOLQHSULRUFDQFHU
WUHDWPHQWEDVHOLQHGLVHDVHVWDWXVDVVHVVPHQWEDVHOLQHWXPRUFKDUDFWHULVWLFVDQGEDVHOLQH
.DUQRIVN\SHUIRUPDQFHVWDWXVZLOOEHSURYLGHGWRGHVFULEHWKHVXEMHFWSRSXODWLRQLQWKLV
VWXG\3DUDPHWHUVWKDWZLOOEHVXPPDUL]HGIRUWKH,77SRSXODWLRQE\WUHDWPHQWDUPIRU
VXEMHFWVUDQGRPL]HGLQWRWKH3KDVHSRUWLRQRIWKHVWXG\DQGDOOVXEMHFWVFRPELQHGDUH
SUHVHQWHGLQ7DEOH
Table 3.4-1 
Baseline Characteristics to be Summarized 
Summary 
Population 
'HPRJUDSKLFV
,77
'LVHDVH+LVWRU\
,77
6XEJURXSVRI,QWHUHVWDW%DVHOLQH
,77
3ULRU&DQFHU7UHDWPHQW
,77
%DVHOLQH'LVHDVH6WDWXV$VVHVVPHQW
,77
%DVHOLQH7XPRU&KDUDFWHULVWLFV
,77
%DVHOLQH.DUQRIVN\3HUIRUPDQFH6WDWXV
,77
'HPRJUDSKLFVZLOOEHVXPPDUL]HGIRUWKHIROORZLQJFKDUDFWHULVWLFVDJH\HDUKHLJKWFP
ZHLJKWNJHWKQLFLW\DQG UDFH6XEMHFWVZLOOEHH[FOXGHGIURPWKHVXPPDU\IRUHDFK
SDUDPHWHULIGDWDDUHPLVVLQJ
'LVHDVHKLVWRU\VXPPDU\ZLOOLQFOXGHIUHTXHQF\GLVWULEXWLRQVIRUVWDJHDWLQLWLDOGLDJQRVLV
,,,,,,$,,,%,9XQNQRZQWXPRUVWDJH77LV77777;QRGHVWDJH1
1111;PHWDVWDVLVVWDJH000;DQGGHVFULSWLYHVWDWLVWLFVRIWLPHIURP
SULPDU\GLDJQRVLVWRVWXG\HQWU\PRQWKV


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
7KHVXEJURXSVRILQWHUHVWDWEDVHOLQHDUHOLVWHGLQ7DEOH6XEJURXSDQDO\VLVRIDQWL
WXPRUDFWLYLW\ZLOOEHSHUIRUPHGLIWKHUHDUHDVXIILFLHQWQXPEHURIVXEMHFWVLQDVXEJURXS
3ULRUFDQFHUWUHDWPHQWZLOOEHVXPPDUL]HGE\XVLQJWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWV
ZKRKDGUHFHLYHGHDFKRIWKHIROORZLQJWKHUDS\FDWHJRULHVFKHPRWKHUDS\ELRORJLF
KRUPRQDOUDGLDWLRQVXUJHU\WUDQVSODQWRURWKHU,QDGGLWLRQWUHDWPHQWW\SHZLOOEH
VXPPDUL]HGIRUWKHIROORZLQJFDWHJRULHVQHRDGMXYDQWDGMXYDQWSULPDU\RUUHFXUUHQFH
ORFDOO\DGYDQFHGRUPHWDVWDWLFDQGEHVWUHVSRQVHRISULRUFDQFHUWUHDWPHQWZLOOEH
VXPPDUL]HGIRUWKHFDWHJRULHVFRPSOHWHUHVSRQVH&5SDUWLDOUHVSRQVH35VWDEOHGLVHDVH
6'SURJUHVVLYHGLVHDVH3'QRWHYDOXDEOHDQGQRWGRQH
7KHEDVHOLQHGLVHDVHVWDWXVDVVHVVPHQWVXPPDU\ZLOOLQFOXGHIUHTXHQF\GLVWULEXWLRQVIRUVLWHV
RIPHWDVWDWLFGLVHDVHDQGVWDJHRIGLVHDVHDWVWXG\HQWU\
%DVHOLQHWXPRUFKDUDFWHULVWLFVLQFOXGHQXPEHUDQGVLWHVRIWDUJHWOHVLRQVDVZHOODVQXPEHU
DQGVLWHVRIQRQWDUJHWOHVLRQVWREHVXPPDUL]HGXVLQJIUHTXHQF\GLVWULEXWLRQ7KHVL]HRI
WDUJHWOHVLRQVZLOOEHDOVRVXPPDUL]HGLQWHUPVRIVXPRIWKHORQJHVWGLDPHWHURIWDUJHW
OHVLRQVXVLQJGHVFULSWLYHVWDWLVWLFV
$VXPPDU\RIEDVHOLQH.DUQRIVN\SHUIRUPDQFHVWDWXVZLOOEHGRQHXVLQJIUHTXHQF\
GLVWULEXWLRQIRUWKHIROORZLQJFDWHJRULHVDQG
Table 3.4-2 
Subgroups of Interest 
Subgroups of Interest 
Description 
*HRJUDSKLF5HJLRQ
1RUWK$PHULFDRUUHVWRIZRUOG
3ULRU8VDJHRI$,
<HVYV1R
%DVHOLQH.L,QGH[
/RZYV+LJK
%DVHOLQH,*),/HYHO
/RZYV+LJK
%DVHOLQH,*),,/HYHO
/RZYV+LJK
$JH6XEJURXS
RU! \HDUV

6WXG\'UXJ([SRVXUH
7DEOHSUHVHQWVWKHVXPPDULHVRIVWXG\GUXJH[SRVXUHWKDWZLOOEHSURYLGHGIRUWKH,77
DQGRUVDIHW\SRSXODWLRQE\WUHDWPHQWDUP


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.5-1 
Study Drug Exposure 
Summary 
Population 
6WXG\7UHDWPHQW([SRVXUH2YHUDOO
,77DQG6DIHW\
6WXG\7UHDWPHQW([SRVXUHE\$,6XEJURXS
,77
'RVLQJ'HOD\DQG0RGLILFDWLRQVRI0(',
6DIHW\
6XPPDU\RI6XEVHTXHQW$OWHUQDWLYH&DQFHU7UHDWPHQW
,77
6XPPDU\RIVWXG\WUHDWPHQWH[SRVXUHZLOOLQFOXGHGHVFULSWLYHVWDWLVWLFVRIWKHIROORZLQJWRWDO
QXPEHURIWUHDWPHQWF\FOHVGHILQHGDVWKHQXPEHURIF\FOHVGXULQJZKLFKVXEMHFWUHFHLYHG
DQ\WUHDWPHQWRI0(',DQGRU$,QXPEHURI0(',GRVHVDQGWRWDO0(',GRVH
UHFHLYHGGXULQJWKHVWXG\GXUDWLRQRI$,WUHDWPHQWGD\VGXULQJWKHVWXG\7KHWRWDOQXPEHU
RIWUHDWPHQWF\FOHVZLOODOVREHVXPPDUL]HGXVLQJIUHTXHQF\GLVWULEXWLRQ7KHGRVHLQWHQVLW\
IRU0(',RU$,DQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQHLVDSHUFHQWRIWRWDODFWXDOGRVH
WKDWDVXEMHFWUHFHLYHGGXULQJWKHVWXG\WUHDWPHQWSHULRGIRU0(',RU$,DQDVWUR]ROH
OHWUR]ROHRUH[HPHVWDQHUHVSHFWLYHO\YHUVXVWRWDOLQWHQGHGGRVHRI0(',RU$,
DQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQHUHVSHFWLYHO\IRUWKHVDPHVWXG\WUHDWPHQWSHULRG
DFFRUGLQJWRWKHVWXG\SURWRFRO,WZLOOEHVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFVDVSDUWRI
WKHVWXG\WUHDWPHQWH[SRVXUHVXPPDU\7KHGRVHLQWHQVLW\FDOFXODWLRQGHWDLOVZLOOEH
SURYLGHGLQWKH633
'RVLQJGHOD\VDQGPRGLILFDWLRQVZLOOEHVXPPDUL]HGIRUWKHIROORZLQJFDWHJRULHVQXPEHURI
VXEMHFWVZLWK0(',GRVHGHOD\VWKHUHDVRQVIRU0(',GRVHGHOD\DGYHUVHHYHQWV
VFKHGXOLQJFRQIOLFWRWKHUWKHWRWDOQXPEHURIVXEMHFWVIRUZKRPWKHHQWLUH0(',GRVH
ZDVQRWDGPLQLVWHUHGDVVFKHGXOHGWKHUHDVRQVWKHHQWLUH0(',GRVHZDVQRW
DGPLQLVWHUHGDVVFKHGXOHGDGYHUVHHYHQWVRWKHUDQGWKHUHDVRQWKHVXEMHFWGLGQRWUHFHLYH
0(',DGYHUVHHYHQWVRWKHU
7KHXVHRIVXEVHTXHQWDOWHUQDWLYHFDQFHUWUHDWPHQWDIWHUWKHGLVFRQWLQXDWLRQRIVWXG\
WUHDWPHQWZLOOEHVXPPDUL]HGE\W\SHRIWUHDWPHQW'HVFULSWLYHVWDWLVWLFVRIWLPHIURP
WUHDWPHQWGLVFRQWLQXDWLRQWRLQLWLDWLRQRIVXEVHTXHQWFDQFHUWUHDWPHQWPRQWKVZLOOEH
SURYLGHG

6XPPDULHVWR6XSSRUWWKH3ULPDU\2EMHFWLYHV
7KHIROORZLQJVXPPDULHVZLOOEHSUHVHQWHGWRVXSSRUWWKHSULPDU\REMHFWLYHV


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI

3ULPDU\(QGSRLQWVRI6DIHW\LQ3KDVHE
7KHSULPDU\VDIHW\HQGSRLQWVDUHWKHIROORZLQJ
x 'RVHOLPLWLQJWR[LFLWLHVGHILQHGLQWKHVWXG\SURWRFRO6HFWLRQRFFXUULQJ
GXULQJWKH'/7SHULRGLQWKH3KDVHESRUWLRQRIWKLVVWXG\
x $GYHUVHHYHQWVDQG6$(VRFFXUULQJGXULQJWKHSURWRFROVSHFLILHGUHSRUWLQJSHULRGDV
GHILQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO
$GYHUVHHYHQWVWUHDWPHQWUHODWHG$(VDQG6$(VZLOOEHVXPPDUL]HGE\V\VWHPRUJDQFODVV
DQG0HG'5$SUHIHUUHGWHUPVHYHULW\DQGUHODWLRQVKLSWRVWXG\WUHDWPHQW7KHQXPEHUDQG
SHUFHQWDJHRIVXEMHFWVZLWK'/7LQWKH(YDOXDEOH3RSXODWLRQIRU3KDVHERIWKLVVWXG\ZLOO
EHVXPPDUL]HG

3ULPDU\(QGSRLQWRI(IILFDF\LQ3KDVH
7KHSULPDU\HQGSRLQWRIWKH3KDVHSRUWLRQRIWKLVVWXG\LVSURJUHVVLRQIUHHVXUYLYDO3)6

3ULPDU\$QDO\VLVRI3)6
3URJUHVVLRQIUHHVXUYLYDO3)6LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOWKHILUVWGRFXPHQWDWLRQ
RIGLVHDVHSURJUHVVLRQRUGHDWKZKLFKHYHURFFXUVILUVW3)6ZLOOEHFHQVRUHGRQWKHGDWHRI
ODVWWXPRUDVVHVVPHQWGRFXPHQWLQJDEVHQFHRIWXPRUSURJUHVVLRQIRUVXEMHFWVZKRKDYHQR
GRFXPHQWHGSURJUHVVLRQDQGDUHVWLOODOLYHSULRUWRGDWDFXWRIIGURSRXWRUWKHLQLWLDWLRQRI
DOWHUQDWHDQWLFDQFHUWUHDWPHQW6XEMHFWVKDYLQJQRWXPRUDVVHVVPHQWVDIWHUUDQGRPL]DWLRQZLOO
KDYH3)6FHQVRUHGRQWKHGDWHRIUDQGRPL]DWLRQ7KHSULPDU\GHILQLWLRQRI3)6YDULDEOHVLV
SUHVHQWHGLQ7DEOHDQGLVFDOFXODWHGLQPRQWKVDVIROORZV
3)6PRQWKV 'DWHRI3'GHDWKRUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
Table 3.6.2.1-1 
Definition and Censoring Information for PFS 
Situation 
Date of PD/death or Censoring 
Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH
3'DVGHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
'HDWKEHIRUHWKHILUVWSRVWEDVHOLQH
GLVHDVHDVVHVVPHQWRUEHWZHHQ
DGHTXDWHWXPRUDVVHVVPHQWYLVLWV
'DWHRIGHDWK
'HDWK


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.6.2.1-1 
Definition and Censoring Information for PFS 
Situation 
Date of PD/death or Censoring 
Outcome 
1R3'DVGHWHUPLQHGE\
LQYHVWLJDWRUGHDWK
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
'HDWKRU3'DVGHWHUPLQHGE\
LQYHVWLJDWRUDIWHUPLVVHG
FRQVHFXWLYHGLVHDVHDVVHVVPHQWV
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
&HQVRUHG
,QLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWR
LQLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
&HQVRUHG
1RWXPRUDVVHVVPHQWDWEDVHOLQHRU
SRVWEDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG
3)6ZLOOEHHYDOXDWHGXVLQJ.DSODQ0HLHUPHWKRGLQWKH,77SRSXODWLRQDQGFRPSDUHGZLWK
DVLGHGVWUDWLILHGORJUDQNWHVWDWĮ VLJQLILFDQFHOHYHORYHUDOOW\SH,HUURUUDWHEHWZHHQ
HDFKRIWKHWZR0(',
RU
$,DUPVDQGWKH$,DORQHDUP7R
DGMXVWIRUPXOWLSOHFRPSDULVRQVWKHQRPLQDOVLJQLILFDQFHOHYHOEDVHGRQVLPXODWLRQZLOOEH
IRUHDFKRIWKHFRPSDULVRQVDVVRFLDWHGZLWK0(',DUPVEHLQJFRPSDUHGWRWKH
$,DORQHDUP7KHVWUDWLILFDWLRQIDFWRUVZLOOEHJHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRI
ZRUOGDQG$,W\SHDQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQH$VVHVVPHQWVRIGLVHDVHUHVSRQVH
E\LQYHVWLJDWRUVZLOOEHWKHEDVLVIRUWKHSULPDU\DQDO\VLV
$VVXSSRUWLYHLQIRUPDWLRQPHGLDQ3)6DQGLWVDQGFRQILGHQFHLQWHUYDO&,ZLOOEH
HVWLPDWHGXVLQJWKH.DSODQ0HLHUPHWKRG7KHKD]DUGUDWLR0(',$,YV$,DORQH
ZLWKWZRVLGHGDQGFRQILGHQFHLQWHUYDOVZLOOEHHVWLPDWHGE\XVLQJWKH&R[
SURSRUWLRQDOKD]DUGPRGHOZLWKWUHDWPHQWJURXSDQGWKHVWUDWLILFDWLRQIDFWRUVLQWKHPRGHO

6XSSRUWLYH$QDO\VLVRI3)6
 6HQVLWLYLW\$QDO\VLVRI3)6RQ$QDO\VLV3RSXODWLRQ
3)6ZLOOEHDQDO\]HGEDVHGRQSHUSURWRFROSRSXODWLRQVLQDGGLWLRQWR,77SRSXODWLRQ
 6HQVLWLYLW\$QDO\VHVRI3)6RQ9DULDEOH'HILQLWLRQ
7KUHHGLIIHUHQWGHILQLWLRQVRI3)6ZLOOEHH[SORUHG)LUVWWKHDVVHVVPHQWVE\EOLQGHG
LQGHSHQGHQWFHQWUDOUHYLHZ%,&5LQDGGLWLRQWRLQYHVWLJDWRUV¶DVVHVVPHQWVZLOOEHXVHGDV
VKRZQLQ7DEOH


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.6.2.2.2-1 
Definition and Censoring Information for PFS Based on BICR 
Situation 
Date of PD/death or Censoring 
Outcome 
3URJUHVVLYH'LVHDVH3'DV
GHWHUPLQHGE\%,&5
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
'HDWKEHIRUHWKHILUVWSRVWEDVHOLQH
GLVHDVHDVVHVVPHQWRUEHWZHHQ
DGHTXDWHWXPRUDVVHVVPHQWYLVLWV
'DWHRIGHDWK
'HDWK
1R3'DVGHWHUPLQHGE\
%,&5GHDWK
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
'HDWKRU3'DVGHWHUPLQHGE\
%,&5DIWHUPLVVHGFRQVHFXWLYH
GLVHDVHDVVHVVPHQWV
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
&HQVRUHG
,QLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWR
LQLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
&HQVRUHG
1RWXPRUDVVHVVPHQWDWEDVHOLQHRU
SRVWEDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG
6HFRQG3)6HYHQWVDUHFRQVLGHUHGDVHYHQWVUHJDUGOHVVRIPLVVLQJYLVLWVEHIRUHWKHHYHQWV
7KHFRUUHVSRQGLQJGHILQLWLRQRI3)6LVSUHVHQWHGLQ7DEOH
Table 3.6.2.2.2-2 
Definition and censoring information for PFS (PFS Events Only) 
Situation 
Date of PD/death or Censoring 
Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH
3'DVGHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
'HDWK
'DWHRIGHDWK
'HDWK
1R3'DVGHWHUPLQHGE\
LQYHVWLJDWRUGHDWK
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
1RWXPRUDVVHVVPHQWDWEDVHOLQHRU
SRVWEDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG
/DVWWKHVFKHGXOHGWXPRUYLVLWGDWHVDFFRUGLQJWRWKHVWXG\SURWRFROZLOOEHXVHGWRDVVLJQ
WKHGDWHVIRUFHQVRULQJDQGHYHQWVLQRUGHUWRDYRLGWKHSRWHQWLDOELDVLQDFWXDOIROORZXS
VFKHGXOHVIRUWXPRUDVVHVVPHQW)RUH[DPSOHDSDWLHQWLVVXSSRVHGWRKDYHWXPRUDVVHVVPHQW
RQ'D\DFFRUGLQJWRWKHVWXG\SURWRFRO+RZHYHUWKHSDWLHQWDFWXDOO\KDVWXPRU
DVVHVVPHQWRQ'D\DQGKDVHYLGHQFHRISURJUHVVLYHGLVHDVH7KHGDWHVRI'D\DQG'D\
ZLOOEHWKHGDWHRIWKHVFKHGXOHGYLVLWDQGWKHDFWXDOGDWHRIWKHHDUOLHVWVLJQRI3'
UHVSHFWLYHO\7KHFRUUHVSRQGLQJ3)6YDULDEOHVDUHVXPPDUL]HGLQ7DEOH


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.6.2.2.2-3 
Definition and Censoring Information for PFS (Uniform 
Progression and Assessment Dates) 
Situation 
Date of PD/death or Censoring 
Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH
3'GRFXPHQWHGEHWZHHQ
VFKHGXOHGYLVLWVGHWHUPLQHGE\
LQYHVWLJDWRU
'DWHRIQH[WVFKHGXOHGYLVLW
3URJUHVVHG
'HDWKEHIRUHWKHILUVWSRVWEDVHOLQH
GLVHDVHDVVHVVPHQWRUEHWZHHQ
DGHTXDWHWXPRUDVVHVVPHQWYLVLWV
'DWHRIGHDWK
'HDWK
1R3'DVGHWHUPLQHGE\
LQYHVWLJDWRUGHDWK
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
'HDWKRU3'DIWHUPLVVHG
FRQVHFXWLYHGLVHDVHDVVHVVPHQWV
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
&HQVRUHG
,QLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWR
LQLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
&HQVRUHG
1RWXPRUDVVHVVPHQWDWEDVHOLQHRU
SRVWEDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG
 6XEJURXS$QDO\VLVRI3)6
6XEJURXSDQDO\VHVRI3)6ZLOOEHEDVHGRQWKHVWUDWLILFDWLRQIDFWRUVDQGEDVHOLQH
FKDUDFWHULVWLFVVSHFLILHGLQ7DEOHLQ,77SRSXODWLRQ7KHVLGHGORJUDQNWHVWZLOOEH
DSSOLHGIRUHDFKVXEJURXSLIWKHUHDUHHQRXJKSDWLHQWVLQWKHVXEJURXSSRSXODWLRQ7KHKD]DUG
UDWLR0(',$,YV$,DORQHZLWKDWZRVLGHGFRQILGHQFHLQWHUYDOIRUHDFK
VXEJURXSZLOOEHHVWLPDWHGE\XVLQJWKH&R[SURSRUWLRQDOKD]DUGPRGHO

6XPPDULHVWR6XSSRUWWKH6HFRQGDU\2EMHFWLYHV

6HFRQGDU\(QGSRLQWVRI6DIHW\DQG7ROHUDELOLW\
6DIHW\DQGWROHUDELOLW\ZLOOEHDVVHVVHGE\VXPPDUL]LQJ$(V6$(VHOHFWURFDUGLRJUDP
(&*UHVXOWVVLJQLILFDQWRULPSRUWDQWFOLQLFDOILQGLQJVLQ.DUQRIVN\SHUIRUPDQFHVWDWXV
ODERUDWRU\DVVHVVPHQWVDQGYLWDOVLJQVGXULQJWKHVWXG\$OOVXPPDULHVIRUWR[LFLW\SURILOH
HYDOXDWLRQZLOOEHGRQHE\WUHDWPHQWDUPEDVHGRQWKHVDIHW\SRSXODWLRQ


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
2QO\WUHDWPHQWHPHUJHQWDGYHUVHHYHQWV7($(VGHILQHGDVHYHQWVSUHVHQWDWEDVHOLQHWKDW
ZRUVHQLQLQWHQVLW\DIWHUDGPLQLVWUDWLRQRIVWXG\WUHDWPHQWRUHYHQWVDEVHQWDWEDVHOLQHWKDW
HPHUJHDIWHUDGPLQLVWUDWLRQRIVWXG\WUHDWPHQWIRUWKHSHULRGH[WHQGLQJWRGD\VDIWHUWKH
ODVWGRVHRIVWXG\WUHDWPHQWZLOOEHVXPPDUL]HGE\V\VWHPRUJDQFODVVDQGSUHIHUUHGWHUP
XVLQJWKH0HG'5$GLFWLRQDU\VHYHULW\JUDGHGDFFRUGLQJWR1&,&7&$(YDQG
UHODWLRQVKLSWRVWXG\WUHDWPHQW7KH$(V6$(VRFFXUULQJIURPWKHVLJQLQJRIWKHLQIRUPHG
FRQVHQWDQGSULRUWRWKHLQLWLDWLRQRIVWXG\WUHDWPHQWZLOOEHOLVWHG7KH$(V6$(VWKDWEHJLQ
GD\VDIWHUODVWGRVHZLOOQRWEHVXPPDUL]HGRUOLVWHG
6XEMHFWVZLOOEHFRXQWHGRQO\RQFHIRUHDFKSUHIHUUHGWHUPRQFHIRUHDFKV\VWHPRUJDQFODVV
DQGE\WKHKLJKHVWHYHQWVHYHULW\UHJDUGOHVVRIKRZPDQ\HYHQWVWKHVXEMHFWH[SHULHQFHG
7DEOHSUHVHQWVWKHWUHDWPHQWHPHUJHQWDGYHUVHHYHQWVXPPDULHVWREHSURYLGHG
Table 3.7.1-1 
Treatment Emergent Adverse Events and Serious Adverse Events 
Summary 
Population 
5DWH6XPPDU\RI$OO7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVE\$,6XEJURXS
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVE\+LJKHVW6HYHULW\$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV6RUWHGE\)UHTXHQF\$OO
6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV*UDGH! $OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV*UDGH! E\$,6XEJURXS
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW5HODWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW5HODWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVE\+LJKHVW
6HYHULW\$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK0(',5HODWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWV$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWVE\$,6XEJURXS
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWVE\6HULRXV$GYHUVH
(YHQWV&ULWHULD$OO6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW5HODWHG7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWV$OO
6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW5HODWHG7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWVE\
+LJKHVW6HYHULW\$OO6XEMHFWV
6DIHW\


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.7.1-1 
Treatment Emergent Adverse Events and Serious Adverse Events 
1XPEHURI6XEMHFWVZLWK0(',5HODWHG7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWV$OO
6XEMHFWV
6DIHW\
1XPEHURI6XEMHFWVZLWK7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV5HVXOWLQJLQ3HUPDQHQW
'LVFRQWLQXDWLRQRI6WXG\WUHDWPHQW$OO6XEMHFWV
6DIHW\
'/7OLNHHYHQWV
7KH'/7OLNHHYHQWVGHILQHGDVDQHYHQWZKLFKPHHWVWKHGHILQLWLRQRI'/7EXWRFFXUV
GXULQJ&\FOHLQDOOVXEMHFWVWUHDWHGZLWKLQWKHVWXG\ZLOOEHVXPPDUL]HGE\WUHDWPHQW
JURXS
(&*3DUDPHWHUV
7DEOHSUHVHQWVWKHVXPPDULHVWREHSURYLGHGIRU(&*SDUDPHWHUV
Table 3.7.1-2 
ECG Parameters 
Summary 
Population 
&KDQJHIURP%DVHOLQHLQ(&*SDUDPHWHUV
6DIHW\
'HVFULSWLYHVWDWLVWLFVIRU(&*SDUDPHWHUVZLOOEHSURYLGHGIRUHDFKVFKHGXOHGWLPHSRLQW
.DUQRIVN\SHUIRUPDQFH3DUDPHWHUV
7DEOHSUHVHQWVWKHVXPPDULHVWREHSURYLGHGIRU.DUQRIVN\SHUIRUPDQFHVWDWXV
.36
Table 3.7.1-3 
Karnofsky Performance Parameters  
Summary 
Population 
6XPPDU\RI.DUQRIVN\SHUIRUPDQFHVWDWXV
6DIHW\
.DUQRIVN\SHUIRUPDQFHVWDWXVZLOOEHVXPPDUL]HGXVLQJDVKLIWWDEOHVKRZLQJFKDQJHLQ.36
IURPEDVHOLQHWRWKHZRUVWSHUIRUPDQFHVWDWXVRQVWXG\DQGWRWKHODVWDVVHVVPHQWRQVWXG\
/DERUDWRU\3DUDPHWHUV
7KHFKDQJHLQHDFKODERUDWRU\SDUDPHWHUIURPEDVHOLQHWRWKH³ZRUVWFDVH´QDGLUDQGRU
]HQLWKRQVWXG\LQFOXGLQJDQ\SRVWEDVHOLQHDVVHVVPHQWVWKDWRFFXUWKURXJKGD\VDIWHU


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
WKHODVWGRVHDQGWRWKHODVWDVVHVVPHQWRQVWXG\LQFOXGLQJDQ\SRVWEDVHOLQHDVVHVVPHQWV
WKDWRFFXUWKURXJKGD\VDIWHUWKHODVWGRVHIRUKHPDWRORJ\FRDJXODWLRQDQGEORRG
FKHPLVWU\ZLOOEHVXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFV%DVHOLQHYDOXHVZLOOEHGHILQHGDVWKH
ODVWYDOLGDVVHVVPHQWSULRUWRWKHILUVWDGPLQLVWUDWLRQRIVWXG\WUHDWPHQW
/DERUDWRU\DEQRUPDOLWLHVZLWKWR[LFLW\JUDGHVDFFRUGLQJWRWKH1&,&7&$(YZLOOEH
GHULYHGDFFRUGLQJWRODERUDWRU\YDOXHV/DERUDWRU\DEQRUPDOLWLHVRFFXUULQJIURPWKHVWDUWRI
VWXG\WUHDWPHQWDGPLQLVWUDWLRQWKURXJKGD\VDIWHUWKHODVWGRVHRIWKHVWXG\WUHDWPHQWZLOO
EHSUHVHQWHG6KLIWWDEOHVIURPEDVHOLQHWRWKHPD[LPXPVHYHULW\JUDGHRQVWXG\DQGWRWKH
ODVWDVVHVVPHQWRQVWXG\ZLOOEHJHQHUDWHGIRUHDFKRIODERUDWRU\SDUDPHWHU
7DEOHSUHVHQWVWKHVXPPDULHVIRUODESDUDPHWHUVWREHSUHSDUHG
Table 3.7.1-4 
Laboratory Parameters to be Summarized 
Summary 
Population 
&KDQJHIURP%DVHOLQHLQ+HPDWRORJ\&RDJXODWLRQ3DUDPHWHUV
6DIHW\
&KDQJHIURP%DVHOLQHLQ&KHPLVWU\3DUDPHWHUV
6DIHW\
7R[LFLW\*UDGHVIRU+HPDWRORJ\&RDJXODWLRQ3DUDPHWHUV
6DIHW\
7R[LFLW\*UDGHVIRU&KHPLVWU\3DUDPHWHUV
6DIHW\
9LWDO6LJQV
'HVFULSWLYHVWDWLVWLFVRIYDOXHDQGFKDQJHIURPEDVHOLQHYDOXHIRUKHDUWUDWHEORRGSUHVVXUH
WHPSHUDWXUHDQGUHVSLUDWRU\UDWHZLOOEHSURYLGHGIRUHDFKVFKHGXOHGWLPHSRLQW7DEOH
SUHVHQWVWKHVXPPDU\WREHSUHSDUHGIRUYLWDOVLJQSDUDPHWHUVEDVHGRQWKHVDIHW\
SRSXODWLRQ
Table 3.7.1-5 
Vital Signs 
Summary 
Population 
&KDQJHIURP%DVHOLQHLQ9LWDO6LJQ3DUDPHWHUV
6DIHW\

6HFRQGDU\(IILFDF\(QGSRLQWV
7KHVHFRQGDU\HQGSRLQWVIRUDVVHVVLQJDQWLWXPRUDFWLYLW\LQFOXGHEHVWGLVHDVHUHVSRQVH
REMHFWLYHUHVSRQVHUDWH255WLPHWRUHVSRQVH775GXUDWLRQRIUHVSRQVH'5WLPHWR
SURJUHVVLRQ773RYHUDOOVXUYLYDO26DQGFKDQJHLQWXPRUVL]H7KH\ZLOOEHVXPPDUL]HG
E\WUHDWPHQWDUPEDVHGRQWKH,773RSXODWLRQLQ3KDVH


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
%HVW2YHUDOO5HVSRQVH
7KHEHVWRYHUDOOUHVSRQVHZLOOEHFDOFXODWHGEDVHGXSRQWKHGLVHDVHDVVHVVPHQWVUHFRUGHG
GXULQJWKHVWXG\YLVLWVDQGVXPPDUL]HGZLWKWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIRUWKH
IROORZLQJFDWHJRULHVFRPSOHWHUHVSRQVH&5ZLWKFRQILUPDWLRQFRPSOHWHUHVSRQVH&5
ZLWKRXWFRQILUPDWLRQSDUWLDOUHVSRQVH35ZLWKFRQILUPDWLRQSDUWLDOUHVSRQVH35ZLWKRXW
FRQILUPDWLRQVWDEOHGLVHDVH6'SURJUHVVLYHGLVHDVH3'DQGQRWHYDOXDEOH1(
&RQILUPHG&5DQG35DUHWKRVHWKDWSHUVLVWRQUHSHDWLPDJLQJVWXG\ZHHNVDIWHUWKH
LQLWLDOGRFXPHQWDWLRQRIUHVSRQVH,IWKHEHVWRYHUDOOUHVSRQVHRIDVXEMHFWFDQEHFDWHJRUL]HG
DVERWKD&5ZLWKRXWFRQILUPDWLRQDQGD35ZLWKFRQILUPDWLRQWKHVXEMHFWZLOOEH
VXPPDUL]HGXQGHU35ZLWKFRQILUPDWLRQ
2EMHFWLYH5HVSRQVH5DWH
7KHREMHFWLYHUHVSRQVHUDWH255ZKLFKLVGHILQHGDVWKHSURSRUWLRQRIVXEMHFWVZLWK
FRQILUPHG&5RUFRQILUPHG35ZLOOEHHVWLPDWHGZLWKDQGFRQILGHQFHLQWHUYDOV
EDVHGRQWKHH[DFWSUREDELOLW\PHWKRG6XEMHFWVWKDWKDYHPLVVLQJRYHUDOOUHVSRQVH
DVVHVVPHQWVZLOOEHFRQVLGHUHGQRQUHVSRQGHUVVRWKH\ZLOOEHFRXQWHGLQWKHGHQRPLQDWRU
EXWQRWLQWKHQXPHUDWRURI255,QDGGLWLRQ255RIWKH0(',WUHDWPHQWDUPVZLOO
EHFRPSDUHGZLWKWKH$,DUPXVLQJWKH&RFKUDQ±0DQWHO±+DHQV]HOWHVWVWUDWLILHGE\
JHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG$,W\SHDQDVWUR]ROHOHWUR]ROHRU
H[HPHVWDQH
7LPHWR5HVSRQVH
7LPHWRUHVSRQVH775LVPHDVXUHGIURPUDQGRPL]DWLRQWRWKHILUVWGRFXPHQWDWLRQRI
GLVHDVHUHVSRQVHDQGZLOOEHHYDOXDWHGRQO\LQVXEMHFWVZKRKDYHDFKLHYHGREMHFWLYHUHVSRQVH
FRQILUPHG&5RUFRQILUPHG357LPHWRUHVSRQVHLVGHILQHGLQPRQWKVDVIROORZV
775PRQWKV 'DWHRIILUVWGLVHDVHUHVSRQVH±'DWHRIUDQGRPL]DWLRQ

7KHPHGLDQ775DQGLWVDQG&,VZLOOEHDVVHVVHGXVLQJWKH.DSODQ0HLHUPHWKRG
'XUDWLRQRI5HVSRQVH
'XUDWLRQRIUHVSRQVH'5LVPHDVXUHGIURPWKHILUVWGRFXPHQWDWLRQRIGLVHDVHUHVSRQVHWR
WKHILUVWGRFXPHQWHGSURJUHVVLYHGLVHDVHDQGZLOOEHHYDOXDWHGRQO\LQVXEMHFWVWKDWKDYH


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
DFKLHYHGREMHFWLYHUHVSRQVHFRQILUPHG&5RUFRQILUPHG35'XUDWLRQRIUHVSRQVHLV
GHILQHGLQPRQWKVDVIROORZV
'5PRQWKV 'DWHRI3'RUFHQVRULQJ±'DWHRIILUVWGLVHDVHUHVSRQVH

ZKHUHGDWHRI3'RUFHQVRULQJLVJLYHQLQ7DEOH7KHPHGLDQWLPHRI'5DQGLWV
DQG&,VZLOOEHDVVHVVHGXVLQJWKH.DSODQ0HLHUPHWKRG
Table 3.7.2-1 
Definition and Censoring Information for DR 
Situation 
Date of PD or Censoring 
Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH3'
DVGHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
1R3'
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
3'DVGHWHUPLQHGE\LQYHVWLJDWRUDIWHU
PLVVHGFRQVHFXWLYHGLVHDVH
DVVHVVPHQWV
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
&HQVRUHG
,QLWLDWLRQRIRWKHUDQWLFDQFHUWKHUDS\
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWR
LQLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
&HQVRUHG
7LPHWR3URJUHVVLRQ
7LPHWRSURJUHVVLRQ773LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOWKHILUVWGRFXPHQWDWLRQRI
GLVHDVHSURJUHVVLRQ7LPHWRSURJUHVVLRQLVGHILQHGLQPRQWKVDVIROORZV
773PRQWKV 'DWHRI3'RUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
ZKHUHGDWHRI3'RUFHQVRULQJLVJLYHQLQ7DEOH7KHPHGLDQ773ZLOOEHHVWLPDWHG
XVLQJWKH.DSODQ0HLHUPHWKRGZLWKDQG&,V
Table 3.7.2-2 
Definition and censoring information for TTP 
Situation 
Date of PD or Censoring 
Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH
3'DVGHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
1R3'
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQW
&HQVRUHG
3'DVGHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIODVWSURJUHVVLRQIUHH
&HQVRUHG


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
Table 3.7.2-2 
Definition and censoring information for TTP 
Situation 
Date of PD or Censoring 
Outcome 
DIWHUPLVVHGFRQVHFXWLYH
GLVHDVHDVVHVVPHQWV
GLVHDVHDVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
,QLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
'DWHRIODVWSURJUHVVLRQIUHH
GLVHDVHDVVHVVPHQWSULRUWR
LQLWLDWLRQRIRWKHUDQWLFDQFHU
WKHUDS\
&HQVRUHG
1RWXPRUDVVHVVPHQWDWEDVHOLQHRU
SRVWEDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG
2YHUDOO6XUYLYDO
2YHUDOOVXUYLYDO26LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOGHDWK)RUVXEMHFWVZKRDUHDOLYH
DWWKHHQGRIVWXG\RUORVWWRIROORZXS26ZLOOEHFHQVRUHGRQWKHODVWGDWHZKHQVXEMHFWV
ZHUHNQRZQWREHDOLYH2YHUDOOVXUYLYDOLVGHILQHGLQPRQWKVDVIROORZV
26PRQWKV 'DWHRIGHDWKRUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
7KHPHGLDQ26ZLOOEHHVWLPDWHGXVLQJWKH.DSODQ0HLHUPHWKRGZLWKDQG&,V
&KDQJHLQ7XPRU6L]H
7KHFKDQJHLQWXPRUVL]HZLOOEHVXPPDUL]HGLQWHUPVRISHUFHQWFKDQJHLQWXPRUVL]H
GHILQHGDVWKHVXPRIORQJHVWGLDPHWHUVRIWKHPHDVXUDEOHWDUJHWWXPRUOHVLRQVIURPEDVHOLQH
WRHDFKVFKHGXOHGYLVLWDVZHOODVQDGLUDQG]HQLWK$WHDFKYLVLWWKHFKDQJHLQWXPRUVL]HZLOO
EHDQDO\]HGXVLQJDPL[HGPRGHOZLWKWUHDWPHQWDUPDQGWLPHDVIDFWRUVDQGJHRJUDSKLF
UHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG$,W\SHDQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQH
DVFRYDULDWHV,QDGGLWLRQWKHFKDQJHLQWXPRUVL]HDWQDGLUDQG]HQLWKDWZHHNVDQG
ZHHNVZLOOEHDQDO\]HGXVLQJDQDO\VLVRIFRYDULDQFH$1&29$ZLWKWUHDWPHQWDUPDVIDFWRU
DQGJHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG$,W\SHDQDVWUR]ROHOHWUR]ROH
RUH[HPHVWDQHDVFRYDULDWHV
6XEJURXS$QDO\VLVRI$QWLWXPRU$FWLYLW\
$VXEJURXSDQDO\VLVRIEHVWRYHUDOOUHVSRQVHREMHFWLYHUHVSRQVHDQG26ZLOOEHSHUIRUPHG
IRUWKHVXESRSXODWLRQVGHILQHGLQ6HFWLRQ


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI

,PPXQRJHQLFLW\RI0(',
$QDO\VLVRI,0UHVXOWVZLOOEHDVVHVVHGE\VXPPDUL]LQJWKHQXPEHUDQGSHUFHQWDJHRI
VXEMHFWVZKRGHYHORSGHWHFWDEOHDQWL0(',DQWLERGLHVIRUDOOVXEMHFWVHQWHUHGLQ
3KDVHEDQG3KDVH$UPDQG$UP7KH$'$WLWHUZLOOEHUHSRUWHGIRUVDPSOHV
FRQILUPHGSRVLWLYHIRUWKHSUHVHQFHRIDQWL0(',DQWLERGLHV7KHHIIHFWRI$'$RQ3.
SKDUPDFRG\QDPLFVDQGVDIHW\ZLOOEHHYDOXDWHGE\WKH0HG,PPXQH*OREDO3.3'	
%LRDQDO\VLVJURXSRUGHVLJQHH

3KDUPDFRORJ\DQG3KDUPDFRG\QDPLFVRI0(',
2WKHUVHFRQGDU\HQGSRLQWVDUHWKHSKDUPDFRNLQHWLFVDQGSKDUPDFRG\QDPLFVHQGSRLQWV7KH
$QDO\VHVZLOOEHSUHIRUPHGE\WKH0HG,PPXQH*OREDO3.3'	%LRDQDO\VLVJURXSRU
GHVLJQHH

([SORUDWRU\6XPPDULHV

([SORUDWRU\$QDO\VHVRI%LRPDUNHUV
([SORUDWRU\DQDO\VHVRIELRPDUNHUVZLOOEHSHUIRUPHGE\WKH0HG,PPXQH7UDQVODWLRQDO
6FLHQFHVJURXSRUGHVLJQHH

([SORUDWRU\$QDO\VLV














0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI



































0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI























,QWHULP$QDO\VHV
1RIRUPDOLQWHULPDQDO\VLVLVSODQQHG

5HIHUHQFHV
0RXULGVHQ+*HUVKDQRYLFK06XQ<3pUH]&DUULyQ5%RQL&0RQQLHU$HWDO6XSHULRU
HIILFDF\RIOHWUR]ROHYHUVXVWDPR[LIHQDVILUVWOLQHWKHUDS\IRUSRVWPHQRSDXVDOZRPHQZLWK
DGYDQFHGEUHDVWFDQFHUUHVXOWVRIDSKDVH,,,VWXG\RIWKH,QWHUQDWLRQDO/HWUR]ROH%UHDVW
&DQFHU*URXS-&OLQ2QFRO0D\


0HG,PPXQH

0(',
3URWRFRO&'210(',9
6WDWLVWLFDO$QDO\VLV3ODQ
-81()LQDO9HUVLRQ

RI
6KL4:DQJ;67LWR50HQGR]D753DQG\D.-DQG&OHHODQG&6$VVHVVLQJ3HUVLVWHQW
&DQFHU3DLQ$&RPSDULVRQRI&XUUHQW3DLQ5DWLQJVDQG3DLQ5HFDOOHGIURPWKH3DVW:HHN-
RI3DLQDQG6\PSWRP0DQDJHPHQW
.LQJ077KHLQWHUSUHWDWLRQRIVFRUHVIURPWKH(257&TXDOLW\RIOLIHTXHVWLRQQDLUH4/4
&4XDO/LIH5HV
2VRED'5RGULJXHV*0\OHV-=HH%3DWHU-,QWHUSUHWLQJWKH6LJQLILFDQFHRI&KDQJHVLQ
+HDOWK5HODWHG4XDOLW\RI/LIH6FRUHV-&OLQ2QFRO
2VRED'%H]MDN$%UXQGDJH0=HH%7X'3DWHU-4XDOLW\RI/LIH&RPPLWWHHRIWKH
1&,&&7*$QDO\VLVDQGLQWHUSUHWDWLRQRIKHDOWKUHODWHGTXDOLW\RIOLIHGDWDIURPFOLQLFDO
WULDOVEDVLFDSSURDFKRI7KH1DWLRQDO&DQFHU,QVWLWXWHRI&DQDGD&OLQLFDO7ULDOV*URXS(XU
-&DQFHU





0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
67$7,67,&$/$1$/<6,63/$1

Protocol Number: &'210(',$PHQGPHQW

$3KDVHE5DQGRPL]HG6WXG\RI0(',LQ&RPELQDWLRQZLWKDQ$URPDWDVH,QKLELWRU
$,9HUVXV$,$ORQHLQ:RPHQZLWK0HWDVWDWLF%UHDVW&DQFHU0%&










0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
7DEOHRI&RQWHQWV
List of In-text Tables.......................................................................................... 3 
List of In-text Figures ........................................................................................ 3 
1 
Introduction............................................................................................... 6 
2 
Study Overview ......................................................................................... 6 
 6WXG\2EMHFWLYHV 
 3ULPDU\6WXG\2EMHFWLYHV 
 6HFRQGDU\6WXG\2EMHFWLYHV 
 ([SORUDWRU\6WXG\2EMHFWLYHV 
 7UHDWPHQW$VVLJQPHQWDQG%OLQGLQJ 
 6DPSOH6L]H 
3 
Statistical Methods.................................................................................... 9 
 *HQHUDO&RQVLGHUDWLRQV 
 $QDO\VLV3RSXODWLRQV 
 6WXG\6XEMHFWV 
 6XEMHFW'LVSRVLWLRQ 
 'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV 
 6WXG\'UXJ([SRVXUH 
 (IILFDF\$QDO\VHV 
 3ULPDU\(IILFDF\(QGSRLQWDQG$QDO\VHVLQ3KDVH 
 
3ULPDU\(IILFDF\(QGSRLQWV 
 
3ULPDU\(IILFDF\$QDO\VLV 
 6HFRQGDU\(IILFDF\(QGSRLQWVDQG$QDO\VHVLQ3KDVH 
 
6HFRQGDU\(IILFDF\(QGSRLQWV 
 
6HFRQGDU\(IILFDF\$QDO\VHV 
 
6XEJURXS$QDO\VHV 
 +DQGOLQJRI'URSRXWVDQG0LVVLQJ'DWDLQ3KDVH 
 
+DQGOLQJRI0LVVLQJ'DWD 
 
2WKHU&HQVRULQJ5XOHV 
 $VVLJQPHQWRI'DWHVRI'LVHDVH3URJUHVVLRQRU'LVHDVH5HVSRQVH 


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
 6DIHW\$QDO\VHV
 3ULPDU\(QGSRLQWVRI6DIHW\LQ3KDVHE
 6HFRQGDU\(QGSRLQWVRI6DIHW\DQG7ROHUDELOLW\LQ3KDVH

$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV

'/7OLNHHYHQWV

&OLQLFDO/DERUDWRU\(YDOXDWLRQ

9LWDO6LJQV

(OHFWURFDUGLRJUDP

.DUQRIVN\3HUIRUPDQFH6WDWXV
 ,PPXQRJHQLFLW\
 3KDUPDFRORJ\DQG3KDUPDFRG\QDPLFVRI0(',
 ([SORUDWRU\6XPPDULHV
 ([SORUDWRU\$QDO\VHVRI%LRPDUNHUV
 ([SORUDWRU\$QDO\VLV





4
Interim Analyses...................................................................................... 24
5
References ................................................................................................ 24

/LVWRI,QWH[W7DEOHV
6XEJURXSVRI,QWHUHVW
6XPPDU\RI&HQVRULQJ*XLGHOLQHVIRU(IILFDF\(QGSRLQWV

/LVWRI,QWH[W)LJXUHV

)LJXUH
6WXG\'HVLJQ



0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
/LVWRI$EEUHYLDWLRQV
Abbreviation or 
Specialized Term 
Definition 
$'$
DQWLGUXJDQWLERG\
$(
DGYHUVHHYHQW
$,
DURPDWDVHLQKLELWRU
$1&29$
DQDO\VLVRIFRYDULDQFH


&,
FRQILGHQFHLQWHUYDO
&0+
&RFKUDQ±0DQWHO±+DHQV]HO
&5
FRPSOHWHUHVSRQVH
&7
FRPSXWHGWRPRJUDSK\
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULD)RU$GYHUVH(YHQWV
'/7
GRVHOLPLWLQJWR[LFLW\
'5
GXUDWLRQRIUHVSRQVH
(&*
HOHFWURFDUGLRJUDP



+(5
KXPDQHSLGHUPDOJURZWKIDFWRUUHFHSWRU
+5
KRUPRQHUHFHSWRUSRVLWLYH
,*),,,
LQVXOLQOLNHJURZWKIDFWRU,,,
,0
LPPXQRJHQLFLW\
,77
LQWHQWWRWUHDW
.36
.DUQRIVN\3HUIRUPDQFH6WDWXV
0%&
PHWDVWDWLFEUHDVWFDQFHU
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
1(
QRWHYDOXDEOH
1&,
1DWLRQDO&DQFHU,QVWLWXWH
25
REMHFWLYHUHVSRQVH
255
REMHFWLYHUHVSRQVHUDWH
26
RYHUDOOVXUYLYDO
3'
SURJUHVVLYHGLVHDVH
3)6
SURJUHVVLRQIUHHVXUYLYDO
3.
SKDUPDFRNLQHWLFV


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
Abbreviation or 
Specialized Term 
Definition 
35
SDUWLDOUHVSRQVH
352
SDWLHQWUHSRUWHGRXWFRPH
5(&,67
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV
6$(
VHULRXVDGYHUVHHYHQW
6'
VWDEOHGLVHDVH
633
VWDWLVWLFDOSURJUDPPLQJSODQ
7($(
WUHDWPHQWHPHUJHQWDGYHUVHHYHQW
775
WLPHWRUHVSRQVH
773
WLPHWRSURJUHVVLRQ



0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

,QWURGXFWLRQ
7KLVGRFXPHQWGHVFULEHVWKHVWDWLVWLFDOPHWKRGRORJ\DQGVXPPDULHVIRUSURWRFRO&'21
0(',DPHQGPHQWDVWXG\RI0(',LQFRPELQDWLRQZLWKDQDURPDWDVH
LQKLELWRU$,YHUVXV$,DORQHLQZRPHQZLWKPHWDVWDWLFEUHDVWFDQFHU0%&$V
EDFNJURXQGLQIRUPDWLRQDQRYHUYLHZRIWKHVWXG\GHVLJQLVSURYLGHG7KHPDLQSRUWLRQRI
WKLVGRFXPHQWGHWDLOVWKHVWDWLVWLFDOVXPPDULHVUHODWLQJWRHDFKVWXG\REMHFWLYHDVZHOODVWKH
JHQHUDOFRQYHQWLRQVDQGGHILQLWLRQVWKDWZLOOEHXVHG
,QDGGLWLRQDVHWRIWDEOHWHPSODWHVDQGVSHFLILFDWLRQVDUHSODQQHGWREHFUHDWHGLQDVWDWLVWLFDO
SURJUDPPLQJSODQ633WRFRPSOHPHQWWKLVGRFXPHQW

6WXG\2YHUYLHZ
7KLVLVD3KDVHEPXOWLFHQWHURSHQODEHOVWXG\WRHYDOXDWHWKHVDIHW\WROHUDELOLW\
DQWLWXPRUDFWLYLW\DQGSKDUPDFRORJ\RI0(',LQFRPELQDWLRQZLWKDQ$,LQDGXOW
VXEMHFWVZLWK+5+(5QHJDWLYH0%&7KLVVWXG\KDVSKDVHVDGRVHHYDOXDWLRQSKDVH
3KDVHEDQGDUDQGRPL]DWLRQSKDVH3KDVH
,QWKH3KDVHESRUWLRQRIWKHVWXG\FRKRUWV&RKRUWV$%DQG&ZLOOEHH[DPLQHG,Q
HDFKFRKRUWWRHYDOXDEOHVXEMHFWVZLOOUHFHLYH0(',DWGRVHVRI
&RKRUW
$
&RKRUW%RU
&RKRUW&E\,9LQIXVLRQRQ'D\RIHDFKGD\
F\FOH$VDFRPELQDWLRQWKHUDS\DQ$,RIWKHLQYHVWLJDWRU¶VFKRLFHDQDVWUR]ROHOHWUR]ROHRU
H[HPHVWDQHZLOODOVREHJLYHQRUDOO\RQFHGDLO\(QUROOPHQWLQWR&RKRUWV$%DQG&ZLOOEH
LQLWLDWHGVHTXHQWLDOO\$SSUR[LPDWHO\HYDOXDEOHVXEMHFWVZLOOEHUHTXLUHGIRUWKLVSRUWLRQ
RIWKHVWXG\1RQHYDOXDEOHVXEMHFWVZLOOEHUHSODFHGLQWKHVDPHGRVHFRKRUW
)ROORZLQJHYDOXDWLRQRIWKHVDIHW\RI0(',DWWKH
GRVHOHYHOLQFRPELQDWLRQ
ZLWKDQ$,LQ3KDVHEDSSUR[LPDWHO\VXEMHFWVZLWK+5+(5QHJDWLYH0%&ZLOOEH
UDQGRPL]HGLQWRWKH3KDVHSRUWLRQRIWKHVWXG\LQDUDWLRWRUHFHLYH0(',DW

DQGDQ$,$UPRUDQ$,DORQH$UP0(',ZLOOEHDGPLQLVWHUHGYLD,9
LQIXVLRQRQ'D\RIGD\F\FOHV$Q$,ZLOOEHJLYHQRUDOO\RQFHGDLO\7KH0(',
WUHDWPHQWUHJLPHQVDQGWKHRYHUDOOVWXG\GHVLJQDUHLOOXVWUDWHGLQ)LJXUH


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

Figure 2.1-1 
Study Design 
$, DURPDWDVHLQKLELWRU'/7 GRVHOLPLWLQJWR[LFLW\
5DQGRPL]DWLRQZLOOEHVWUDWLILHGE\JHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG
$,W\SH$OOVXEMHFWVZLOOEHIROORZHGHYHU\ZHHNVWKUHHGD\F\FOHVXQWLOGLVHDVH
SURJUHVVLRQDQGWKHQIROORZHGIRUVXUYLYDOHYHU\PRQWKVXQWLOWKHHQGRIWKHVWXG\DV
GHILQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO
6XEMHFWVZLOOEHWUHDWHGXQWLOXQDFFHSWDEOHWR[LFLW\GRFXPHQWDWLRQRIGLVHDVHSURJUHVVLRQRU
RWKHUUHDVRQVIRUVXEMHFWZLWKGUDZDOVHH6HFWLRQRIWKHVWXG\SURWRFRO8SWR
LQYHVWLJDWLRQDOVLWHVLQ1RUWK$PHULFDZLOOSDUWLFLSDWHLQWKH3KDVHESRUWLRQRIWKHVWXG\
DQGDSSUR[LPDWHO\LQYHVWLJDWLRQDOVLWHVZRUOGZLGHZLOOSDUWLFLSDWHLQWKH3KDVHSRUWLRQ
RIWKHVWXG\7KHVFKHGXOHRIHYDOXDWLRQVLVRXWOLQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO
7XPRUPHDVXUHPHQWVDQGDVVHVVPHQWVZLOOEHEDVHGRQ5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG
7XPRUV5(&,67JXLGHOLQHV(LVHQKDXHUHWDO'HWDLOVDUHGHVFULEHGLQ6HFWLRQ
RIWKHVWXG\SURWRFRO
'D\
'RVH&RKRUW$


$,RUDOO\RQFHSHUGD\
'RVH&RKRUW%


$,RUDOO\RQFHSHUGD\
3KDVHE
3KDVH
$UP


$,RUDOO\RQFHSHUGD\
$UP
1 
$,RUDOO\RQFHSHUGD\
0(',
6DIHW\)ROORZXS3HULRGWKURXJKGD\V
DIWHUILQDOGRVHRUXQWLOVWDUWRIDQRWKHU
DQWLFDQFHUWKHUDS\
6XUYLYDO)ROORZXS3HULRG6XUYLYDOZLOO
EHIROORZHGDSSUR[LPDWHO\HYHU\
PRQWKVXQWLOWKHHQGRIWKHVWXG\
0(',ZLOOEHLQLWLDWHGRQ'D\RIHDFKGD\F\FOHXQWLOSURJUHVVLYH
GLVHDVHXQDFFHSWDEOHWR[LFLW\RURWKHUUHDVRQVIRUVXEMHFWZLWKGUDZDO$,ZLOO
EHDGPLQLVWHUHGGDLO\
2QFHGDLO\$,ZLOOEHDGPLQLVWHUHGXQWLOSURJUHVVLYHGLVHDVHXQDFFHSWDEOH
WR[LFLW\RURWKHUUHDVRQVIRUVXEMHFWZLWKGUDZDO
'D\7UHDWPHQW&\FOH
'D\7UHDWPHQW&\FOH
'D\7UHDWPHQW&\FOH
,Q3KDVHELIRIRURQO\RIVXEMHFWVH[SHULHQFHVD'/7LQ&RKRUW$%
RU&3KDVHPD\EHJLQ
'RVH&RKRUW&


$,RUDOO\RQFHSHUGD\
'D\7UHDWPHQW&\FOH


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

6WXG\2EMHFWLYHV

3ULPDU\6WXG\2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKHGRVHHYDOXDWLRQSKDVH3KDVHERIWKLVVWXG\LVWRHYDOXDWHWKH
VDIHW\DQGWROHUDELOLW\RIGRVHOHYHOVRI0(',LQFRPELQDWLRQZLWKDQ$,LQVXEMHFWV
ZLWK+5+(5QHJDWLYH0%&
7KHSULPDU\REMHFWLYHRIWKHUDQGRPL]DWLRQSKDVH3KDVHRIWKLVVWXG\LVWRHYDOXDWHWKH
SURJUHVVLRQIUHHVXUYLYDO3)6RIVXEMHFWVZLWK+5+(5QHJDWLYH0%&WUHDWHGZLWK
0(',DQGDQ$,YHUVXVWUHDWPHQWZLWKDQ$,DORQH

6HFRQGDU\6WXG\2EMHFWLYHV
7KHVHFRQGDU\REMHFWLYHVRIWKLVVWXG\DUH
x 7RGHVFULEHWKHVDIHW\DQGWROHUDELOLW\RI0(',ZKHQXVHGLQFRPELQDWLRQZLWK
DQ$,
x 7RHYDOXDWHWKHDQWLWXPRUDFWLYLW\RI0(',ZKHQXVHGLQFRPELQDWLRQZLWKDQ$,
YHUVXVWUHDWPHQWZLWKDQ$,DORQH
x 7RHYDOXDWHRYHUDOOVXUYLYDO26LQVXEMHFWVWUHDWHGZLWK0(',ZKHQXVHGLQ
FRPELQDWLRQZLWKDQ$,YHUVXVWUHDWPHQWZLWKDQ$,DORQH
x 7RGHVFULEHWKH3.RI0(',LQFRPELQDWLRQZLWKDQ$,
x 7RGHWHUPLQHWKHSKDUPDFRG\QDPLFVRI0(',LQFRPELQDWLRQZLWKDQ$,RQ
FLUFXODWLQJOHYHOVRI,*),DQG,*),,
x 7RGHWHUPLQHWKH,0RI0(',LQFRPELQDWLRQZLWKDQ$,

([SORUDWRU\6WXG\2EMHFWLYHV
7KHH[SORUDWRU\REMHFWLYHVRIWKLVVWXG\DUH
x 7RHYDOXDWHELRPDUNHUVUHODWHGWR0(',WUHDWPHQW
x 7RLQYHVWLJDWHWKHHIIHFWVRI0(',RQSDWLHQWUHSRUWHGRXWFRPHV352V

7UHDWPHQW$VVLJQPHQWDQG%OLQGLQJ
7KLVLVDQRSHQODEHOVWXG\%OLQGLQJLVQRWDSSOLFDEOHWRWKLVVWXG\'HWDLOVRIWUHDWPHQW
DVVLJQPHQWDQGUDQGRPL]DWLRQDUHGHVFULEHGLQ6HFWLRQWRRIWKHVWXG\SURWRFRO


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

6DPSOH6L]H
,QWKH3KDVHESRUWLRQRIWKHVWXG\DPLQLPXPRIHYDOXDEOHVXEMHFWVHDFKDWWKH
0(',
GRVHOHYHOVZLOOEHUHTXLUHGWRGHWHUPLQHWKHVDIHW\DQG
WROHUDELOLW\RIGRVHVRI0(',LQFRPELQDWLRQZLWKDQ$,8SWRHYDOXDEOHVXEMHFWV
VXEMHFWVHDFKDWWKH0(',GRVHOHYHOVPD\EHQHHGHGLIGRVHOLPLWLQJWR[LFLW\
'/7RFFXUV$VXEMHFWZLOOEHFRQVLGHUHGHYDOXDEOHLIWKHVXEMHFWUHFHLYHVIXOOF\FOHRI
0(',DQGLVIROORZHGIRUVDIHW\WKURXJKWKH'/7HYDOXDWLRQSHULRGDVGHILQHGLQ
6HFWLRQRIWKHVWXG\SURWRFRORULIWKHVXEMHFWH[SHULHQFHVD'/7LQWKH'/7
HYDOXDWLRQSHULRG$Q\QRQHYDOXDEOHVXEMHFWZLOOEHUHSODFHG
,QWKH3KDVHSRUWLRQRIWKHVWXG\WKHSULPDU\REMHFWLYHLVWRFRPSDUH3)6DPRQJVXEMHFWV
WUHDWHGDW
0(',DQGDQ$,YHUVXVVXEMHFWVWUHDWHGZLWKVLQJOHDJHQW$,
DORQH$VVXPLQJWKDWWKHPHGLDQ3)6IRUVXEMHFWVZLWKVLQJOHDJHQW$,DORQHLVPRQWKV
0RXULGVHQHWDODQGWKDWWKHH[SHFWHGPHGLDQ3)6IRUVXEMHFWVUHFHLYLQJWKH
GRVHVRI0(',SOXVDQ$,LVPRQWKVDQLPSURYHPHQWLQ3)6RI
ZRXOGEHDFKLHYHGFRUUHVSRQGLQJWRDKD]DUGUDWLRRI%DVHGRQWKHVHDVVXPSWLRQVDQG
VLPXODWLRQVDWRWDORIHYHQWVLHVXEMHFWVZLWKGLVHDVHSURJUHVVLRQRUGHDWKDUHUHTXLUHG
WRSURYLGHSRZHUIRUDORJUDQNWHVWDWDWZRVLGHGVLJQLILFDQFHOHYHORI:LWKD
SODQQHGDFFUXDOSHULRGRIPRQWKVDQGDPLQLPXPIROORZXSSHULRGRIPRQWKVLWLV
HVWLPDWHGWKDWDWRWDORIDSSUR[LPDWHO\VXEMHFWVDUHQHHGHGWRREVHUYH3)6HYHQWVE\
WKHHQGRIWKHPLQLPXPIROORZXSSHULRG7KHSULPDU\DQDO\VLVORJUDQNWHVWZLOOEH
SHUIRUPHGDIWHU3)6HYHQWVKDYHRFFXUUHG,IWKHH[SHFWHGPHGLDQ3)6LQWKH0(',
JURXSLVPRQWKVFRUUHVSRQGLQJWR+5RIWKHSRZHUZLOOFKDQJHWRZLWK
3)6HYHQWV6XEMHFWVZLOOQRWEHUHSODFHGLQWKLVSKDVHRIWKHVWXG\

6WDWLVWLFDO0HWKRGV

*HQHUDO&RQVLGHUDWLRQV
$OOGDWDZLOOEHSURYLGHGLQGDWDOLVWLQJVDQGVRUWHGE\WUHDWPHQWJURXSVXEMHFWQXPEHUDQG
GDWHFROOHFWHGZKHUHDSSURSULDWH$OOWDEXODUVXPPDULHVZLOOEHSUHVHQWHGE\WUHDWPHQWJURXS
DQGDOOVXEMHFWVFRPELQHG&DWHJRULFDOGDWDZLOOEHVXPPDUL]HGE\WKHQXPEHUDQG
SHUFHQWDJHRIVXEMHFWVZLWKLQHDFKFDWHJRU\,QJHQHUDOFRQWLQXRXVYDULDEOHVZLOOEH
VXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFVLQFOXGLQJPHDQVWDQGDUGGHYLDWLRQPHGLDQPLQLPXP
DQGPD[LPXP&RQILGHQFHLQWHUYDOVZKHQHYHUVSHFLILHGZLOOEHSURGXFHGDWWRDOLJQ
ZLWKWKHQRPLQDOVLJQLILFDQFHOHYHOIRUWKLVVWXG\DQGDOVRDWIRUFRQYHQLHQFHRI
FRPSDULVRQZLWKWUDGLWLRQDO&,LQOLWHUDWXUH


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
$OODYDLODEOHGDWDZLOOEHXVHGDQGWKXVPLVVLQJGDWDZLOOQRWEHLPSXWHGIRUWKHSULPDU\
DQDO\VLV6XEMHFWVZLWKPLVVLQJGDWDIRUDSDUDPHWHUZLOOEHH[FOXGHGIURPWKHVXPPDU\RI
WKDWSDUDPHWHU7KLVUXOHLVDSSOLFDEOHIRUWKHVXPPDULHVRIGHPRJUDSKLFVDQGEDVHOLQH
FKDUDFWHULVWLFVODERUDWRU\HOHFWURFDUGLRJUDP(&*DQG.36
7KHGDWDDQDO\VHVZLOOEHFRQGXFWHGXVLQJWKH6$66\VWHP9HUVLRQ6$6,QVWLWXWH
,QF&DU\1&LQD81,;HQYLURQPHQW$OO6$6SURJUDPVXVHGWRJHQHUDWHDQDO\WLFDOUHVXOWV
ZLOOEHGHYHORSHGDQGYDOLGDWHGDFFRUGLQJWR0HG,PPXQH6$6SURJUDPPLQJVWDQGDUGVDQG
0HG,PPXQH6$6YDOLGDWLRQSURFHGXUHV

$QDO\VLV3RSXODWLRQV
7KHIROORZLQJVXEMHFWSRSXODWLRQVZLOOEHXVHGZKHQVXPPDUL]LQJGDWD
x ,QWHQWWR7UHDW,773RSXODWLRQ6XEMHFWVZKRUHFHLYHDQ\VWXG\LQYHVWLJDWLRQDO
SURGXFWZLOOEHLQFOXGHGLQWKH,77SRSXODWLRQDQGVXEMHFWVZLOOEHDQDO\]HG
DFFRUGLQJWRWKHLUUDQGRPL]HGWUHDWPHQWJURXS(YDOXDEOH3RSXODWLRQIRU3KDVHE
LQFOXGHVDOOVXEMHFWVHQWHUHGLQWKH3KDVHEZKRUHFHLYHDWOHDVWIXOOF\FOHRI
0(',DQGFRPSOHWHWKHVDIHW\IROORZXSWKURXJKWKH'/7HYDOXDWLRQSHULRG
ZKLFKLVGHILQHGDV&\FOH'D\WKURXJK'D\RUH[SHULHQFHDQ\'/7GXULQJWKH
'/7HYDOXDWLRQSHULRG
x 6DIHW\3RSXODWLRQ6XEMHFWVZKRUHFHLYHDQ\VWXG\LQYHVWLJDWLRQDOSURGXFWZLOOEH
LQFOXGHGLQWKHVDIHW\SRSXODWLRQDQGVXEMHFWVZLOOEHDQDO\]HGDFFRUGLQJWRWKH
WUHDWPHQWWKH\DFWXDOO\UHFHLYH$,ZLOOEHGHILQHGDVWKHILUVW$,7\SHWRZKLFKWKH
VXEMHFWZDVH[SRVHG
8QOHVVVWDWHGRWKHUZLVHDQDO\VHVSHUIRUPHGRQWKHHIILFDF\EDVHOLQHDQGGHPRJUDSKLFV
GLVSRVLWLRQFRQFRPLWDQWPHGLFDWLRQVDQGH[SRVXUHGDWDZLOOEHEDVHGRQWKH,77SRSXODWLRQ
$QDO\VHVSHUIRUPHGRQWKHVDIHW\
GDWDZLOOEHEDVHGRQWKHVDIHW\SRSXODWLRQ
)RUWKHHYDOXDEOHSRSXODWLRQ3KDVHEDQGWKHVDIHW\SRSXODWLRQWKHWUHDWPHQWJURXSZLOOEH
DVVLJQHGDFFRUGLQJWRWKHVWXG\WUHDWPHQWWKDWLVDFWXDOO\UHFHLYHGDWWKHILUVWGRVH
7KHQXPEHUDQGSHUFHQWRIVXEMHFWVLQHDFKVXEMHFWSRSXODWLRQIRUHYDOXDWLRQZLOOEH
VXPPDUL]HGE\WUHDWPHQWJURXSDQGDOOVXEMHFWVFRPELQHG


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

6WXG\6XEMHFWV

6XEMHFW'LVSRVLWLRQ
6XPPDULHVZLOOEHSUHSDUHGE\WUHDWPHQWJURXSDQGDOOVXEMHFWVFRPELQHGEDVHGRQWKH,77
SRSXODWLRQ
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVHQUROOHGUDQGRPL]HGE\VLWHZLOOEHSURYLGHG
7KHVXPPDU\RIVXEMHFWVWDWXVDWWKHHQGRIVWXG\WUHDWPHQWZLOOLQFOXGHDIUHTXHQF\
GLVWULEXWLRQRIUHDVRQIRUWUHDWPHQWGLVFRQWLQXDWLRQ
6XEMHFWVWDWXVDWWKHHQGRIVWXG\ZLOOEHVXPPDUL]HGLQWHUPVRIWKHQXPEHUDQGSHUFHQWDJH
RIVXEMHFWVZKRFRPSOHWHGWKHVWXG\)RUWKRVHZKRGLGQRWFRPSOHWHWKHVWXG\DVXPPDU\
WDEOHRIUHDVRQVZLOOEHSURYLGHG
)RUVXEMHFWVZKRGLHRQVWXG\WKHFDXVHRIGHDWKGXHWRGLVHDVHYVQRWGXHWRGLVHDVHDQG
WKHUHODWLRQVKLSWRVWXG\WUHDWPHQWUHODWHGYVQRWUHODWHGDQG0(',UHODWHGYVQRW
UHODWHGZLOOEHVXPPDUL]HG)RUWKRVHVXEMHFWVZKRGLHGZLWKLQGD\VIURPWKHODVWGRVH
GDWHWKHDGYHUVHHYHQWUHVXOWLQJLQGHDWKDQGWKHDGYHUVHHYHQWUHODWLRQVKLSWR0(',
ZLOODOVREHVXPPDUL]HG


'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV
6XPPDULHVRIGHPRJUDSKLFVGLVHDVHKLVWRU\VXEJURXSVRILQWHUHVWDWEDVHOLQHSULRUFDQFHU
WUHDWPHQWEDVHOLQHGLVHDVHVWDWXVDVVHVVPHQWEDVHOLQHWXPRUFKDUDFWHULVWLFVDQGEDVHOLQH
.DUQRIVN\SHUIRUPDQFHVWDWXVZLOOEHSURYLGHGWRGHVFULEHWKHVXEMHFWSRSXODWLRQLQWKLV
VWXG\3DUDPHWHUVZLOOEHVXPPDUL]HGIRUWKH,77SRSXODWLRQE\WUHDWPHQWJURXSIRUVXEMHFWV
UDQGRPL]HGLQWRWKH3KDVHSRUWLRQRIWKHVWXG\DQGDOOVXEMHFWVFRPELQHG
6XEMHFWVZLOOEHH[FOXGHGIURPWKHVXPPDU\IRUHDFKSDUDPHWHULIGDWDDUHPLVVLQJ
'LVHDVHKLVWRU\VXPPDU\ZLOOLQFOXGHIUHTXHQF\GLVWULEXWLRQVIRUVWDJHDWLQLWLDOGLDJQRVLV
WXPRUVWDJHQRGHVWDJHPHWDVWDVLVVWDJHDQGGHVFULSWLYHVWDWLVWLFVRIWLPHIURPSULPDU\
GLDJQRVLVWRVWXG\HQWU\PRQWKV
7KHVXEJURXSVRILQWHUHVWDWEDVHOLQHDUHOLVWHGLQ7DEOH6XEJURXSDQDO\VLVRIDQWL
WXPRUDFWLYLW\ZLOOEHSHUIRUPHGLIWKHUHDUHDVXIILFLHQWQXPEHURIVXEMHFWVLQDVXEJURXS
3ULRUFDQFHUWUHDWPHQWWUHDWPHQWW\SHDQGEHVWUHVSRQVHRISULRUFDQFHUWUHDWPHQWZLOOEH
VXPPDUL]HGE\IUHTXHQF\GLVWULEXWLRQV


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
7KHEDVHOLQHGLVHDVHVWDWXVDVVHVVPHQWVXPPDU\ZLOOLQFOXGHIUHTXHQF\GLVWULEXWLRQVIRUVLWHV
RIPHWDVWDWLFGLVHDVHDQGVWDJHRIGLVHDVHDWVWXG\HQWU\
%DVHOLQHWXPRUFKDUDFWHULVWLFVLQFOXGHQXPEHUDQGVLWHVRIWDUJHWOHVLRQVDVZHOODVQXPEHU
DQGVLWHVRIQRQWDUJHWOHVLRQVWREHVXPPDUL]HGXVLQJDIUHTXHQF\GLVWULEXWLRQ7KHVL]HRI
WDUJHWOHVLRQVZLOOEHDOVRVXPPDUL]HGLQWHUPVRIVXPRIWKHORQJHVWGLDPHWHURIWDUJHW
OHVLRQVXVLQJGHVFULSWLYHVWDWLVWLFV
$VXPPDU\RIEDVHOLQH.36ZLOOEHSURYLGHGXVLQJIUHTXHQF\GLVWULEXWLRQV
3.3-1    Subgroups of Interest 
 
Subgroups of Interest 
Description 
*HRJUDSKLF5HJLRQ
1RUWK$PHULFDRUUHVWRIZRUOG
$,W\SH
$QDVWUR]ROH/HWUR]ROHRU([HPHVWDQH
%DVHOLQH.L,QGH[
/RZYV+LJK
%DVHOLQH,*),/HYHO
/RZYV+LJK
%DVHOLQH,*),,/HYHO
/RZYV+LJK

6WXG\'UXJ([SRVXUH
6XPPDULHVRIVWXG\GUXJH[SRVXUHZLOOEHSURYLGHGIRUWKH,77DQGRUVDIHW\SRSXODWLRQE\
WUHDWPHQWJURXS
6XPPDU\RIVWXG\WUHDWPHQWH[SRVXUHZLOOLQFOXGHGHVFULSWLYHVWDWLVWLFVRIWKHIROORZLQJWRWDO
QXPEHURIWUHDWPHQWF\FOHVGHILQHGDVWKHQXPEHURIF\FOHVGXULQJZKLFKVXEMHFWUHFHLYHG
DQ\WUHDWPHQWRI0(',DQGRU$,QXPEHURI0(',GRVHVDQGWRWDO0(',GRVH
UHFHLYHGGXULQJWKHVWXG\GXUDWLRQRI$,WUHDWPHQWGD\VGXULQJWKHVWXG\7KHWRWDOQXPEHU
RIWUHDWPHQWF\FOHVZLOODOVREHVXPPDUL]HGXVLQJIUHTXHQF\GLVWULEXWLRQ7KHGRVHLQWHQVLW\
IRU0(',RU$,LVDSHUFHQWRIWRWDODFWXDOGRVHWKDWDVXEMHFWUHFHLYHGGXULQJWKHVWXG\
WUHDWPHQWSHULRGIRU0(',RU$,UHVSHFWLYHO\YHUVXVWRWDOLQWHQGHGGRVHRI0(',
RU$,UHVSHFWLYHO\IRUWKHVDPHVWXG\WUHDWPHQWSHULRGDFFRUGLQJWRWKHVWXG\SURWRFRO,WZLOO
EHVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFVDVSDUWRIWKHVWXG\WUHDWPHQWH[SRVXUHVXPPDU\
7KHGRVHLQWHQVLW\FDOFXODWLRQGHWDLOVZLOOEHSURYLGHGLQWKH633
'RVLQJGHOD\VDQGPRGLILFDWLRQVZLOOEHVXPPDUL]HGIRUWKHIROORZLQJFDWHJRULHVQXPEHURI
VXEMHFWVZLWK0(',GRVHGHOD\VWKHUHDVRQVIRU0(',GRVHGHOD\WKHWRWDOQXPEHU
RIVXEMHFWVIRUZKRPWKHHQWLUH0(',GRVHZDVQRWDGPLQLVWHUHGDVVFKHGXOHGWKH
UHDVRQVWKHHQWLUH0(',GRVHZDVQRWDGPLQLVWHUHGDVVFKHGXOHGDQGWKHUHDVRQWKH
VXEMHFWGLGQRWUHFHLYH0(',


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
7KHXVHRIVXEVHTXHQWDOWHUQDWLYHFDQFHUWUHDWPHQWDIWHUWKHGLVFRQWLQXDWLRQRIVWXG\
WUHDWPHQWZLOOEHVXPPDUL]HGE\W\SHRIWUHDWPHQW'HVFULSWLYHVWDWLVWLFVRIWLPHIURP
WUHDWPHQWGLVFRQWLQXDWLRQWRLQLWLDWLRQRIVXEVHTXHQWFDQFHUWUHDWPHQWPRQWKVZLOOEH
SURYLGHG

(IILFDF\$QDO\VHV

3ULPDU\(IILFDF\(QGSRLQWDQG$QDO\VHVLQ3KDVH

3ULPDU\(IILFDF\(QGSRLQWV
7KHSULPDU\HQGSRLQWRIWKH3KDVHSRUWLRQRIWKLVVWXG\LVSURJUHVVLRQIUHHVXUYLYDO3)6
GHILQHGDVWKHWLPHIURPUDQGRPL]DWLRQXQWLOWKHILUVWGRFXPHQWDWLRQRIGLVHDVHSURJUHVVLRQ
RUGHDWKZKLFKHYHURFFXUVILUVW
3)6PRQWKV 'DWHRI3'GHDWKRUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
5HIHUWR7DEOHIRUGDWHRI3'GHDWKRUFHQVRULQJ

3ULPDU\(IILFDF\$QDO\VLV
3URJUHVVLRQIUHHVXUYLYDO3)6ZLOOEHHYDOXDWHGXVLQJWKH.DSODQ0HLHUPHWKRGLQWKH,77
SRSXODWLRQDQGFRPSDUHGZLWKDWZRVLGHGVWUDWLILHGORJUDQNWHVWDWĮ VLJQLILFDQFHOHYHO
RYHUDOOW\SH,HUURUUDWHEHWZHHQ0(',
$,JURXSDQGWKH$,DORQHJURXS
7KHVWUDWLILFDWLRQIDFWRUVZLOOEHJHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG$,
W\SHDQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQH$VVHVVPHQWVRIGLVHDVHUHVSRQVHE\
LQYHVWLJDWRUVZLOOEHWKHEDVLVIRUWKHSULPDU\DQDO\VLV
$VVXSSRUWLYHLQIRUPDWLRQPHGLDQ3)6DQGLWVDQGFRQILGHQFHLQWHUYDO&,ZLOOEH
HVWLPDWHGXVLQJWKH.DSODQ0HLHUPHWKRG7KH3)6UDWHZLOOEHSUHVHQWHGDWDQG
PRQWKV7KHSYDOXHIURPWKHWZRVLGHGVWUDWLILHGORJUDQNWHVWZLOOEHXVHGIRUWKHSULPDU\
DVVHVVPHQWRIHIILFDF\7KHVWUDWLILFDWLRQIDFWRUVZLOOEHUHJLRQ1$YHUVXVUHVWRIZRUOGDQG
$,W\SHDQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQH7KHKD]DUGUDWLR0(',
$,YV
$,DORQHZLWKWZRVLGHGDQGFRQILGHQFHLQWHUYDOVZLOOEHHVWLPDWHGXVLQJD&R[
SURSRUWLRQDOKD]DUGPRGHOZLWKWUHDWPHQWDQGWKHVWUDWLILFDWLRQIDFWRUVDVH[SODQDWRU\
YDULDEOHVLQWKHPRGHO
6XEJURXSDQDO\VHVRI3)6E\VXEJURXSVGHILQHGLQ7DEOHZLOODOVREHSHUIRUPHGLQWKH
,77SRSXODWLRQ+D]DUGUDWLRV0(',
$,YV$,DORQHZLWKDWZRVLGHG
DQGFRQILGHQFHLQWHUYDOVZLOOEHHVWLPDWHGE\DQRQVWUDWLILHG&R[SURSRUWLRQDOKD]DUG
PRGHOXVLQJWKHVXEJURXSVGHILQHGLQ7DEOH


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

6HFRQGDU\(IILFDF\(QGSRLQWVDQG$QDO\VHVLQ3KDVH

6HFRQGDU\(IILFDF\(QGSRLQWV
7KHVHFRQGDU\HQGSRLQWVIRUDVVHVVLQJDQWLWXPRUDFWLYLW\LQFOXGHEHVWRYHUDOOGLVHDVH
UHVSRQVHREMHFWLYHUHVSRQVHUDWH255WLPHWRUHVSRQVH775GXUDWLRQRIUHVSRQVH'5
WLPHWRSURJUHVVLRQ773RYHUDOOVXUYLYDO26DQGFKDQJHLQWXPRUVL]H7KH\ZLOOEH
VXPPDUL]HGE\WUHDWPHQWJURXSEDVHGRQWKH,77SRSXODWLRQLQ3KDVH

6HFRQGDU\(IILFDF\$QDO\VHV
 %HVW2YHUDOO5HVSRQVH
7KHEHVWRYHUDOOUHVSRQVHZLOOEHFDOFXODWHGEDVHGXSRQWKHGLVHDVHDVVHVVPHQWVUHFRUGHG
GXULQJWKHVWXG\YLVLWVDQGVXPPDUL]HGZLWKWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIRUWKH
IROORZLQJFDWHJRULHVFRPSOHWHUHVSRQVH&5SDUWLDOUHVSRQVH35VWDEOHGLVHDVH6'
SURJUHVVLYHGLVHDVH3'DQGQRWHYDOXDEOH1($WOHDVWZHHNVIURPWKHEDVHOLQHGLVHDVH
DVVHVVPHQWPXVWHODSVHZLWKRXWSURJUHVVLYHGLVHDVH3'LQRUGHUWRDVVLJQDEHVWRYHUDOO
UHVSRQVHRI6'&RQILUPDWLRQRI35DQG&5LVUHTXLUHGDQGPXVWRFFXUDWOHDVWZHHNVDIWHU
LQLWLDOGRFXPHQWDWLRQRI35RU&5,I35RU&5LVSHQGLQJFRQILUPDWLRQDWDQDVVHVVPHQW
IROORZHGE\RUPRUHQRQHYDOXDEOHDVVHVVPHQWVRUDVVHVVPHQWVRI6'UHVSRQVHPD\EH
FRQILUPHGWKHUHDIWHU
 2EMHFWLYH5HVSRQVH5DWH
7KHREMHFWLYHUHVSRQVHUDWH255GHILQHGDVSURSRUWLRQRIVXEMHFWVZLWKFRQILUPHG&5RU
FRQILUPHG35ZLOOEHHVWLPDWHGZLWKDQGFRQILGHQFHLQWHUYDOVEDVHGRQWKHH[DFW
SUREDELOLW\PHWKRG6XEMHFWVWKDWKDYHPLVVLQJRYHUDOOUHVSRQVHDVVHVVPHQWVZLOOEH
FRQVLGHUHGQRQUHVSRQGHUVVRWKH\ZLOOEHFRXQWHGLQWKHGHQRPLQDWRUEXWQRWLQWKH
QXPHUDWRURI255,QDGGLWLRQ255RIWKH0(',
$,WUHDWPHQWJURXSZLOO
EHFRPSDUHGZLWKWKDWRIWKH$,DORQHJURXSXVLQJWKH&RFKUDQ±0DQWHO±+DHQV]HO&0+
WHVWVWUDWLILHGE\JHRJUDSKLFUHJLRQ1RUWK$PHULFDYVUHVWRIZRUOGDQG$,W\SH
DQDVWUR]ROHOHWUR]ROHRUH[HPHVWDQH
 7LPHWR5HVSRQVH
7LPHWRUHVSRQVH775LVPHDVXUHGIURPUDQGRPL]DWLRQWRWKHILUVWGRFXPHQWDWLRQRI
GLVHDVHUHVSRQVHDQGZLOOEHHYDOXDWHGRQO\LQVXEMHFWVZKRKDYHDFKLHYHGREMHFWLYHUHVSRQVH
FRQILUPHG&5RUFRQILUPHG357LPHWRUHVSRQVHLVGHILQHGLQPRQWKVDVIROORZV


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
775PRQWKV 'DWHRIILUVWGLVHDVHUHVSRQVH±'DWHRIUDQGRPL]DWLRQ

7KHPHGLDQ775DQGLWVDQG&,VZLOOEHDVVHVVHGXVLQJWKH.DSODQ0HLHUPHWKRG
 'XUDWLRQRI5HVSRQVH
'XUDWLRQRIUHVSRQVH'5LVPHDVXUHGIURPWKHILUVWGRFXPHQWDWLRQRIGLVHDVHUHVSRQVHWR
WKHILUVWGRFXPHQWHGSURJUHVVLYHGLVHDVHDQGZLOOEHHYDOXDWHGRQO\LQVXEMHFWVWKDWKDYH
DFKLHYHGREMHFWLYHUHVSRQVHFRQILUPHG&5RUFRQILUPHG35'XUDWLRQRIUHVSRQVHLV
GHILQHGLQPRQWKVDVIROORZV
'5PRQWKV 'DWHRI3'RUFHQVRULQJ±'DWHRIILUVWGLVHDVHUHVSRQVH

ZKHUHGDWHRI3'RUFHQVRULQJLVJLYHQLQ7DEOH7KHPHGLDQWLPHRI'5DQGLWV
DQG&,VZLOOEHDVVHVVHGXVLQJWKH.DSODQ0HLHUPHWKRG
 7LPHWR3URJUHVVLRQ
7LPHWRSURJUHVVLRQ773LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOWKHILUVWGRFXPHQWDWLRQRI
GLVHDVHSURJUHVVLRQ7LPHWRSURJUHVVLRQLVGHILQHGLQPRQWKVDVIROORZV
773PRQWKV 'DWHRI3'RUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
ZKHUHGDWHRI3'RUFHQVRULQJLVJLYHQLQ7DEOH7KHPHGLDQ773ZLOOEHHVWLPDWHG
XVLQJWKH.DSODQ0HLHUPHWKRGZLWKDQG&,V
7KHKD]DUGUDWLR0(',
$,YV$,DORQHZLWKWZRVLGHGDQG
FRQILGHQFHLQWHUYDOVZLOOEHHVWLPDWHGE\D&R[SURSRUWLRQDOKD]DUGPRGHOZLWKWUHDWPHQW
DQGWKHVWUDWLILFDWLRQIDFWRUVDVH[SODQDWRU\YDULDEOHVLQWKHPRGHO
 2YHUDOO6XUYLYDO
2YHUDOOVXUYLYDO26LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOGHDWK2YHUDOOVXUYLYDOLVGHILQHG
LQPRQWKVDVIROORZV
26PRQWKV 'DWHRIGHDWKRUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
7KHPHGLDQ26ZLOOEHHVWLPDWHGXVLQJWKH.DSODQ0HLHUPHWKRGZLWKDQG&,V
7KHKD]DUGUDWLR0(',
$,YV$,DORQHZLWKWZRVLGHGDQG
FRQILGHQFHLQWHUYDOVZLOOEHHVWLPDWHGE\D&R[SURSRUWLRQDOKD]DUGPRGHOZLWKWUHDWPHQW
DQGWKHVWUDWLILFDWLRQIDFWRUVDVH[SODQDWRU\YDULDEOHVLQWKHPRGHO



0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
7LPHWR'LVHDVH$VVHVVPHQWV
7LPHWR'LVHDVH$VVHVVPHQWV7'$LVPHDVXUHGIURPUDQGRPL]DWLRQXQWLOHDFKGLVHDVH
DVVHVVPHQW(VWLPDWHVRIPHGLDQWLPHWRGLVHDVHDVVHVVPHQWVLQHDFKJURXSZLOOEHFDOFXODWHG
XVLQJ.DSODQ0HLHUPHWKRGV7KHPHGLDQWLPHWRGLVHDVHDVVHVVPHQWIRUWKHILUVWVL[GLVHDVH
DVVHVVPHQWVRQVWXG\ZLOOEHUHSRUWHGZLWKFRQILGHQFHLQWHUYDOV6XEMHFWVORVWWRIROORZ
XSRUWKDWUHDFKWKHVXUYLYDOHQGSRLQWSULRUWRWKHSODQQHGGLVHDVHDVVHVVPHQWZLOOEH
FHQVRUHGDWWKHGDWHRIWKHLUODVWGLVHDVHDVVHVVPHQW)RUGLVHDVHDVVHVVPHQWVWKDWVSDQ
PXOWLSOHGD\VWKHGLVHDVHDVVHVVPHQWGDWHDVVLJQHGZLOOEHWKHGDWHZKHQWKHILUVWLPDJLQJ
VFDQIURPWKHGLVHDVHDVVHVVPHQWZDVSHUIRUPHG
7LPHWR'LVHDVH$VVHVVPHQWVLVGHILQHGLQGD\VDVIROORZV
7'$GD\V 'DWHRIGLVHDVHDVVHVVPHQWRUFHQVRULQJ±'DWHRIUDQGRPL]DWLRQ
 %HVW3HUFHQW&KDQJHLQ7DUJHW/HVLRQ6L]HV
)RUHDFKVXEMHFWWDUJHWOHVLRQGLDPHWHUVZLOOEHOLVWHGE\YLVLW,QDGGLWLRQEHVWSHUFHQW
FKDQJHLQWKHVXPRIWKHWDUJHWOHVLRQVL]HVLGHQWLILHGDWEDVHOLQHZLOOEHOLVWHGDQGSUHVHQWHG
E\VXEMHFWLQDZDWHUIDOOJUDSK'HVFULSWLYHVWDWLVWLFVZLOOEHXVHGWRVXPPDUL]HWKHEHVW
SHUFHQWFKDQJHLQWKHVXPRIWKHWDUJHWOHVLRQVL]HV,QDGGLWLRQSHUFHQWFKDQJHLQWKHVXPRI
WKHWDUJHWOHVLRQVL]HVLGHQWLILHGDWEDVHOLQHZLOOEHOLVWHGSHUYLVLW

6XEJURXS$QDO\VHV
6XEJURXSDQDO\VHVRIEHVWRYHUDOOUHVSRQVH255773DQG26E\VXEJURXSVGHILQHGLQ
7DEOHZLOODOVREHSHUIRUPHGLQWKH,773KDVHSRSXODWLRQ+D]DUGUDWLRV0(',
$,YV$,DORQHZLWKDWZRVLGHGDQGFRQILGHQFHLQWHUYDOVZLOOEH
HVWLPDWHGE\DQRQVWUDWLILHG&R[SURSRUWLRQDOKD]DUGPRGHOXVLQJWKHVXEJURXSVGHILQHGLQ
7DEOH

+DQGOLQJRI'URSRXWVDQG0LVVLQJ'DWDLQ3KDVH
7KHVHUXOHVZLOODSSO\XQLIRUPO\WRDOOHIILFDF\DQDO\VHVUHVXOWLQJIURPLQYHVWLJDWRUDVVHVVHG
WXPRU PHDVXUHPHQWV XVLQJ 5(&,67  ,Q JHQHUDO VXEMHFWV QRW FODVVLILDEOH XQGHU WKH
5(&,67UHVSRQVHFDWHJRULHVGXHWRLQVXIILFLHQWGDWDRUHDUO\GHDWKZLOOEHFODVVLILHGDV
QRQHYDOXDEOHIRUREMHFWLYHUHVSRQVHEXWZLOOEHFRXQWHGLQWKHGHQRPLQDWRURIDOOUHVSRQVH
UDWHFDOFXODWLRQV


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

+DQGOLQJRI0LVVLQJ'DWD
 0LVVLQJ'DWDDW%DVHOLQH
,IDVXEMHFWKDVPLVVLQJOHVLRQGDWDDWEDVHOLQHWKHVXEMHFWZLOOEHDVVLJQHG3'LIFULWHULDIRU
3'LVH[KLELWHGDWWKHILUVWGLVHDVHDVVHVVPHQW2WKHUZLVHWKHVXEMHFWZLOOEHFODVVLILHGDV
QRQHYDOXDEOHIRUREMHFWLYHUHVSRQVHDQGFHQVRUHGDWGDWHRIUDQGRPL]DWLRQIRU773)RU3)6
WKHVXEMHFWZLOOEHFHQVRUHGDWGDWHRIUDQGRPL]DWLRQXQOHVVWKHVXEMHFWGLHVZLWKLQWKHILUVW
VFKHGXOHGGLVHDVHDVVHVVPHQWSHULRGSRVWEDVHOLQHLQZKLFKFDVHWKLVGDWHZLOOTXDOLI\DVD
3)6HYHQW
 0LVVLQJ'DWDDWD'LVHDVH$VVHVVPHQW
,IDVXEMHFWKDVPLVVLQJWXPRUPHDVXUHPHQWVDWVRPHDVVHVVPHQWIRURUPRUHWDUJHWOHVLRQV
WKH VXP RI WKH ORQJHVW GLDPHWHUV 6/' ZLOO EH UHSRUWHG IRU WKH UHPDLQLQJ WDUJHW OHVLRQV
7KHVHGDWDZLOOEHXVHGWRLQGLFDWHUDGLRORJLFGLVHDVHSURJUHVVLRQLIWKH6/'IRUWKHREVHUYHG
OHVLRQVLQFUHDVHVDWOHDVWIURPWKHQDGLU6/'RIDOOOHVLRQVDQGGHPRQVWUDWHVDWOHDVWD
PPDEVROXWHLQFUHDVHIURPWKHQDGLU6/'RIDOOOHVLRQVLQVSLWHRIWKHPLVVLQJGDWDRULI
RWKHUFULWHULDIRU3'DUHPHW,IDVXEMHFWKDVPLVVLQJWXPRUDVVHVVPHQWVDWVRPHDVVHVVPHQW
IRU  RU PRUH QRQWDUJHW OHVLRQV UDGLRORJLF GLVHDVH SURJUHVVLRQ ZLOO EH GHWHUPLQHG LI WKH
UHPDLQLQJQRQWDUJHWOHVLRQVTXDOLWDWLYHO\GHPRQVWUDWHXQHTXLYRFDOSURJUHVVLRQRULIRWKHU
FULWHULDIRU3'DUHPHW,IDVXEMHFWKDVPLVVLQJWXPRUPHDVXUHPHQWVDWVRPHDVVHVVPHQWV
IRURUPRUHWDUJHWRUPLVVLQJUHFRUGHGVWDWXVDWVRPHDVVHVVPHQWVIRURUPRUHQRQWDUJHW
OHVLRQVDQGFULWHULDIRU3'DUHQRWPHWDQRYHUDOOUHVSRQVHRIQRQHYDOXDEOHZLOOEHDVVLJQHG
IRUWKHDVVHVVPHQWV
 0LVVLQJ'LVHDVH$VVHVVPHQWV
,IDVXEMHFWKDVPRUHWKDQWZRFRQVHFXWLYHFRPSOHWHO\PLVVHGRUQRQHYDOXDEOHDVVHVVPHQWV
IROORZHGE\GHDWKRUDQDVVHVVPHQWVKRZLQJUDGLRORJLFGLVHDVHSURJUHVVLRQWKHQWKHVXEMHFW
ZLOOEHFHQVRUHGDWWKHGDWHRIWKHODVWSURJUHVVLRQIUHHGLVHDVHDVVHVVPHQWSULRUWRWKHPLVVHG
RUQRQHYDOXDEOHDVVHVVPHQWV,IDVXEMHFWKDVPRUHWKDQWZRFRQVHFXWLYHPLVVHGRUQRQ
HYDOXDEOHDVVHVVPHQWVIROORZHGE\DQDVVHVVPHQWVKRZLQJQRUDGLRORJLFGLVHDVHSURJUHVVLRQ
WKHQ WKH DVVXPSWLRQ ZLOO EH WKDW WKH VXEMHFW UHPDLQHG VWDEOH GXULQJ WKH PLVVHG RU QRQ
HYDOXDEOHDVVHVVPHQWV

2WKHU&HQVRULQJ5XOHV
6XEMHFWVKDYLQJQRWXPRUDVVHVVPHQWVDIWHUUDQGRPL]DWLRQZLOOKDYH3)6DQG773FHQVRUHG
DWWKHGDWHRIUDQGRPL]DWLRQ6XEMHFWVZKRUHDFKWKHVXUYLYDOHQGSRLQWGXHWRDQ\UHDVRQ


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
SULRUWRH[SHULHQFLQJDUDGLRORJLFGLVHDVHSURJUHVVLRQZLOOEHFHQVRUHGIRU773DWWKHGDWHRI
WKHLUODVWFRPSOHWHGLVHDVHDVVHVVPHQW6XEMHFWVUHPDLQLQJRQVWXG\ZLWKRXWUDGLRORJLF
GLVHDVHSURJUHVVLRQRUGHDWKDWWKHWLPHRIDQDO\VLVZLOOEHFHQVRUHGIRU773DQG3)6DWWKH
GDWHRIWKHLUODVWFRPSOHWHGLVHDVHDVVHVVPHQW6XEMHFWVORVWWRIROORZXSSULRUWR
H[SHULHQFLQJDUDGLRORJLFGLVHDVHSURJUHVVLRQRUGHDWKZLOOEHFHQVRUHGIRU773DQG3)6DW
WKHGDWHRIWKHLUODVWFRPSOHWHGLVHDVHDVVHVVPHQW$GGLWLRQDOO\DVHQVLWLYLW\DQDO\VLVPD\EH
SHUIRUPHGFHQVRULQJ3)6RQWKHGDWHRIODVWSURJUHVVLRQIUHHDVVHVVPHQWSULRUWRLQLWLDWLRQRI
DOWHUQDWHDQWLFDQFHUWKHUDS\6XEMHFWVZKRDUHDOLYHDWWKHHQGRIVWXG\RUORVWWRIROORZXS
ZLOOEHFHQVRUHGIRU26RQWKHODVWGDWHZKHQWKHVXEMHFWVZHUHNQRZQWREHDOLYH
$Q\VXEMHFWUHFHLYLQJORFRUHJLRQDOWKHUDS\LQFOXGLQJVXUJHU\ZKLOHRQVWXG\WKDWGLUHFWO\
DIIHFWVRQHRUPRUHRIWKHWDUJHWOHVLRQVVHOHFWHGDWEDVHOLQHDQGUHVXOWVLQDVXEVHTXHQW
UHVSRQVHRU6'ZLOOEHFRQVLGHUHGWREHQRQHYDOXDEOHDWDOOGLVHDVHDVVHVVPHQWVWKDWRFFXU
RQRUDIWHUWKHGDWHRIORFRUHJLRQDOWKHUDS\2WKHUZLVHWKHVXEMHFWZLOOEHDVVHVVHGLJQRULQJ
WKHORFRUHJLRQDOWKHUDS\
3.4-1    Summary of Censoring Guidelines for Efficacy Endpoints 
 
Situation 
Date of PD/Death or Censoring 
PFS/TTP Outcome 
'RFXPHQWHG3URJUHVVLYH'LVHDVH3'DV
GHWHUPLQHGE\LQYHVWLJDWRU
'DWHRIHDUOLHVWVLJQRI3'
3URJUHVVHG
'HDWKEHIRUHWKHILUVWSRVWEDVHOLQHGLVHDVH
DVVHVVPHQWRUEHWZHHQDGHTXDWHWXPRU
DVVHVVPHQWYLVLWV
'DWHRIGHDWK3)6

'DWHRIODVWSURJUHVVLRQIUHHGLVHDVH
DVVHVVPHQW773
'HDWK3)6

&HQVRUHG773
1R3'DVGHWHUPLQHGE\LQYHVWLJDWRURU
GHDWKDWWLPHRIDQDO\VLVRUORVWWRIROORZXS
'DWHRIODVWSURJUHVVLRQIUHHGLVHDVH
DVVHVVPHQW
&HQVRUHG
'HDWKRU3'DVGHWHUPLQHGE\LQYHVWLJDWRU
DIWHUPLVVHGFRQVHFXWLYHGLVHDVH
DVVHVVPHQWV
'DWHRIODVWSURJUHVVLRQIUHHGLVHDVH
DVVHVVPHQWSULRUWRPLVVHG
DVVHVVPHQWV
&HQVRUHG
,QLWLDWLRQRIDOWHUQDWLYHDQWLFDQFHUWKHUDS\
'DWHRIODVWSURJUHVVLRQIUHHGLVHDVH
DVVHVVPHQWSULRUWRLQLWLDWLRQRIRWKHU
DQWLFDQFHUWKHUDS\
&HQVRUHGIRU
6HQVLWLYLW\$QDO\VHV
1RWXPRUDVVHVVPHQWDWEDVHOLQHRUSRVW
EDVHOLQH
'DWHRIUDQGRPL]DWLRQ
&HQVRUHG

$VVLJQPHQWRI'DWHVRI'LVHDVH3URJUHVVLRQRU'LVHDVH5HVSRQVH
)RU DOO DQDO\VHV RI HQGSRLQWV DQDO\VHV UHVXOWLQJ IURP LQYHVWLJDWRU DVVHVVHG WXPRU
PHDVXUHPHQWVXVLQJ5(&,67WKHUHPD\EHFDVHVLQZKLFKGLVHDVHDVVHVVPHQWVVSDQD
VHULHVRIGDWHV)RUHVWDEOLVKLQJWKHVWDUWGDWHRIDVXEVHTXHQWO\FRQILUPHGUHVSRQVHLQZKLFK
WKHGLVHDVHDVVHVVPHQWVSDQVPXOWLSOHGD\VWKHUHVSRQVHGDWHDVVLJQHGZLOOEHWKHODWHVWGDWH
RIHYDOXDWLRQVFRUUHVSRQGLQJWRWKHGLVHDVHDVVHVVPHQW 7KHGDWHRIODWHVWDVVHVVPHQW ZLOO


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI
DOVREHDVVLJQHGIRUDPLGVWXG\DVVHVVPHQWVKRZLQJ6'DVWKHGDWHDVVLJQHGWRWKDW6'IRU
WKHSXUSRVHVRIFHQVRULQJGXUDWLRQRI6'
7KH GDWH RI 3' ZLOO EH WKH VW GDWH DW ZKLFK DQ\ REMHFWLYH GLDJQRVWLF WHVW SURYLGHV GDWD
LQGLFDWLQJ3'6SHFLILFDOO\WKHGDWHRI3'ZLOOEHWKHHDUOLHVWRIWKHIROORZLQJGDWHV
x 'DWHRI3'DVLQGLFDWHGE\WDUJHWOHVLRQVLI3'LVWULJJHUHGE\DFKDQJHLQ6/'RI
WDUJHWOHVLRQVDQGDOOHYDOXDWLRQVRFFXUUHGRQWKHVDPHGD\DVVLJQWKDWGDWH,IWKH
GDWHVRIHYDOXDWLRQRIWKHWDUJHWOHVLRQVYDU\IRUWKHVDPHDVVHVVPHQWDVVLJQWKHILUVW
HYDOXDWLRQGDWHDPRQJWDUJHWOHVLRQV
x 'DWHRI3'DVLQGLFDWHGE\QRQWDUJHWOHVLRQVWKHVWGDWHIRUZKLFKDQ\QRQWDUJHW
OHVLRQH[KLELWVDUHVSRQVHRI3'
x 'DWHRI3'DVLQGLFDWHGE\QHZOHVLRQVWKHVWGDWHIRUZKLFKDQ\QHZOHVLRQLV
GHWHFWHG

6DIHW\$QDO\VHV

3ULPDU\(QGSRLQWVRI6DIHW\LQ3KDVHE
7KHSULPDU\VDIHW\HQGSRLQWVDUHWKHIROORZLQJ
x $GYHUVHHYHQWVDQG6$(VRFFXUULQJGXULQJWKHSURWRFROVSHFLILHGUHSRUWLQJSHULRGDV
GHILQHGLQ6HFWLRQRIWKHVWXG\SURWRFRO
x 'RVHOLPLWLQJWR[LFLWLHVGHILQHGLQWKHVWXG\SURWRFRO6HFWLRQRFFXUULQJ
GXULQJWKH'/7SHULRGLQWKH3KDVHESRUWLRQRIWKLVVWXG\
$GYHUVHHYHQWVWUHDWPHQWHPHUJHQW$(VDQG6$(VZLOOEHVXPPDUL]HGE\V\VWHPRUJDQ
FODVVDQG0HG'5$SUHIHUUHGWHUPVHYHULW\DQGUHODWLRQVKLSWRVWXG\WUHDWPHQW7KHQXPEHU
DQGSHUFHQWDJHRIVXEMHFWVZLWK'/7LQWKHHYDOXDEOHSRSXODWLRQIRU3KDVHERIWKLVVWXG\
ZLOOEHVXPPDUL]HG

6HFRQGDU\(QGSRLQWVRI6DIHW\DQG7ROHUDELOLW\LQ3KDVH
6DIHW\DQGWROHUDELOLW\ZLOOEHDVVHVVHGE\VXPPDUL]LQJ$(V6$(VHOHFWURFDUGLRJUDP
(&*UHVXOWVVLJQLILFDQWRULPSRUWDQWFOLQLFDOILQGLQJVLQ.DUQRIVN\SHUIRUPDQFHVWDWXV
ODERUDWRU\DVVHVVPHQWVDQGYLWDOVLJQVGXULQJWKHVWXG\$OOVXPPDULHVIRUWR[LFLW\SURILOH
HYDOXDWLRQZLOOEHGRQHE\WUHDWPHQWJURXSEDVHGRQWKHVDIHW\SRSXODWLRQ


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
2QO\WUHDWPHQWHPHUJHQWDGYHUVHHYHQWV7($(VGHILQHGDVHYHQWVSUHVHQWDWEDVHOLQHWKDW
ZRUVHQLQLQWHQVLW\DIWHUDGPLQLVWUDWLRQRIVWXG\WUHDWPHQWRUHYHQWVDEVHQWDWEDVHOLQHWKDW
HPHUJHDIWHUDGPLQLVWUDWLRQRIVWXG\WUHDWPHQWIRUWKHSHULRGH[WHQGLQJWRGD\VDIWHUWKH
ODVWGRVHRIVWXG\WUHDWPHQWZLOOEHVXPPDUL]HGE\V\VWHPRUJDQFODVVDQGSUHIHUUHGWHUP
XVLQJWKH0HG'5$GLFWLRQDU\VHYHULW\JUDGHGDFFRUGLQJWR1&,&7&$(YDQG
UHODWLRQVKLSWRVWXG\WUHDWPHQW7KH$(V6$(VRFFXUULQJIURPWKHVLJQLQJRIWKHLQIRUPHG
FRQVHQWDQGSULRUWRWKHLQLWLDWLRQRIVWXG\WUHDWPHQWZLOOEHOLVWHG7KH$(V6$(VWKDWEHJLQ
GD\VDIWHUODVWGRVHZLOOQRWEHVXPPDUL]HGRUOLVWHG
6XEMHFWVZLOOEHFRXQWHGRQO\RQFHIRUHDFKSUHIHUUHGWHUPRQFHIRUHDFKV\VWHPRUJDQFODVV
DQGE\WKHKLJKHVWHYHQWVHYHULW\UHJDUGOHVVRIKRZPDQ\HYHQWVWKHVXEMHFWH[SHULHQFHG
6XPPDULHVZLOOEHSURYLGHGIRU7($(VUHVXOWLQJLQSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJ
DQG7($(VUHVXOWLQJWRGHDWK6XSSRUWLQJOLVWLQJVZLOOEHSURYLGHGIRU$(VUHVXOWLQJLQ
SHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJDQG$(VUHVXOWLQJWRGHDWK

'/7OLNHHYHQWV
7KH'/7OLNHHYHQWVGHILQHGDVDQHYHQWZKLFKPHHWVWKHGHILQLWLRQRI'/7EXWRFFXUV
GXULQJ&\FOHLQDOOVXEMHFWVWUHDWHGZLWKLQWKHVWXG\ZLOOEHVXPPDUL]HGE\WUHDWPHQW
JURXS

&OLQLFDO/DERUDWRU\(YDOXDWLRQ
7KHFKDQJHLQHDFKODERUDWRU\SDUDPHWHUIURPEDVHOLQHWRWKH³ZRUVWFDVH´QDGLUDQGRU
]HQLWKRQVWXG\LQFOXGLQJDQ\SRVWEDVHOLQHDVVHVVPHQWVWKDWRFFXUWKURXJKGD\VDIWHU
WKHODVWGRVHDQGWRWKHODVWDVVHVVPHQWRQVWXG\LQFOXGLQJDQ\SRVWEDVHOLQHDVVHVVPHQWV
WKDWRFFXUWKURXJKGD\VDIWHUWKHODVWGRVHIRUKHPDWRORJ\FRDJXODWLRQDQGEORRG
FKHPLVWU\ZLOOEHVXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFV%DVHOLQHYDOXHVZLOOEHGHILQHGDVWKH
ODVWYDOLGDVVHVVPHQWSULRUWRWKHILUVWDGPLQLVWUDWLRQRIVWXG\WUHDWPHQW
/DERUDWRU\DEQRUPDOLWLHVZLWKWR[LFLW\JUDGHVDFFRUGLQJWRWKH1&,&7&$(YZLOOEH
GHULYHGDFFRUGLQJWRODERUDWRU\YDOXHV/DERUDWRU\DEQRUPDOLWLHVRFFXUULQJIURPWKHVWDUWRI
VWXG\WUHDWPHQWDGPLQLVWUDWLRQWKURXJKGD\VDIWHUWKHODVWGRVHRIWKHVWXG\WUHDWPHQWZLOO
EHSUHVHQWHG6KLIWWDEOHVIURPEDVHOLQHWRWKHPD[LPXPVHYHULW\JUDGHRQVWXG\DQGWRWKH
ODVWDVVHVVPHQWRQVWXG\ZLOOEHJHQHUDWHGIRUHDFKRIODERUDWRU\SDUDPHWHU


0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

9LWDO6LJQV
'HVFULSWLYHVWDWLVWLFVRIYDOXHDQGFKDQJHIURPEDVHOLQHYDOXHIRUKHDUWUDWHEORRGSUHVVXUH
ERG\WHPSHUDWXUHDQGUHVSLUDWRU\UDWHZLOOEHSURYLGHGIRUHDFKVFKHGXOHGWLPHSRLQW

(OHFWURFDUGLRJUDP
'HVFULSWLYHVWDWLVWLFVIRUHOHFWURFDUGLRJUDP(&*SDUDPHWHUVZLOOEHSURYLGHGIRUHDFK
VFKHGXOHGWLPHSRLQW

.DUQRIVN\3HUIRUPDQFH6WDWXV
.DUQRIVN\SHUIRUPDQFHVWDWXVZLOOEHVXPPDUL]HGXVLQJDVKLIWWDEOHVKRZLQJFKDQJHLQ.36
IURPEDVHOLQHWRWKHZRUVWSHUIRUPDQFHVWDWXVRQVWXG\DQGWRWKHODVWDVVHVVPHQWRQVWXG\

,PPXQRJHQLFLW\
$QDO\VLVRILPPXQRJHQLFLW\,0UHVXOWVZLOOEHDVVHVVHGE\VXPPDUL]LQJWKHQXPEHUDQG
SHUFHQWDJHRIVXEMHFWVZKRGHYHORSGHWHFWDEOHDQWL0(',DQWLERGLHVIRUDOOVXEMHFWV
HQWHUHGLQ3KDVHEDQG3KDVH*URXSDQG*URXS7KH$'$WLWHUZLOOEHUHSRUWHGIRU
VDPSOHVFRQILUPHGSRVLWLYHIRUWKHSUHVHQFHRIDQWL0(',DQWLERGLHV7KHHIIHFWRI
$'$RQ3.SKDUPDFRG\QDPLFVDQGVDIHW\ZLOOEHHYDOXDWHGE\WKH0HG,PPXQH*OREDO
3.3'	%LRDQDO\VLVJURXSRUGHVLJQHH

3KDUPDFRORJ\DQG3KDUPDFRG\QDPLFVRI0(',
2WKHUVHFRQGDU\HQGSRLQWVDUHWKHSKDUPDFRNLQHWLFVDQGSKDUPDFRG\QDPLFVHQGSRLQWV7KH
DQDO\VHVZLOOEHSHUIRUPHGE\WKH0HG,PPXQH*OREDO3.3'	%LRDQDO\VLVJURXSRU
GHVLJQHH

([SORUDWRU\6XPPDULHV

([SORUDWRU\$QDO\VHV




([SORUDWRU\$QDO\VLV





0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI




































0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI


































0HG,PPXQH

0(',
3URWRFRO&'210(',
6WDWLVWLFDO$QDO\VLV3ODQ
6(3)LQDO9HUVLRQ

RI

,QWHULP$QDO\VHV
1RIRUPDOLQWHULPDQDO\VLVLVSODQQHG

5HIHUHQFHV
(LVHQKDXHU($7KHUDVVH3%RJDHUWV-6FKZDUW]/+6DUJHQW')RUG5HWDO1HZUHVSRQVH
HYDOXDWLRQFULWHULDLQVROLGWXPRXUVUHYLVHG5(&,67JXLGHOLQHYHUVLRQ(XU-&DQFHU

0RXULGVHQ+*HUVKDQRYLFK06XQ<3pUH]&DUULyQ5%RQL&0RQQLHU$HWDO6XSHULRU
HIILFDF\RIOHWUR]ROHYHUVXVWDPR[LIHQDVILUVWOLQHWKHUDS\IRUSRVWPHQRSDXVDOZRPHQZLWK
DGYDQFHGEUHDVWFDQFHUUHVXOWVRIDSKDVH,,,VWXG\RIWKH,QWHUQDWLRQDO/HWUR]ROH%UHDVW
&DQFHU*URXS-&OLQ2QFRO0D\
6KL4:DQJ;67LWR50HQGR]D753DQG\D.-DQG&OHHODQG&6$VVHVVLQJ3HUVLVWHQW
&DQFHU3DLQ$&RPSDULVRQRI&XUUHQW3DLQ5DWLQJVDQG3DLQ5HFDOOHGIURPWKH3DVW:HHN-
RI3DLQDQG6\PSWRP0DQDJHPHQW
.LQJ077KHLQWHUSUHWDWLRQRIVFRUHVIURPWKH(257&TXDOLW\RIOLIHTXHVWLRQQDLUH4/4
&4XDO/LIH5HV
2VRED'5RGULJXHV*0\OHV-=HH%3DWHU-,QWHUSUHWLQJWKH6LJQLILFDQFHRI&KDQJHVLQ
+HDOWK5HODWHG4XDOLW\RI/LIH6FRUHV-&OLQ2QFRO
2VRED'%H]MDN$%UXQGDJH0=HH%7X'3DWHU-4XDOLW\RI/LIH&RPPLWWHHRIWKH
1&,&&7*$QDO\VLVDQGLQWHUSUHWDWLRQRIKHDOWKUHODWHGTXDOLW\RIOLIHGDWDIURPFOLQLFDO
WULDOVEDVLFDSSURDFKRI7KH1DWLRQDO&DQFHU,QVWLWXWHRI&DQDGD&OLQLFDO7ULDOV*URXS(XU
-&DQFHU


